WO2014167530A1 - Cannabinoid compounds - Google Patents

Cannabinoid compounds Download PDF

Info

Publication number
WO2014167530A1
WO2014167530A1 PCT/IB2014/060636 IB2014060636W WO2014167530A1 WO 2014167530 A1 WO2014167530 A1 WO 2014167530A1 IB 2014060636 W IB2014060636 W IB 2014060636W WO 2014167530 A1 WO2014167530 A1 WO 2014167530A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
cycloalkyl
compound
nrr
Prior art date
Application number
PCT/IB2014/060636
Other languages
French (fr)
Inventor
Matthew James BOWDEN
James Peter Bernard WILLIAMSON
Original Assignee
Bowden Matthew James
Williamson James Peter Bernard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bowden Matthew James, Williamson James Peter Bernard filed Critical Bowden Matthew James
Publication of WO2014167530A1 publication Critical patent/WO2014167530A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present invention relates generally to cannabinoid compounds and compositions, more particularly new indole and indazole cannabinoids and compositions, and applications of these.
  • Cannabinoids are a class of diverse chemical compounds that activate cannabinoid receptors.
  • the broader definition of the term “cannabinoids” refers to a group of compounds that are structurally related to tetrahydrocannabinol (THC) or that bind to cannabinoid receptors.
  • THC tetrahydrocannabinol
  • Such compounds include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (produced chemically by humans).
  • the most notable cannabinoid is delta-9 THC, the primary psychoactive compound of cannabis.
  • Delta-9 THC the principle active component of cannabis, is a member of a large family of cannabinoid compounds that mediate physiological and psychotropic effects including immunosuppression, analgesia, inflammation, emesis, and intraocular pressure.
  • Cannabinoids work through selective binding to G-protein coupled cannabinoid receptors.
  • Two types of cannabinoid receptors have been cloned: CBi and CB 2 .
  • the CBi receptor is found mainly on cells of the central nervous system, while the CB 2 receptor is found mainly on cells of the peripheral nervous system including cells comprising the immune system, such as lymphoid cells.
  • Cannabinoid compounds that bind to CBi and/or CB 2 receptors, such as delta-9 THC, are known to have gastrointestinal, cardiovascular, and/or central nervous system activity. Such compounds may, therefore, offer therapeutic approaches to a variety of diseases or conditions.
  • the present invention provides a compound of formula I,
  • B is selected from CH or N;
  • Ri is selected from CONRi 2a Ri 2b , CORi 2a , COORi 2a , Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg fluoroalkyl, Ci-C 8 bromoalkyl, C 2 -C 8 haloalkenyl, C 2 -C 8 haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted; R2-R5 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO 3 H, NRi 2a Ri2b, S0 2 NR 12a
  • R 6a and R 6 b are each independently selected from Ci-C 8 alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring;
  • R 6c is selected from Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 haloalkyl, C 2 -C 8 haloalkenyl, C 2 -C 8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
  • Ri 2a and Ri3 ⁇ 4 are each independently selected from hydrogen, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
  • the present invention provides a compound of formula I,
  • B is selected from CH or N;
  • Ri is selected from CONRi 2a Ri 2b , CORi 2a , COORi 2a , Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 fluoroalkyl, Ci-C 8 bromoalkyl, C 2 -C 8 haloalkenyl, C 2 -C 8 haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
  • R2-R5 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NRi 2a Ri2b, S0 2 NRi2aRi2b, CONRi 2a Ri2b, halo, Ci-Cs alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Q- Cs alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
  • R 6a and R 6b are each independently selected from Ci-Cs alkyl or R6 a and R 6b together form a C3-C6 cycloalkyl ring;
  • R 6c is selected from Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg haloalkyl, C 2 -Cs haloalkenyl, C2-C8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
  • Ri2a and Ri 2 b are each independently selected from hydrogen, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
  • the invention provides the present invention provides a compound of formula I,
  • R 6a and R 6b together form 3 to 7 membered heterocycle
  • Y, B, Ri, R2-R5, and R 6c are as defined in first aspect above;
  • the invention provides the present invention provides a compound of formula I,
  • R 6c is cyano
  • Y, B, Ri, R2-R5, R 6a and R 6b are as defined in the first aspect above;
  • the present invention provides a compound of formula la,
  • Yi is selected from O, S, or S0 2 ;
  • Y 2 is selected from CH 2 , O, or NH;
  • B is selected from CH or N;
  • Ri is selected from CONRi 2a Ri 2b , CORi 2a , COORi 2a , Q-Q alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 fluoroalkyl, Ci-C 8 bromoalkyl, C 2 -C 8 haloalkenyl, C 2 -C 8 haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
  • R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NRi 2a Ri 2b , S0 2 NRi 2a Ri 2b , CONRi 2a Ri 2b , halo, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
  • R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring or 3 to 7 membered heterocyclyl ring;
  • Ri2a and R 12b are each independently selected from hydrogen, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -Cg alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
  • Yi is selected from O, S, or S0 2 ;
  • Y 2 is selected from CH 2 , O, or NH;
  • B is selected from CH or N;
  • Ri is selected from CONR 12a Ri 2b , COR 12a , COORi 2a , Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cg bromoalkyl, C 2 -Cg haloalkenyl, C 2 -Cg haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
  • R 2 -R5 and R7-R11 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NRi 2a Ri2b, S0 2 NRi 2a Ri 2b , CONRi 2a Ri 2b , halo, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
  • R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring; and Ri2a and Ri 2b are each independently selected from hydrogen, Ci-Cg alkyl, C 2 -C8 alkenyl, C 2 -Cs alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
  • the invention provides the present invention provides a compound of formula la,
  • R 6a and R 6b together form 3 to 7 membered heterocycle
  • Yi, Y 2 , B, Ri, R 2 -R5 and R7-R11 are as defined in fifth aspect above;
  • the invention in another aspect, relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.
  • the invention in another aspect, relates to a compound of the invention for use in treating pain in a subject.
  • the invention related to a compound of the invention for use in treating nausea and/or emesis in a subject.
  • the invention relates to a compound of the invention for use in stimulating appetite in a subject.
  • the invention relates to a compound of the invention for use in inducing a euphoric effect in a subject.
  • the invention in another aspect, relates to a compound of the invention for use in relaxing a subject.
  • the invention in another aspect, relates to a compound of the invention for use in inducing a positive mood change in a subject.
  • Figure 1 shows a 1H NMR scan for the compound SGT-42.
  • Figure 2 shows a 13C NMR scan for the compound SGT-42. 5.
  • therapeutically effective amount means the amount of an active compound, or a material, composition, composition, or dosage form comprising an active compound, which is effective for producing some desired therapeutic or prophylactic effect, commensurate with a reasonable benefit/risk ratio.
  • Therapeutically effective amounts can be determined using routine optimisation techniques well known in the art.
  • pharmaceutically acceptable refers to compounds of the invention, ingredients, materials and the like, which are within the scope of sound medical judgment, suitable for use in contact with the tissues of a human without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier must also be “acceptable” in the sense of being compatible with the other ingredients of the composition.
  • treatment and related terms, such as “treating” and “treat” as used herein, in the context of treating a condition, relates generally to treatment of a human, in which some desired therapeutic effect is achieved.
  • the therapeutic effect may, for example, be the inhibition of progress of the condition, including a reduction in the rate of progress; a halt in the rate of progress of the condition; amelioration of the condition; and cure of the condition.
  • Treatment as a prophylactic measure i.e., prophylaxis
  • Treatment also includes combination treatments and therapies, in which two or more treatments or therapies are used, for example, sequentially or simultaneously, in combination.
  • a therapeutically effective amount of a compound of the invention could be combined with or used in conjunction with a known cannabinoid compound.
  • alkyl means a saturated hydrocarbon radical containing normal, secondary, or tertiary carbon atoms.
  • suitable alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1-propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, -CH(CH 3 ) 2 ), 1 -butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl- 1-propyl (i- Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2
  • alkenyl means a hydrocarbon radical containing normal, secondary, tertiary or cyclic carbon atoms with at least one double bond.
  • alkynyl means a hydrocarbon radical containing normal, secondary, tertiary or cyclic carbon atoms with at least one triple bond.
  • alkynyl groups include, but are not limited to, acetylenic (-C ⁇ CH), propargyl (-CH 2 C ⁇ CH), and the like.
  • cycloalkyl means a hydrocarbon radical containing a saturated ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle.
  • Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms.
  • Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system, or spiro-fused rings.
  • aryl means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
  • an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms.
  • Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like.
  • alkoxy means a group having the formula -O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom.
  • suitable alkoxy groups include, but are not limited to, methoxy (-O-CH 3 or -OMe), ethoxy
  • halo as used herein means iodo, bromo, chloro, or fluoro.
  • haloalkyl means an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halo group.
  • suitable haloalkyl groups include, but are not limited to, -(CH 2 ) n F, -CF 3 , -CHF 2 , -CFH 2 , -CH 2 CF 3 , and the like.
  • haloalkenyl and “haloalkynyl” have analogous meanings.
  • optionally substituted in reference to a particular moiety of the compound of the invention (e.g., an optionally substituted aryl group) refers to a moiety having 0, 1, 2, or more substituents.
  • substituted in reference to alkyl, alkenyl, alkynyl, halogen, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl means alkyl, alkenyl, alkynyl, halogen, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent.
  • a C1-4 substituted alkyl refers to a C1-4 alkyl, which can be substituted with groups having more than the, e.g., 4 carbon atoms.
  • prodrug refers to any compound that when administered to a biological system generates the compound of the invention, i.e., active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalysed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s).
  • a prodrug is thus a covalently modified analogue or latent form of a therapeutically active compound.
  • heteroalkyl refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S.
  • the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH 3 , etc.), an amine (e.g., -NHCH 3 , -N(CH 3 ) 2 , etc.), or a thioalkyl group (e.g., -SCH 3 ).
  • a heteroatom e.g., O, N, or S
  • the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH 3 , etc.), an amine (e.g., -NHCH 3 , -N(CH 3 ) 2 , etc.), or a thioalkyl group (e.g., -SCH 3 ).
  • the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g., -CH2CH2-O-CH3, etc.), an alkyl amine (e.g., -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , etc.), or a thioalkyl ether (e.g.,-CH 2 -S-CH 3 ).
  • an alkyl ether e.g., -CH2CH2-O-CH3, etc.
  • an alkyl amine e.g., -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , etc.
  • a thioalkyl ether e.g.,-CH 2 -S-CH 3
  • the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g., -CH 2 CH 2 -OH), an aminoalkyl group (e.g., -CH 2 NH 2 ), or an alkyl thiol group (e.g., -CH 2 CH 2 -SH).
  • a heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • a Ci-C 6 heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
  • heterocycle or “heterocyclyl” as used herein include by way of example and not limitation those heterocycles described in Paquette, Leo A.; Principles of Modern
  • heterocyclic Chemistry W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and /. Am. Chem. Soc. (1960) 82:5566.
  • the terms “heterocycle” and “heterocyclyl” include saturated rings (i.e., heterocycloalkyls), partially unsaturated rings, and aromatic rings ⁇ i.e., heteroaromatic rings).
  • heterocycle and heterocyclyl also include substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups.
  • substituted heterocycles include, but are not limited to, 4,4-difluoro-l-piperidinyl and N-methyl-2-piperidinyl.
  • heterocycle or “heterocyclyl” employed alone or in combination with other terms means, unless otherwise stated, a saturated or unsaturated non-aromatic monocyclic heterocyclyl ring or a bicyclic heterocyclyl ring.
  • Monocyclic heterocyclyl rings include monovalent 3-, 4-, 5-, 6-, or 7-membered rings containing one or more heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur in the ring.
  • Monocyclic heterocyclyl groups are connected to the parent molecular moiety through any available carbon atom or nitrogen atom within the ring. Examples of monocyclic
  • heterocyclyl groups include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazoliny
  • Bicyclic heterocyclyl rings include monovalent monocyclic heterocyclyl rings fused to phenyl rings, cycloalkyl rings, or other monocyclic heterocyclyl rings. Bicyclic heterocyclyl groups are connected to the parent molecular moiety through any available carbon atom or nitrogen atom within the rings.
  • bicyclic heterocyclyl groups include, but are not limited to, 1,3-benzodioxolyl, 1,3-benzodithiolyl, 2,3-dihydro-l,4-benzodioxinyl, 2,3- dihydro- 1 -benzofuranyl, 2,3-dihydro-l-benzothienyl, 2,3-dihydro-lH-indolyl, and 1,2,3,4- tetrahydroquinolinyl.
  • the heterocyclyl is monocyclic.
  • Heteroaryl refers to an aromatic heterocyclyl.
  • suitable heteroatoms which can be included in the aromatic ring include oxygen, sulphur, and nitrogen.
  • heteroaryl rings include pyridinyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc.
  • carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan,
  • tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5- pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4- thiazolyl, or 5-thiazolyl.
  • halogenating agent includes phosphorous oxychloride, thionyl chloride, oxalyl chloride, phosphorous trichloride, phosphorous pentachloride, and diphosgene.
  • halogenated solvent includes chloroform, dichloromethane, and carbon tetrachloride.
  • chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are
  • stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
  • Diastereomer refers to a stereoisomer with two or more centres of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
  • Enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
  • the invention provides cannabinoid compounds that have a range of therapeutic activities including analgesic, anti-inflammatory, and anti-emetic.
  • the compounds of the invention also have psychotropic effects so can be used as relaxants to induce positive mood change.
  • the present invention provides a compound of formula I,
  • B is selected from CH or N;
  • Ri is selected from CONRi 2a Ri2b, CORi 2a , COORi 2a , C r C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cg bromoalkyl, C 2 -Cg haloalkenyl, C 2 -Cg haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
  • R 2 -R5 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NRi 2a Ri2b, S0 2 NRi 2a Ri2b, CONRi2aRi 2b , halo, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Q- Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
  • R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring;
  • R 6c is selected from Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 haloalkyl, C 2 -C 8 haloalkenyl, C 2 -Cg haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
  • Ri 2a and Ri3 ⁇ 4 are each independently selected from hydrogen, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
  • the present invention provides a compound of formula I,
  • B is selected from CH or N;
  • R 6a and R 6 b are each independently selected from Ci-C 8 alkyl or R6 a and R 6 b together form a C 3 -C 6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring;
  • each X is independently halo
  • each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C6-Ci 2 fluoroaryl, C 6 -Ci2 aryl Ci- Cg alkyl, C 3 -Ci 2 cycloalkyl, bridged C6-Ci 2 cycloalkyl, halo or perhalo substituted C 3 -Ci 2 cycloalkyl, or a C 3 -Ci 2 heterocycle; or
  • the invention provides the present invention provides a compound of formula I,
  • R 6a and R 6 b together form 3 to 7 membered heterocycle
  • Y, B, Ri, R 2 -R5, and R 6c are as defined in preceding aspect
  • the invention provides the present invention provides a compound of formula I,
  • R 6c is cyano
  • Y, B, Ri, and R2-R5 are as defined in the preceding aspect.
  • R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring
  • the present invention provides a compound of formula I,
  • B is selected from CH or N;
  • R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C3-C6 cycloalkyl ring;
  • each X is independently halo
  • each R is independently H, Ci-C 8 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
  • Ri2 a and Ri2b are each independently selected from hydrogen, Ci-C 8 alkyl, or C6-C12 aryl.
  • Ri2 a and Ri2b are each independently selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, n-pentyl, or phenyl.
  • each X is independently halo
  • each R is independently H, Ci-Cio alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 fluoroaryl, C 6 -Ci 2 aryl Ci- C 8 alkyl, C 3 -Ci 2 cycloalkyl, bridged C6-Ci 2 cycloalkyl, halo or perhalo substituted C 3 -Ci 2 cycloalkyl, or a C 3 -Ci 2 heterocycle.
  • each X is independently halo
  • each R is independently H, Ci-Cio alkyl, C 6 -Ci 2 aryl, C6-C 12 fluoroaryl, C 6 -Ci 2 aryl Cp
  • each X is independently halo
  • each R is independently H, C 1 -C 10 alkyl, C 6 -Ci 2 aryl, C6-C 12 fluoroaryl, C 6 -Ci 2 aryl Ci- Cg alkyl, C3-C 12 cycloalkyl, bridged C 6 -Ci 2 cycloalkyl, halo or perhalo substituted C 3 -C 12 cycloalkyl, or a C 3 -C 12 heterocycle.
  • each X is independently halo
  • each R is independently H, C 1 -C 10 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 fluoroaryl, C 6 -Ci 2 aryl Ci- Cg alkyl, C 3 -C 12 cycloalkyl, bridged C 6 -Ci 2 cycloalkyl, perhalo substituted C 3 -C 12 cycloalkyl, or a C 3 -C 12 heterocycle.
  • each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
  • each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl.
  • Ri is selected from C1-C6 alkyl, Ci-C 6 bromoalkyl, C1-C6 fluoroalkyl, C 6 -Ci2 aryl, C3-C12 cycloalkyl, Ci-C 6 alkylene-3,3-difluoro- l-cyclohexyl, Ci-C 6 alkylene-p- fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2-bicyclo[2.2.1]heptanyl, or Ci-C 6 alkylene- tetrahydropyranyl, wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro.
  • Ri is Ci-C 6 alkylene-4,4-difluoro- l-cyclohexyl.
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, 4-cyano-l -butyl, 3,3-dimethyl- 1-butyl, 1- hexyl, 1-heptyl, methylene cyclohexyl, methylene-4,4-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene-4- tetrahydropyranyl, methyleneC(0)NH(cyclohexyl), methyleneC(0)NH(t-butyl), 1-ethylene- 2-(N-morpholinyl), l-ethylene-2-(N-piperidinyl), and l-ethylene-2-(4,4-difluoro-N
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene cyclohexyl, methylene-3,3-difluoro- l-cyclohexyl, methylene-p-fluoro-phenyl, methylene- adamantyl, methylene-N-methyl-2-piperidinyl, methylene-cycloheptanyl, methylene-2- bicyclo[2.2.1]heptanyl, and methylene-4-tetrahydropyranyl.
  • Ri is methylene-4,4-difluoro- l -cyclohexyl.
  • each X is independently halo
  • each R is independently H, Ci-C 8 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
  • R 3 -R5, X, and R are as defined in the preceding embodiment.
  • R 2 is hydrogen or halo
  • R 3 -R5, X, and R are as defined in the preceding embodiment.
  • R3-R5, X, and R are as defined in the preceding embodiment.
  • R 2 is hydrogen or halo
  • R3-R5, X, and R are as defined in the preceding embodiment.
  • R 2 -R5 are each independently selected from hydrogen or halo, preferably hydrogen.
  • R 6a and R 6b are each independently selected from C 1 -C4 alkyl or R 6a and R 6 b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring.
  • R 6a and R 6b are each independently selected from C 1 -C4 alkyl or R 6a and R 6b together form a C3-C5 cycloalkyl ring, preferably methyl. In another embodiment, R 6a and R 6 b together form a C 3 -C 6 cycloalkyl ring, preferably cyclopropyl.
  • R 6a and R 6b together form a 3 to 6 membered heterocyclyl ring.
  • the heterocyclyl ring is a 5 or 6 membered ring.
  • the heterocyclyl ring comprises from 3 to 6 carbon atoms, from 3 to 5 carbon atoms, or from 4 to 5 carbon atoms.
  • the heterocyclyl ring is a 4,4-tetrahydropyranyl ring.
  • R 6a and R 6b are each methyl or R 6a and R 6b together form a cyclopropyl or cyclopentyl ring.
  • R 6c is selected from Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 haloalkyl, C 2 -Cg haloalkenyl, C 2 -C 8 haloalkynyl, C 6 -Ci 2 aryl, C 6 -Ci 2 haloaryl, C 3 -Ci 2 cycloalkyl, Ci-Ci 2 heteroalkyl, C 3 -Ci 2 heterocyclyl, C 6 -Ci 2 heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl,
  • each X is independently halo
  • each R is independently H, Ci-C 8 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-C 8 alkyl, or C 3 -C8 heterocycle.
  • each X is independently halo
  • each R is independently H, Ci-Cs alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-Cs alkyl, or C 3 -C 8 heterocycle.
  • R 6c is cyano.
  • each X is independently halo
  • each R is independently H, Ci-Cg alkyl, C 6 -Ci 2 aryl, C 6 -Ci2 aryl Ci-Cg alkyl, or C 3 -C 8 heterocycle.
  • each X is independently halo
  • each R is independently H, Ci-C 8 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
  • each X is independently halo
  • each R is independently H, Ci-C 8 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
  • each X is independently halo
  • each R is independently H, Ci-C 8 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-C 8 alkyl, or C3-C8 heterocycle.
  • each X is independently halo
  • each R is independently H, Ci-C 8 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
  • R 6c is selected from Ci-C 8 alkylene heterocyclyl, C 2 -C 8 alkynyl, C 6 -Ci 2 aryl, or C 6 -Ci 2 haloaryl, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
  • R 6c is selected from Ci-C 8 alkylene heterocyclyl, C 2 -C 8 alkynyl, C6-Ci 2 aryl, C 6 -Ci 2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
  • the Ci-Cs alkylene heterocyclyl is Ci-C 6 alkylene heterocyclyl. In one embodiment, the Ci-C 6 alkylene heterocyclyl is methylene heterocyclyl. In one embodiment, the heterocyclyl ring is a pyrrolidinyl ring. In one embodiment, the methylene heterocyclyl is methylene pyrrolidinyl, for example methylene-N-pyrrolidinyl.
  • the C 2 -C 8 alkynyl is C 2 -C6 alkynyl. In one embodiment, the C 2 -C 6 alkynyl is ethynyl. In one embodiment, the C 6 -Ci2 aryl is phenyl.
  • the C 6 -Ci2 haloaryl is halophenyl.
  • the halophenyl is chlorophenyl or fluorophenyl.
  • R 6c is selected from methylene heterocyclyl, C 2 -C6 alkynyl, phenyl, halophenyl or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
  • R 6c is selected from methylene pyrrolidinyl, ethynyl, phenyl, chlorophenyl, fluorophenyl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
  • R 6c is selected from Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 6 -Ci2 aryl, C 6 -Ci2 haloaryl, C3-C12 cycloalkyl, or C3-C12 heterocyclyl, wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more halo.
  • R 6c is selected from C1-C6 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 haloaryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo.
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl.
  • each X is independently halo
  • each R is independently H, Ci-Cs alkyl, C 6 -Ci2 aryl, C 6 -Ci2 aryl Ci-Cs alkyl, or C3-C8 heterocycle;
  • each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C 3 -Ci2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
  • each X is independently halo
  • each X is independently halo
  • each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C 3 -Ci2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C 3 -Ci2 heterocycle.
  • each X is independently halo
  • each R is independently H, Ci-Cg alkyl, C 6 -Ci2 aryl, C 6 -Ci2 aryl Ci-Cg alkyl, or C 3 -Cg heterocycle;
  • each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
  • each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C 3 -Ci2 cycloalkyl.
  • B is selected from CH or N;
  • Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C6-C i 2 aryl, C p
  • R 2 -R5, R 6a , Rfti, R 6 c, Ri 2 a and Ri 2 b are as defined above in the second aspect of the invention, or
  • Ri is C1-C0 alkylene-4,4-difluoro-l-cyclohexyl
  • Y, B , R 2 -R5, R 6a , 6 b, R 6 c, Ri 2 a and Ri3 ⁇ 4 are as defined in the preceding embodiment.
  • B is selected from CH or N;
  • Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, C i-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C i-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C 3 -C i 2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R 2 -R5 are each independently selected from hydrogen or halo
  • R 6 a> R6b> and R 6c are as defined above in the second aspect of the invention, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
  • Y, B , R 2 -R5, R 6a , Rib, and R 6c are as defined in the preceding embodiment.
  • B is selected from CH or N;
  • Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C 3 -Ci 2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R 2 -R5 are hydrogen
  • R 6 a, 6 b, and R 6c are as defined above in the second aspect of the invention, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is C1-C0 alkylene-4,4-difluoro-l-cyclohexyl;
  • Y, B, R 2 -R5, R 6a , R 6 b, and R 6c are as defined in the preceding embodiment.
  • B is selected from CH or N;
  • Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C 3 -Ci 2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R 2 -R5 are hydrogen
  • R 6a and R 6 are each independently selected from methyl or R 6a and Rg together form a cyclopropyl ring;
  • R 6c is as defined above in the second aspect of the invention, or
  • Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl; and Y, B, R2-R5, 6a > R6b, and R 6 c are as defined in the preceding embodiment.
  • B is selected from CH or N;
  • Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C 3 -Ci 2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and Rg together form a cyclopropyl ring;
  • R 6c is selected from C1-C6 alkyl, C6-C12 aryl, C 6 -Ci 2 haloaryl, or C 3 -Ci 2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo, or
  • Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
  • Y, B, R2-R5, R 6a , R 6 b, and R 6c are as defined in the preceding embodiment.
  • B is selected from CH or N;
  • Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C 3 -Ci 2 cycloalkyl, wherein each of said alkyl, aryl, heterocyclyl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R 2 -R5 are hydrogen;
  • R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
  • R 6c is selected from Ci-C 6 alkyl, C 6 -Cio aryl, C6-C10 haloaryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo, or
  • Ri is Q-Ce alkylene-4,4-difluoro-l-cyclohexyl
  • Y, B, R2-R5, 6 a, 6 b, and R 6c are as defined in the preceding embodiment.
  • B is selected from CH or N;
  • Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro- phenyl, C1-C6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci 2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is Ci-Ce alkylene-4,4-difluoro- 1 -cyclohexyl
  • Y, B, R 2 -R5, R 6a , R 6 b, and R 6c are as defined in the preceding embodiment.
  • B is selected from CH or N;
  • Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is Q-Ce alkylene-4,4-difluoro- 1 -cyclohexyl
  • Y, B, R2-R5, R 6 a, R 6 b, and R 6c are as defined in the preceding embodiment.
  • B is selected from CH or N;
  • Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is Ci-C 6 alkylene-4,4-difluoro- 1 -cyclohexyl; and
  • Y, B, R2-R5, R 6a , R 6 b, and R 6c are as defined in the preceding embodiment.
  • Ri is selected from Ci-C 6 alkyl, Ci-Ce bromoalkyl, Ci-C 6 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro- l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is Ci-C 6 alkylene-4,4-difluoro- 1 -cyclohexyl
  • Y, B, R2-R5, R 6 a, R6b, and R 6c are as defined in the preceding embodiment.
  • B is selected from CH or N;
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is methylene-4,4-difluoro- l -cyclohexyl
  • Y, B, R2-R5, R 6a , R 6 b, and R 6c are as defined in the preceding embodiment.
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Y, B, R2-R5, R 6 a, R 6 b, and R 6c are as defined in the preceding embodiment.
  • B is CH
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Y, B, R2-R5, R 6a , 6 b, and R 6c are as defined in the preceding embodiment.
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Y, B, R2-R5, R 6 a, R 6 b, and R 6c are as defined in the preceding embodiment.
  • B is CH
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b together form a cyclopropyl ring
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Y, B, R2-R5, R 6 a, R 6 b, and R 6c are as defined in the preceding embodiment.
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b together form a cyclopropyl ring; and R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Y, B, R2-R5, 6 a > R6b, and R 6 c are as defined in the preceding embodiment.
  • B is CH
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl
  • R 6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Y, B, R2-R5, R 6 a, R6b, and R 6c are as defined in the preceding embodiment.
  • the present invention provides a compound of formula la,
  • Yi is selected from O, S, or SO2;
  • Y2 is selected from CH2, O, or NH;
  • Ri is selected from CH or N;
  • Ri is selected from CONRi 2a Ri 2b , CORi 2a , COORi 2a , Q-Q alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 fluoroalkyl, Ci-C 8 bromoalkyl, C 2 -C 8 haloalkenyl, C 2 -C 8 haloalkynyl, aryl, cycloalkyl, or Ci-C 6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
  • R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NRi 2a Ri 2b , S0 2 NRi 2a Ri 2b , CONRi 2a Ri 2b , halo, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-C 8 alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
  • R 6a and R 6b are each independently selected from Ci-C 8 alkyl or R6 a and R 6b together form a C3-C6 cycloalkyl ring;
  • Ri 2a and R 12b are each independently selected from hydrogen, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
  • the present invention provides a compound of formula la,
  • Yi is selected from O, S, or S0 2 ;
  • Y 2 is selected from CH 2 , O, or NH;
  • B is selected from CH or N;
  • R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , S0 3 H, NRi 2a Ri 2b , S0 2 NRi 2a Ri 2b , CONRi 2a Ri 2b , halo, Ci-C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg alkoxy, C6-C 2 o aryl, C 3 -C 2 o cycloalkyl, Ci-C 2 o heteroalkyl, C 3 -C 2 o
  • R 6a and R 6 b are each independently selected from Ci-Cg alkyl or R6 a and R 6 b together form a C 3 -Cg cycloalkyl ring or a 3 to 7 membered heterocyclyl ring;
  • each X is independently halo
  • each R is independently H, C1-C10 alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 fluoroaryl, C 6 -Ci 2 aryl Ci- Cs alkyl, C 3 -Ci 2 cycloalkyl, bridged Cg-Ci 2 cycloalkyl, halo or perhalo substituted C 3 -Ci 2 cycloalkyl, or a C 3 -Ci 2 heterocycle; or
  • the invention provides the present invention provides a compound of formula la,
  • R 6a and R 6b together form 3 to 7 membered heterocycle
  • Yi, Y 2 , B, Ri, R2-R5 and R7-R11 are as defined in the preceding aspect;
  • the present invention provides a compound of formula la,
  • Yi is selected from O, S, or S0 2 ;
  • Y 2 is selected from CH 2 , O, or NH;
  • B is selected from CH or N;
  • R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N0 2 , CHO, S0 2 , SO3H, NR 12a R 12b , S0 2 NR 12a R 12b , CONR 12a R 12b , halo, C r C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, Ci-Cg alkoxy, C6-C 2 o aryl, C3-C
  • R 6a and R 6b are each independently selected from Ci-C 8 alkyl or R6a and R 6b together form a C 3 -C 6 cycloalkyl ring;
  • each X is independently halo
  • each R is independently H, C1-C10 alkyl, C 6 -Ci 2 aryl, C6-Ci 2 fluoroaryl, C 6 -Ci 2 aryl Ci- C 8 alkyl, C 3 -Ci 2 cycloalkyl, bridged C6-Ci 2 cycloalkyl, perhalo substituted C 3 -Ci 2 cycloalkyl, or a C 3 -Ci 2 heterocycle; or
  • each X is independently halo
  • each R is independently H, Ci-Cs alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-Cs alkyl, or C3-C8 heterocycle.
  • Ri 2a and Ri 3 ⁇ 4 are each independently selected from hydrogen, Ci-Cg alkyl, or C6-C12 aryl.
  • Ri 2a and Ri 3 ⁇ 4 are each independently selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, n-pentyl, or phenyl.
  • Yi is selected from O, S, or S0 2> preferably Yi is selected from O or S. In one embodiment, Yi is O.
  • Y 2 is selected from CH 2 , O, or NH, preferably Y 2 is selected from NH or O.
  • Yi is O; and Y 2 is NH or O.
  • Yi is O; and Y 2 is NH.
  • B is CH. In one embodiment, B is N.
  • each X is independently halo
  • each R is independently H, C1-C10 alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- C 8 alkyl, C 3 -C12 cycloalkyl, bridged C6-C12 cycloalkyl, perhalo substituted C 3 -C12 cycloalkyl, or a C 3 -C12 heterocycle.
  • each X is independently halo
  • each R is independently H, Ci-C 8 alkyl, C 6 -Ci2 aryl, C6-C12 aryl Ci-C 8 alkyl, or C 3 -C 8 heterocycle.
  • each R is independently H, Ci-Cio alkyl, C 6 -Ci2 aryl, C 6 -Ci2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C 3 -C12 cycloalkyl.
  • Ri is selected from C1-C6 alkyl, Ci-C 6 bromoalkyl, C1-C6 fluoroalkyl, C 6 -Ci2 aryl, Ci-C 6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2-bicyclo[2.2.1]heptanyl, C3-C12 cycloalkyl, or Ci-C 6 alkylene- tetrahydropyranyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo.
  • Ri is C1-C6 alkylene-4,4-difluoro- l-cyclohexyl.
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, 4-cyano-l -butyl, 3,3-dimethyl- 1-butyl, 1- hexyl, 1-heptyl, methylene cyclohexyl, methylene-4,4-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene-4- tetrahydropyranyl, methyleneC(0)NH(cyclohexyl), methyleneC(0)NH(t-butyl), 1-ethylene- 2-(N-morpholinyl), l-ethylene-2-(N-piperidinyl), and l-ethylene-2-(4,4-difluoro-N
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene- 3, 3- difluoro-1 -cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N- methyl-2-piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2. l]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl.
  • Ri is methylene-4,4-difluoro- l -cyclohexyl.
  • each X is independently halo
  • each R is independently H, Ci-Cs alkyl, C 6 -Ci 2 aryl, C 6 -Ci 2 aryl Ci-Cs alkyl, or C 3 -C 8 heterocycle.
  • R 3 -R5, R7-R11 , X, and R are as defined in the preceding embodiment.
  • R 2 is hydrogen or halo
  • R 3 -R5, R7-R11 , X, and R are as defined in the preceding embodiment.
  • R3-R5, R7-R 11 , X, and R are as defined in the preceding embodiment.
  • R 2 is hydrogen or halo
  • R3-R5, R7-R 11 , X, and R are as defined in the preceding embodiment.
  • R 2 -R5, R7- R 11 are each independently selected from hydrogen or halo.
  • R 2 -R5, R7, Rs, Rio, and Rn are hydrogen and R is halo. In one embodiment, R 2 -R5, R7, Rs, Rio, and Rn are hydrogen and R9 is fluoro.
  • R 6a and R 6b are each independently selected from C 1 -C4 alkyl or R 6a and R 6 b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring. In one embodiment, R 6a and R 6b are each independently selected from C 1 -C4 alkyl or R 6a and R 6b together form a C3-C5 cycloalkyl ring.
  • R 6a and R 6b are each methyl or R 6a and R 6b together form a cyclopropyl or cyclopentyl ring.
  • R 6a and R 6b together form a 3 to 6 membered heterocyclyl ring.
  • the heterocyclyl ring is a 5 or 6 membered ring. In one embodiment, the heterocyclyl ring comprises from 3 to 6 carbon atoms, from 3 to 5 carbon atoms, or from 4 to 5 carbon atoms.
  • the heterocyclyl ring is a 4,4-tetrahydropyranyl ring.
  • R 6a and R 6b are each independently methyl.
  • R 6a and R 6b together form a cyclopropyl ring.
  • Yi is selected from O, S, or S0 2 ;
  • Y 2 is selected from CH 2 , O, or NH;
  • each R is independently H, Ci-Cio alkyl, C6-C12 aryl, C 6 -Ci 2 fluoroaryl, C6-C12 aryl Ci- Cs alkyl, C 3 -Ci 2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C 3 -Ci 2 cycloalkyl, or a C 3 -Ci 2 heterocycle.
  • Yi is O
  • Y 2 is selected from NH or O
  • each R is independently H, Ci-Cio alkyl, C 6 -Ci2 aryl, C6-C 12 fluoroaryl, C 6 -Ci2 aryl Cp Cg alkyl, C3-C 12 cycloalkyl, bridged C 6 -C i2 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
  • Yi is O
  • Y2 is selected from NH
  • each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
  • each R is independently H, C 1-C 10 alkyl, C 6 -Ci2 aryl, C 6 -C i2 fluoroaryl, C 6 -Ci2 aryl Ci- Cs alkyl, C 3 -C 12 cycloalkyl.
  • Yi is selected from O or S;
  • Y 2 is selected from CH 2 , O, or NH;
  • Ri, R2-R5, R6a, R 6 b, R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • Ri, R2-R5, 6a, R 6 b, R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, Ci-C alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C 3 -C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo; and
  • R2-R5, R 6a , R6b, R7-R11, Ri2a and Ri 2 b are as defined above in the sixth aspect of the invention, or
  • Ri is Q-Ce alkylene-4,4-difluoro-l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, R7-R11, Ri2a and Ri 2 b are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C 3 -C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen or halo
  • R 6a , R 6b , and R7-R11 and Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
  • Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, 6 a, R 6 b, R7-R11, Ri2a and Ri2b are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O; B is selected from CH or N;
  • Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C 3 -C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6 a, 6b , and R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
  • Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, 6a, R 6 b, R7-R11, Ri2a and Ri2b are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene-
  • Ci-C 6 alkylene-p-fluoro-phenyl Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C 3 -C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R7-R11 are each independently selected from hydrogen, OH, NO2, CHO, SO2, SO 3 H, halo, Ci-Cs alkyl, or Ci-C 8 alkoxy, or
  • Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, 6 a, R 6b , and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from Ci-C 8 alkyl, Ci-C 8 bromoalkyl, Ci-C 8 fluoroalkyl, C1-C6 alkylene-
  • Ci-C 6 alkylene-p-fluoro-phenyl Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R7-R11 are each independently selected from hydrogen, OH, NO2, CHO, SO2, SO3H, halo, methyl, ethyl, n-propyl, methoxy, or ethoxy, or
  • Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, Ci-C 6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R7-R11 are each independently selected from hydrogen, halo, methyl, ethyl, n-propyl, methoxy, or ethoxy, or a pharmaceutically acceptable salt or prodrug thereof.
  • Ri is Ci-C 6 alkylene-4,4-difluoro- l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, R 6b , and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
  • R7-R11 are each independently selected from hydrogen or halo, or
  • Ri is Ci-C 6 alkylene-4,4-difluoro- l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6a , R 6b , and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, Ci-C 6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, heterocyclyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen; R 6a and R 6 are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring; and
  • R7, Rs, Rio, and Rn are hydrogen, or
  • Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and Rg b together form a cyclopropyl ring;
  • Rg is fluoro
  • R7, Rs, Rio, and Rn are hydrogen, or
  • Ri is C1-C6 alkylene-4,4-difluoro-l-cyclohexyl
  • Yi, Y2, B, R2-R5, R 6 a, 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from Ci-C 6 alkyl, C1-C6 bromoalkyl, Ci-C 6 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Cio aryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6b are each independently selected from methyl or R 6a and Rg together form a cyclopropyl ring;
  • R9 IS fluoro
  • R7, Rs, Rio, and Rn are hydrogen, or
  • Ri is Q-Ce alkylene-4,4-difluoro- l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
  • Rg is fluoro
  • R7, Rg, Rio, and Rn are hydrogen, or
  • Ri is methylene-4,4-difluoro- l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R6a, R 6b , and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, Ci-C alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, heterocyclyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R7- R11 are hydrogen, or
  • Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C 6 alkylene-cycloheptanyl, Ci-C 6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and Rg together form a cyclopropyl ring;
  • R7- R11 are hydrogen, or
  • Ri is Ci-C 6 alkylene-4,4-difluoro-l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S; Y 2 is selected from NH or O;
  • B is selected from CH or N;
  • Ri is selected from Ci-C 6 alkyl, Ci-C 6 bromoalkyl, Ci-C 6 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C 6 alkylene-p-fluoro-phenyl, Ci-C 6 alkylene-adamantyl, Ci-C 6 alkylene-N-methyl-2-piperidinyl, Ci-C alkylene-cycloheptanyl, Ci-C alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C 6 alkylene-tetrahydropyranyl, C 6 -Cio aryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • R7- R11 are hydrogen, or
  • Ri is C1-C0 alkylene-4,4-difluoro-l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is selected from CH or N;
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and Rg together form a cyclopropyl ring;
  • R7- R11 are hydrogen, or
  • Ri is methylene-4,4-difluoro- l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S; Y 2 is selected from NH or O;
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 b together form a cyclopropyl ring;
  • Rg is fluoro
  • R7, Rs, Rio, and Rn are hydrogen, or
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is CH
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl or R 6a and R 6 together form a cyclopropyl ring;
  • Rg is fluoro
  • R7, Rg, Rio, and Rn are hydrogen, or
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S; Y 2 is selected from NH or O;
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl
  • R7, Rs, Rio, and Rn are hydrogen, or
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R6a, R 6 b > and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is CH
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl
  • Rg is fluoro
  • R 7 , Rs, Rio, and Rn are hydrogen, or
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b together form a cyclopropyl ring
  • R9 IS fluoro
  • R7, Rs, Rio, and Rn are hydrogen, or
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is CH
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b together form a cyclopropyl ring
  • R9 IS fluoro
  • R7, Rg, Rio, and Rn are hydrogen, or
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
  • R7- R11 are hydrogen, or
  • Ri is methylene-4,4-difluoro- l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R6a > R 6b , and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is CH
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6b are each independently selected from methyl or R 6a and R 6b together form a cyclopropyl ring;
  • R7- R11 are hydrogen, or
  • Ri is methylene-4,4-difluoro- l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6a , R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl
  • R7- R11 are hydrogen, or
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • B is CH
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b are each independently selected from methyl
  • R7- R11 are hydrogen, or
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R 6 a, 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y2 is selected from NH or O
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b together form a cyclopropyl ring; and R 7 - Rii are hydrogen, or
  • Ri is methylene-4,4-difluoro-l-cyclohexyl
  • Yi, Y 2 , B, R2-R5, 6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • Yi is selected from O or S;
  • Y 2 is selected from NH or O
  • B is CH
  • Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
  • R2-R5 are hydrogen
  • R 6a and R 6 b together form a cyclopropyl ring
  • R7- R11 are hydrogen, or
  • Ri is methylene-4,4-difluoro-l -cyclohexyl
  • Yi, Y 2 , B, R2-R5, R6a, R 6 b, and R7-R11 are as defined in the preceding embodiment.
  • the compound of the invention is SGT-23, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is SGT-24, or a pharmaceutically acceptable salt or prodrug thereof
  • the compound of the invention is SGT-25, or a pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is SGT-41, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is SGT-42, or a pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is SGT-55, or a pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is SGT-56, or a pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is SGT-60, or a pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is SGT-65, or a pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is SGT-67, or a pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is acceptable salt or prodrug thereof.
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the com ound of the invention is
  • the compound of the invention is any pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is any pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is any pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is any pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the compound of the invention is selected from the group comprising: SGT-23, SGT-24, SGT-25, SGT-41, SGT-42, SGT-55, SGT-56, SGT-60, SGT-65, SGT-67, MJ1-MJ12, MJ14, and MJ15, or a pharmaceutically acceptable salt or prodrug thereof.
  • the compound of the invention is selected from the compounds listed in Tables 1, 2, and 3 in the Examples, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is selected from the compounds listed in Tables 1 and 2 in the Examples, or a pharmaceutically acceptable salt or prodrug thereof.
  • Asymmetric centres may exist in the compounds of the invention.
  • the asymmetric centres may be designated by the symbols "R” or “S”, depending on the configuration of substituents in three dimensional space at the chiral carbon atom. All stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and 1- isomers, and mixtures thereof of the compounds are contemplated herein.
  • Individual enantiomers of the compounds can be prepared synthetically from commercially available enantiopure starting materials or by preparing enantiomeric mixtures of the compounds and resolving the mixture into individual enantiomers.
  • Resolution methods include conversion of the enantiomeric mixture into a mixture of diastereomers and separation of the diastereomers by, for example, recrystallisation or chromatography; direct separation of the enantiomers on chiral chromatographic columns; and any other appropriate method known in the art.
  • d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory.
  • a compound prefixed with (+) or d is dextrorotatory.
  • these stereoisomers are identical except that they are mirror images of one another.
  • a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
  • a 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereo specificity in a chemical reaction or process.
  • racemic mixture and racemate refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
  • the compounds of the invention may also exist as geometric isomers. All cis, trans, syn, anti,
  • Z) isomers, as well as the appropriate mixtures thereof of the compounds are contemplated herein.
  • the compounds may also exist as tautomers, for example, keto/enol; imine/enamine;
  • the compounds may also exist as isotopologues and isotopomers, wherein one or more atoms in the compounds are replaced with different isotopes.
  • Suitable isotopes include, for example, 2 H (D), 3 H (T), 12 C, 13 C, 14 C, 16 0, and ls O.
  • the compounds may exist in solvated or unsolvated forms. If the solvent is water, the solvate may be referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, or a tri-hydrate. All solvates of the compounds are contemplated herein.
  • Salts of the compounds of the invention include, for example, acid addition salts, base addition salts, and quaternary salts of basic nitrogen-containing groups.
  • Acid addition salts can be prepared by reacting compounds, in free base form, with inorganic or organic acids.
  • inorganic acids include, but are not limited to, hydrochloric; hydrobromic; hydroiodic; nitric; carbonic; sulfuric; and phosphoric acid.
  • organic acids include, but are not limited to, cholic; sorbic; lauric; acetic; trifluoroacetic; formic; propionic; succinic; glycolic; gluconic; digluconic; lactic; malic; tartaric; citric; ascorbic; glucuronic; maleic; fumaric; pyruvic; aspartic; glutamic; aryl carboxylic; anthranilic acid; mesylic; stearic; salicylic; phenylacetic; mandelic; embonic (pamoic); alkylsulfonic; ethanesulfonic; arylsulfonic; benzenesulfonic; pantothenic; sulfanilic;
  • cyclohexylaminosulfonic ⁇ -hydroxybutyric; galactaric; galacturonic; adipic, alginic; butyric; camphoric; camphor sulfonic; cyclopentanepropionic; dodecylsulfic; glycoheptanoic;
  • glycerophosphic heptanoic; hexanoic; nicotinic; 2-naphthalesulfonic; oxalic; palmoic;
  • pectinic 3-phenylpropionic; picric; pivalic; thiocyanic; tosylic; and undecanoic acid.
  • Base addition salt can be prepared by reacting compounds, in free acid form, with inorganic or organic bases.
  • base addition salts include metal salts and organic salts.
  • Preferred metal salts include alkali metal salts, alkaline earth metal salts, and other physiologically acceptable metal salts.
  • the metal salt comprises aluminium, calcium, lithium, magnesium, potassium, sodium, or zinc.
  • Organic salts may be made from amines, such as trimethylamine, diethylamine, N,N-dibenzylethylenediamine,
  • chloroprocaine ethanolamine, diethanolamine, ethylenediamine, meglumine ( ⁇ - methylglucamine), and procaine.
  • LG is an appropriate leaving group and includes halo, tosyl, triflate, mesyl, and any other highly stabilised anionic leaving group.
  • Such leaving groups are known to those of skill in the art.
  • ⁇ means azobisisobutyronitrile.
  • NBS N-bromo succinimide.
  • DCM dichloromethane (CH 2 CI 2 ).
  • Et means ethyl.
  • EtOAc means ethylacetate.
  • Me means methyl (-CH 3 ).
  • MeOH means methanol.
  • MeCN means acetonitrile.
  • Pr means propyl.
  • i-Pr means isopropyl (-CH(CH 3 )2).
  • i-PrOH means isopropanol.
  • rt means room temperature.
  • THF means tetrahydrofuran.
  • TLC means thin layer chromatography.
  • protecting groups include prodrug moieties and chemical protecting groups.
  • PG Protecting groups
  • PG are optionally used to prevent side reactions with the protected group during synthetic procedures, i.e. routes or methods to prepare the compounds of the invention. For the most part the decision as to which groups to protect, when to do so, and the nature of the chemical PG will be dependent upon the chemistry of the reaction to be protected against (e.g., acidic, basic, oxidative, reductive or other conditions) and the intended direction of the synthesis.
  • the PG groups do not need to be, and generally are not, the same if the compound is substituted with multiple PG.
  • PG will be used to protect functional groups such as carboxyl, hydroxyl, thio, or amino groups and to thus prevent side reactions or to otherwise facilitate the synthetic efficiency.
  • PGs for -OH groups include "ether- or ester-forming groups”.
  • Ether- or ester-forming groups are capable of functioning as chemical PGs in the synthetic schemes set forth herein.
  • some hydroxyl and thio PGs are neither ether- nor ester-forming groups, as will be understood by those skilled in the art, and are included with amides, discussed below.
  • phosphonamidate esters phosphorothioate esters, phosphonate esters, and phosphon-bis- amidates
  • carboxyl ester- forming groups and (3) sulphur ester- forming groups, such as sulphonate, sulfate, and sulfinate.
  • the compounds of the invention may be synthesised according to the general methods described below.
  • Compounds of formula (Ha), (lib), and (lid) can be either obtained from commercial suppliers or synthesised as needed.
  • many compounds of formula (lib) wherein LG is halo, for example bromo are commercially available.
  • compounds of (lib) may be prepared from their corresponding alcohols.
  • compounds of formula (lib) wherein LG is, for example, tosyl or mesyl may be prepared from the corresponding alcohol by reaction with p-toluene sulfonyl chloride or methane sulfonyl chloride and a base such as triethylamine in dichloromethane.
  • a compound of formula (Ila) together with an appropriate base, such as sodium hydride is stirred in an anhydrous solvent at 0°C.
  • a solution containing compound (lib) in an anhydrous solvent is added dropwise to the solution containing the compound of formula (Ila), and the resulting mixture is stirred at 0°C for at least 30 minutes, after which the mixture is allowed to return to room temperature and stirred for a further 30 minutes.
  • Suitable reaction conditions would be known to one of skill in the art or could be found in /. Med. Chem. 1991 ; 34(3): 1099- 1110 and Bioorg. Med. Chem. Lett. 1994; 4(4): 563-566.
  • the compound of formula (lie) is isolated via standard work up procedures known to those of skill in the art. For example, an organic solvent and water is added to the reaction mixture containing the compound of formula (lie). The aqueous phase is extracted with an organic solvent and the combined organic extracts washed with brine, separated, and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, crystallisation, or preparative HPLC.
  • a solution containing a halogenating agent, such as thionyl chloride, oxalyl chloride, or phosphorous oxychloride, in an anhydrous solvent is added dropwise to a stirred solution of compound (lie) in the same anhydrous solvent at 0°.
  • a stirred solution of compound (lie) in the same anhydrous solvent at 0°.
  • the resulting mixture is stirred at 0°C for at least 30 minutes, returned to room temperature, and stirred for at least 30 minutes.
  • the mixture is then cooled to 0°C.
  • a solution containing compound (lid) and a base such as triethylamine or
  • the first step of the synthesis is as described above with respect to General method A.
  • an activating agent such as N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU) or ⁇ , ⁇ -dicyclohexylcarbodiimide (DCC)
  • HBTU N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l- yl)uronium hexafluorophosphate
  • DCC ⁇ , ⁇ -dicyclohexylcarbodiimide
  • the reaction mixture is allowed to warm to room temperature and then stirred for 12 hours.
  • a base such as diisopropylethylamine is added to reaction mixture following the addition of the activating agent.
  • the order of addition of the reagents may be varied, as appropriate.
  • Standard work-up and, optionally, purification provide the compound of formula (He).
  • the reaction mixture is filtered through Celite, concentrated under reduced pressure , and then purified by column chromatorgraphy and then crystallisation from an appropriate solvent or mixture of solvents, for example a mixture of hexane-ethyl acetate.
  • General method C Compounds of formula (He) can also be prepared using the synthetic route detailed in Scheme IB, in which R l5 R2-R5, R6 a -R6c > Yi, Y 2 , and B are as defined for the compounds of the invention and LG is an appropriate leaving group.
  • a compound of formula (Ila) is coupled with a compound of formula (lid).
  • the compound of formula (Ila) is treated with a suitable activating agent, for example N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU), in an ahydrous aprotic organic solvent, typically N,N-dimethylformamide (DMF), at ambient temperature under an atmosphere of argon.
  • a suitable activating agent for example N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU)
  • HBTU ahydrous aprotic organic solvent
  • DMF N,N-dimethylformamide
  • activating agents may be used, depending on the nature and reactivity of the compound of formula (lib).
  • compounds of formula (lib) wherein one or more of R2-R5 is halo for example fluoro
  • N,N- dicyclohexylcarbodiimide (DCC) may be used as the activating agent.
  • DCC N,N- dicyclohexylcarbodiimide
  • a wide range of activating agents are known in the art for activating, for example, carboxylic acid groups for reaction with alcohols and amines.
  • a base such as triethylamine or diisopropylamine
  • a base is then added dropwise at ambient temperature over suitable period of time, for example 2 hours.
  • the period of time over which the base is added may depend on the scale of the reaction.
  • reaction mixture is then stirred at ambient temperature for 15 hours before gradually heating to 120°C, for example at 25°C per hour, and then heating at 120°C for 3 hours.
  • the progress of the reaction may be monitored by any suitable means known in the art, for example thin layer chromatography or HPLC.
  • Standard workup and, optionally, purification provides the compound of formula (X).
  • the reaction mixture is allowed to cool, the solvent removed under reduced pressure, and then saturated sodium carbonate solution added and resultant mixture cooled to below 5°C to form a precipitate.
  • the precipitate is filtered and washed with water, triturated with saturated sodium carbonate solution, and then filtered and washed again with water. Finally, toluene is added and then evaporated to provide the compound of formula (X).
  • reaction is carried out by combining the compound of formula (X) and anhydrous potassium carbonate in a suitable solvent, for example anhydrous DMF, and then adding the compound of formula (lib) at ambient temperature. The reaction mixture is then heated at 70°C for 15 hours.
  • a suitable solvent for example anhydrous DMF
  • Standard workup and, optionally, purification provides the compound of formula (He).
  • the reaction mixture is allowed to cool, the solvent removed under reduced pressure, and then ethyl acetate added.
  • the mixture is then poured onto ice and, once the ice has melted, the organic layer separated.
  • the aqueous layer is then extracted with ethyl acetate, and the combined organic extracts washed with sodium carbonate solution, then dried over sodium sulfate and filtered.
  • the solvent is removed, ethyl acetate added and the solution passed through silica. Fractions containing the compound of formula (He) are combined and the solvent removed to provide the desired compound.
  • Other workup and purification methods may be used, as appropriate.
  • a compound of formula (IIIc) can be prepared using the synthetic route detailed in Scheme 2, in which, Ri, R2-R5, R6 a -R6c > Y 2 , and B are as defined for the invention, and LG is an appropriate leaving group.
  • Compounds of formula (Ilia), (lib), and (lid) can be either obtained from commercial suppliers or synthesised as needed.
  • a compound of formula (Ilia) together with an appropriate base, such as sodium hydride, is stirred in an anhydrous solvent at 0°C.
  • a solution containing compound (lib) in an anhydrous solvent is added dropwise to the solution containing the compound of formula (Ilia), and the resulting mixture is stirred at 0°C for at least 30 minutes, after which the mixture is allowed to return to room temperature and stirred for a further 30 minutes.
  • the compound of formula (Illb) is isolated as an oil via standard work up procedures known to those of skill in the art. For example, an organic solvent and water is added to the reaction mixture containing the compound of formula (Illb). The aqueous phase is extracted with an organic solvent and the combined organic extracts washed with brine, separated, and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, or preparative HPLC.
  • a solution containing compound (Illb), AIBN, and NBS in a halogenated solvent and acid is stirred at room temperature for at least five minutes, and then irradiated for at least 4 hours.
  • Water may be added and the mixture extracted with a halogenated solvent.
  • the compound of formula (IIIc) is isolated as an oil via standard work up procedures known to those of skill in the art. For example, a halogenated solvent and water is added to the reaction mixture containing the compound of formula (IIIc).
  • the aqueous phase is extracted with a halogenated solvent and the combined organic extracts washed with brine, separated and dried over anhydrous magnesium sulfate.
  • the combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, or preparative HPLC.
  • the compounds of the invention may also be synthesised according to the schemes described below using the techniques set out in general methods A and B and using reaction conditions known to those of skill in the art.
  • Ri, R2-R5, R6a-R6c, PG, and B are as defined for the invention, and LG is an appropriate leaving group.
  • compositions of the invention comprise one or more compounds of the present invention, together with one or more acceptable carriers and optionally other therapeutic ingredients.
  • the carriers must be "acceptable” in the sense of being compatible with the other ingredients of the composition and physiologically innocuous to the recipient.
  • the carrier must also be suitable for the mode of administration of the active agent.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof and a
  • compositions containing the active ingredient may be in any form suitable for the intended method of administration.
  • Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration.
  • gel, caps, tablets, troches, lozenges, aqueous or oil When used for oral use for example, gel, caps, tablets, troches, lozenges, aqueous or oil
  • compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions.
  • Such compositions may contain one or more agents including sweetening agents, flavouring agents, colouring agents and preserving agents, in order to provide a palatable preparation.
  • the compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain carriers, excipients, glidants, fillers, binders and the like. Aqueous compositions are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All compositions will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986), herein incorporated by reference in its entirety.
  • Carriers and excipients include methylsulfonylmethane (MSM), 2-hydroxypropyl beta-cyclodextrin, mannitol, ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like.
  • the pH of the compositions ranges from about 3 to about 11, but is ordinarily about 7 to 10.
  • the compound of the invention may exist in a suspension.
  • Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorb
  • the aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more colouring agents, one or more flavouring agents and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives such as ethyl or n-propyl p-hydroxy-benzoate
  • colouring agents such as ethyl or n-propyl p-hydroxy-benzoate
  • flavouring agents such as sucrose or saccharin.
  • sweetening agents such as sucrose or saccharin.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives.
  • a dispersing or wetting agent e.g., a suspending agent
  • Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.
  • Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oil suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents, such as those set forth herein, and flavouring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
  • Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate.
  • the emulsion may also contain sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such compositions may also contain a demulcent, a preservative, a flavouring or a colouring agent.
  • sweetening agents such as glycerol, sorbitol or sucrose.
  • Such compositions may also contain a demulcent, a preservative, a flavouring or a colouring agent.
  • the oily phase of the emulsions may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat.
  • the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax
  • the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of cream compositions.
  • Emulgents and emulsion stabilisers suitable for use in the composition of the invention include Tween® 20 or 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
  • Oral compositions include Tween® 20 or 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
  • the composition of the invention is an oral composition.
  • the composition is in the form of a pill, tablet, or dragee.
  • a tablet is made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable carrier, which is suitable for manufacture of tablets.
  • non-toxic pharmaceutically acceptable carrier may be, for example, inert diluents, such as 2-hydroxypropyl beta-cyclodextrin, methylsulfonylmethane (MSM), mannitol, calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatine or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including
  • the composition of the invention comprises methylsulfonylmethane (MSM) as the carrier.
  • MSM methylsulfonylmethane
  • the composition of the invention comprises 2- hydroxypropyl beta-cyclodextrin as the carrier.
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules (gel caps), cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be administered as a bolus, electuary or paste.
  • compositions for oral use may be also presented as hard gelatine capsules (gel caps) where the active ingredient is mixed with an inert solid carrier, for example methylsulfonylmethane (MSM), 2-hydroxypropyl beta-cyclodextrin, mannitol, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • MSM methylsulfonylmethane
  • 2-hydroxypropyl beta-cyclodextrin mannitol
  • mannitol calcium phosphate or kaolin
  • an oil medium such as peanut oil, liquid paraffin or olive oil.
  • an oral pharmaceutical composition of the invention is prepared as follows: a compound of the invention is dissolved in a solvent, such as acetone or diethyl ether, and is mixed with a suitable diluent at a ratio of active ingredient:diluent of 1:99.
  • suitable diluents include those that are approved for use in food, dietary supplements, or tabletting, and may include 2-hydroxypropyl beta-cyclodextrin, mannitol or
  • methylsulfonylmethane more preferably methylsulfonylmethane.
  • Optional carriers and/or excipients may also be added. The solvent may then be removed.
  • the resulting powder may be then divided up into capsules or pressed into tablets.
  • compositions suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 ⁇ (including particle sizes in a range between 0.1 and 500 ⁇ in increments such as 0.5 ⁇ , 1 ⁇ , 30 ⁇ , 35 ⁇ , etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs.
  • Suitable compositions include aqueous or oily solutions of the active ingredient.
  • Compositions suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other suitable therapeutic agents.
  • an inhalable composition of the invention comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.
  • an inhalable composition of the invention is prepared as follows: a compound of the invention is dissolved in a solution of water and propylene glycol, and optionally a surfactant, a fungicide, and/or a bacteriostatic agent.
  • the ratio of propylene glycohwater may be in the range of 0.5: 10 to 3: 10, preferably 1.5: 10.
  • the ratio of surfactant:water may be in the range of 0.001: 10 to 0.5:10, preferably 0.05:10.
  • the surfactant, if present may be Tween 20.
  • a compound of the invention is dissolved initially in propylene glycol with stirring.
  • a surfactant, a fungicide, and/or a bacteriostatic agent is then added followed by water.
  • the mixture is heated with stirring to ensure the compound of the invention dissolves into solution.
  • the mixture is administered nasally.
  • An e-cigarette is an electronic inhaler that vaporises a liquid solution (e-liquid) into an aerosol mist, simulating the act of tobacco smoking.
  • the invention provides an e-liquid comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.
  • the e-liquid is a mixture of propylene glycol and glycerine, preferably vegetable glycerine.
  • the e-liquid has a preferred ratio of propylene glycokglycerine may be from 1:1 to 4: 1, more preferably 3:2.
  • the e-liquid further comprises a flavour enhancer, such as Tasty Puff or similar.
  • the e-liquid optionally includes a surfactant to enhance solubility.
  • the surfactant may be present at a concentration of between 0.01% and 5% by weight, more preferably 0.5% by weight.
  • the surfactant may be chosen from the group consisting of Triton X- 100, Tween 20 and Tween 60, more preferably Tween 20.
  • an e-liquid of the invention may be prepared as follows: the compound of the invention is dissolved in propylene glycol, which may be at room temperature or heated. Preferably, the propylene glycol is heated to 60-90 °C, preferably 80 0 C, with stirring until the compound of the invention is in solution.
  • Vegetable glycerine and optionally a surfactant, is added with stirring, and the mixture is allowed to slowly return to room temperature. The mixture may be filtered. A smoking composition is intended to be smoked in a cigarette or pipe.
  • the invention provides a smoking composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.
  • a smoking composition of the invention is prepared as follows: the compound of the invention is dissolved in acetone and then mixed with a base herb in a large mixing machine.
  • the base herb is selected from damiana, marshmallow, mugwort, passionflower, lion's tail, blue lotus, calea zacatechichi and salvia divinorum, more preferably damiana.
  • food colours are added to the acetone solution to colour the final product.
  • the mixture is mixed for approximately 30-60 minutes, preferably approximately 40 minutes to ensure even distribution of the compound of the invention through the base herb.
  • the wet mixture is dried to remove the acetone.
  • the dry mixture is then ready for packing and use.
  • the dry mixture is sprayed with flavouring agents, which are dissolved in a propylene glycol and/or ethanol base.
  • flavouring agents which are dissolved in a propylene glycol and/or ethanol base.
  • the mixture is mixed in a mixing machine after being sprayed with a flavouring agent, and then dried for approximately 30 minutes before packing and use.
  • a preferred blend contains 500g of the compound of the invention and 1kg of powdered food colour (e.g. Brilliant Blue) dissolved in 6 litres of acetone sprayed onto 25kg of damiana. The mixture is then dried over a 12 hour period before being sprayed with 2.5 litres of "Tasty Puff flavour liquid.
  • powdered food colour e.g. Brilliant Blue
  • compositions of the invention may be administered topically, for example in a cream.
  • the composition of the invention is a topical composition.
  • the composition is in the form of an ointment, cream, eye drop, or paste.
  • the choice of suitable oils or fats for a topical composition is based on achieving the desired cosmetic properties.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters.
  • the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
  • the topical compositions may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogues.
  • compositions suitable for administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
  • the active ingredient is preferably present in such compositions in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.
  • the compositions are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w.
  • the active ingredients may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredients may be formulated in a cream with an oil-in-water cream base.
  • compositions suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatine and glycerine, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • the composition of the invention is an oral topical composition, preferably the composition is in the form of a lozenge.
  • compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
  • a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned herein.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilised powder.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile fixed oils may conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid may likewise be used in the preparation of injectables.
  • the composition of the invention is an injectable composition.
  • compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • compositions for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray compositions containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Controlled release compositions of the invention may be presented as pessaries, tampons, creams, gels, pastes, foams or spray compositions containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Compounds of the invention can also be formulated to provide controlled release of the active ingredient to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the active ingredient. Accordingly, the invention also provides compositions comprising one or more compounds of the invention formulated for sustained or controlled release.
  • the composition of the invention is a time-release composition.
  • a time-release composition intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight: weight).
  • the pharmaceutical composition can be prepared to provide easily measurable amounts for administration.
  • an aqueous solution intended for intravenous infusion may contain from about 3 to 500 ⁇ g of the active ingredient per millilitre (ml) of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
  • compositions of the invention include those suitable for the foregoing administration routes.
  • the compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.), herein incorporated by reference in its entirety. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
  • the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • compositions are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
  • sterile liquid carrier for example water for injection
  • Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage compositions are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
  • compositions of this invention may include other agents conventional in the art having regard to the type of composition in question, for example those suitable for oral
  • administration may include flavouring agents.
  • the effective dose of an active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses) or against an active disease or condition, the method of delivery, and the pharmaceutical composition, and will be determined by the clinician using conventional dose escalation studies.
  • the effective dose can be expected to be from about 0.0001 to about 100 mg/kg body weight per day. Typically, from about 0.01 to about 10 mg kg body weight per day. More typically, from about 0.01 to about 5 mg/kg body weight per day. More typically, from about 0.05 to about 0.5 mg kg body weight per day.
  • the daily candidate dose for an adult human of approximately 70 kg body weight will range from 0.01 mg to 1000 mg, or between 0.05 mg and 500 mg, and may take the form of single or multiple doses.
  • the composition of the invention is in a dosage form which contains at least 0.001 mg of the compound of the invention, preferably 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, or 500 mg of the compound of the invention.
  • the composition of the invention is in a dosage form which contains 0.001-500 mg of the compound of the invention, preferably 0.005-500, 0.01-500, 0.05-500, 0.1-500, 0.2-500, 0.3-500, 0.4-500, 0.5-500, 0.6-500, 0.7-500, 0.8-500, 0.9-500, 1-500, 2- 500, 3-500, 4-500, 5-500, 6-500, 7-500, 8-500, 9-500, 10-500, 15-500, 20-500, 25-500, 30- 500, 35-500, 40-500, 45-500, 50-500, 60-500, 75-500, 80-500, 85-500, 90-500, 95-500, 100- 500, 110-500, 120-500, 130-500, 140-500, 150-500, 150-500, 160-500, 170-500, 180-500, 190-500, 200-500, 250-500, 300-500, 350-500, 400-500, or 450-500 mg of the compound of the compound
  • the dosage form is in an inhalable, topical, oral, smokable, or injectable dosage form.
  • the composition of the invention is an e-liquid which contains at least 0.1 mg/ml of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/ml of the compound of the invention.
  • the composition of the invention is an e-liquid which contains 0.1-200 mg/ml of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4-200, 5- 200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40-200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120- 200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190-200 mg/ml of the compound of the invention.
  • the composition of the invention is a smoking composition which contains at least 0.1 mg/g of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/g of the compound of the invention.
  • the composition of the invention is smoking composition which contains 0.1-200 mg/g of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4- 200, 5-200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40- 200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190-200 mg/g of the compound of the invention.
  • the composition of the invention is an inhalable composition which contains at least 1 mg/ml of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/g of the compound of the invention.
  • the composition of the invention is an inhalable composition which contains 0.1-200 mg/ml of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4-200, 5-200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40-200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190- 200 mg/ml of the compound of the invention.
  • the compounds of the invention bind to CBi and/or CB 2 receptors.
  • Compounds that bind to these receptors are known to have gastrointestinal, cardiovascular, and/or central nervous system activity.
  • the compound of the invention is a CBi and/or CB 2 receptor agonist.
  • the EC50 of the compound of the invention in a CBi and/or CB 2 receptor affinity assay is less than about 1000 ⁇ , 500 ⁇ , 250 ⁇ , 100 ⁇ , 50 ⁇ , 25 ⁇ , 10 ⁇ , 5 ⁇ , 3 ⁇ , 1 ⁇ , 750 ⁇ , 500 ⁇ , 400 ⁇ , 300 ⁇ , 200 ⁇ , 100 ⁇ , 90 ⁇ , 80 ⁇ , 70 ⁇ , 60 ⁇ , 50 ⁇ , 40 ⁇ , 20 ⁇ , 10 ⁇ , 9 ⁇ , 8 ⁇ , 7 ⁇ , 6 ⁇ , 5 ⁇ , 4 ⁇ , 3 ⁇ , 2 nM, 1 ⁇ , 0.9 ⁇ , 0.8 ⁇ , 0.7 ⁇ , 0.6 ⁇ , 0.5 ⁇ , 0.4 ⁇ , 0.3 ⁇ , 0.2 ⁇ , 0.1 ⁇ , 0.05 ⁇ , 0.01 ⁇ , 0.001 nM, or 0.0001 nM, and useful ranges may be selected between any of these values.
  • the EC50 is from about 0.0001 nM to about 1000 ⁇ , from about 0.0001 nM to about 100 ⁇ , from about 0.0001 to about 10 ⁇ , from about 0.001 nM to about 500 ⁇ , from about 0.001 nM to about 100 ⁇ , from about 0.001 nM to about 50 ⁇ , from about 0.001 nM to about 10 ⁇ , from about 0.001 nM to about 5 ⁇ , from about 0.01 nM to about 500 ⁇ , from about 0.01 nM to about 100 ⁇ , from about 0.01 nM to about 50 ⁇ , from about 0.01 nM to about 10 ⁇ , from about 0.01 nM to about 5 ⁇ , from about 0.05 nM to about 500 ⁇ , from about 0.05 nM to about 100 ⁇ , from about 0.05 nM to about 50 ⁇ , from about 0.05 nM to about 10 ⁇ , or from about 0.05 nM to about 5 ⁇ .
  • the CBi and/or CB 2 receptor affinity assay measures the effect of the compound on cAMP modulation using the HTRF detection method.
  • the CBi and/or CB 2 receptor affinity assay is substantially as described herein in the Examples. The inventors have advantageously found that certain compounds of formula (I) exhibit selective affinity for CBi and/or CB 2 .
  • the compound of the invention is a selective CBi and/or CB 2 receptor agonist.
  • the compound of the invention is selective for CBi and/or CB 2 over at least one G-protein coupled receptor or ligand-gated ion channel selected from the group consisting of adenosine Al, adenosine A2A, adenosine A3, adrenergic al, adrenergic a2, adrenergic ⁇ , adrenergic ⁇ 2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2, cholecystokinin CCK1, dopamine Dl, dopamine D2S, endothelin ETA, GABA (nonselective), galanin GAL2, chemokine CXCR2, chemokine CCR1, histamine HI, histamine H2, melatonin MT1, muscarininc Ml, muscarininc M2, muscarininc M3, tachykinin NK2, ta
  • the compounds is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000, or 10000 times more selective for CBi and/or CB 2 than for the G-protein coupled receptor or ligand-gated ion channel.
  • Selectivity may be measured by any suitable method known in the art, for example by comparing the Ki or EC50 of the compound for CBi and/or CB 2 with the Ki or EC50 of the compound for the G-protein coupled receptor or ligand-gated ion channel.
  • the compound has an inhibition of control specific binding of less than about 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% and/or a control specific binding of at least 40, 50, 60, 70, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% for at least one G-protein coupled receptor or ligand-gated ion channel selected from the group consisting of adenosine Al, adenosine A2A, adenosine A3, adrenergic al, adrenergic al, adrenergic ⁇ , adrenergic ⁇ 2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2, cholecystokinin CCK1, dopamine Dl, dop
  • the compound has an inhibition of control specific binding of less than about 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% and/or a control specific binding of at least 40, 50, 60, 70, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% for all of the aforementioned G-protein coupled receptors and ligand-gated ion channels.
  • control specific binding and/or control specific binding is measured using a reference radioligand for each G-protein coupled receptor and ligand- gated ion channel.
  • the reference radioligand is as defined in Table 6 below.
  • the invention relates to a use of a compound of the invention in the
  • the invention related to use of a compound of the invention in the manufacture for treating nausea and/or emesis in a subject.
  • the invention relates to a use of a compound of the invention in the manufacture of a medicament for stimulating appetite in a subject.
  • the invention relates to a use of a compound of the invention in the manufacture of a medicament for inducing a euphoric effect in a subject.
  • the invention relates to a use of a compound of the invention in the manufacture of a medicament for relaxing a subject in a subject.
  • the invention relates to a use of a compound of the invention in the manufacture of a medicament for inducing a positive mood change in a subject.
  • the invention in another aspect, relates to a method of treating pain in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
  • the invention relates to a method for treating nausea and/or emesis in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
  • the invention relates to a method for stimulating appetite in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
  • the invention relates to a method of inducing a euphoric effect in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
  • the invention relates to a method of relaxing a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
  • the invention relates to method of inducing a positive mood change in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
  • the invention in another aspect, relates to a compound of the invention for use in treating pain in a subject.
  • the invention relates to a compound of the invention for use in treating nausea and/or emesis in a subject. In another aspect, the invention relates to a compound of the invention for use in stimulating appetite in a subject.
  • the invention in another aspect, relates to a compound of the invention for use in inducing a euphoric effect in a subject.
  • the invention in another aspect, relates to a compound of the invention for use in relaxing a subject.
  • the invention in another aspect, relates to a compound of the invention for use in inducing a positive mood change in a subject.
  • the nausea and/or emesis is caused by injury, pain, cancer, AIDS, tuberculosis, glaucoma, menstruation, hepatitis, chemotherapy, radiotherapy, or headaches (such as muscle tension headaches, eyes strain headaches, migraines, or cluster headaches).
  • the appetite is stimulated to treat loss of appetite caused by wasting.
  • the wasting is caused by cystic fibrosis, anorexia, old age, cancer, AIDS, tuberculosis, chronic diarrhoea, or cachexia, preferably cancer cachexia.
  • the pain is selected from nociceptive pain, neuropathic pain, or psychogenic pain.
  • the nociceptive pain is caused by: inflammation, joint pain (such as arthritis, osteoarthritis, rheumatoid arthritis, or repetitive strain injury), headaches (such as muscle tension headaches, eyes strain headaches, migraines, or cluster headaches), back pain (such as back pain caused by slipped or bulging discs, spinal stenosis, compression fractures (such as those associated with osteoporosis), soft tissue damage, traumatic fractures, or structural deformities (such as scoliosis, kephosis, or lordosis)), fibromyalgia, surgery, or trauma.
  • joint pain such as arthritis, osteoarthritis, rheumatoid arthritis, or repetitive strain injury
  • headaches such as muscle tension headaches, eyes strain headaches, migraines, or cluster headaches
  • back pain such as back pain caused by slipped or bulging discs, spinal stenosis, compression fractures (such as those associated with osteoporosis), soft tissue damage, traumatic fractures, or structural
  • the neuropathic pain is caused by: multiple sclerosis, phantom limb pain, peripheral (diabetic) neuropathy, post-mastectomy pain, sciatica, spinal cord injury (such as bulging or slipped discs or trauma), carpel tunnel syndrome, cancer, radiotherapy, chemotherapy, radiation injury, surgery, or HIV- associated peripheral neuropathy.
  • the psychogenic pain is caused by: headache, muscle pain, back pain, or stomach pain.
  • the pain is atypical or neuropathic pain.
  • the pain is phantom limb pain.
  • One or more compounds of the invention (herein also referred to as the active ingredients) are administered by any route appropriate to the condition to be treated.
  • Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with, for example the condition of the recipient.
  • An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.
  • SGT-24 was synthesised according to Scheme 1 (as shown above).
  • l-Pentyl-lH-indazole-3-carboxylic acid (lie) was prepared by reaction of commercially available indazole-3-carboxylic acid (Ila) with 1-bromopentane (lib) in the presence of sodium hydride in dimethylformamide. Reaction conditions were as set out in J. Med. Chem. 1991; 34(3): 1099-1110 and Bioorg. Med. Chem. Lett. 1994; 4(4): 563-566.
  • Oxalyl dichloride (5.74 g, 45.2 mmol) was slowly added to a stirred solution of 1-pentyl-lH- indazole-3-carboxylic acid (10.0 g, 43.0 mmol) in dichloromethane (100 mL) at 0°C in an ice-bath. The reaction was stirred for 30 minutes. Triethylamine (9.0 mL, 64.58 mmol) was then added, followed by 2-phenylpropan-2-amine (5.82g, 43.0 mmol). The reaction was stirred for 1 hour and monitored by TLC. The reaction was diluted with water and separated into phases.
  • N,N-diisopropylethylamine (215 mL, 2.0 molar eq.) drop wise over a period of at least 2 hours.
  • the reaction mixture was then stirred for at least 15 hours at ambient temperature under an argon blanket.
  • the reaction mixture was the gradually heated in increments of 25 °C per hour up to an internal temperature of 120°C. Once the reaction mixture reached 120°C, it was continuously heated at an internal temperature of 120°C for at least 3 hours.
  • the reaction mixture was rotary evaporated to remove the DMF that a bath temperature of 80°C under reduced pressure.
  • the crude product was placed in an ice bath and mixed with saturated sodium carbonate solution (10 volumes, 1 L).
  • the resultant mixture was continuously stirred and the ice bath until the internal temperature dropped below 5°C.
  • a beige coloured precipitate formed that was filtered and washed with cold purified water (10 x 2.5 volumes, 10 x 250 mL).
  • the wet filter cake was then triturated in saturated sodium carbonate solution (5 volumes, 500 mL) for at least one hour at room temperature.
  • the suspension was then filtered and rinsed with purified water (5 1 volume, 5 x 100 mL).
  • the resultant product was dried under air vacuum, and then co-evaporated with toluene four times prior to final drying on a rotary evaporator with a bath temperature of 60°C to constant weight.
  • the evaporated residue was mixed with ethyl acetate (5 volumes) and then poured into ice (5 weight equivalents). The mixture was stirred until the ice melted. The bilayer was separated and the aqueous layer extracted with ethyl acetate (4 x 3 volumes). The combined extracts were washed with 50% saturated sodium carbonate solution (4 x 1 volume), then dried over sodium sulfate and filtered. The filtrate was evaporated at a 40° bath temperature and co-evaporated with ethyl acetate (3 x 2.5 volumes). The resultant residue was redissolved and hot ethyl acetate (4 volumes) and filtered through 60 angstrom silica (2.5 volumes) topped with a layer of anhydrous sodium sulphate.
  • the filter bed was washed with hot ethyl acetate (2 volumes per fraction) until all of the product was released.
  • Product containing fractions were evaporated with a bath temperature of 40°C.
  • the crude product was triturated with methyl tert-butyl ether (MTBE)(2 volumes) at room temperature of the 2 hours, and then in an ice bath for one hour.
  • the suspension was filtered, then rinsed with cold MTBE (4 x 1 volume).
  • the resulting white solid was then dried under vacuum to constant weight, mp 112.7 ⁇ 0.5 .
  • SGT 174 was synthesized according to Scheme 1A (as shown above) by the following general procedure. Alkylation of an indole-3-carboxylic acid or indazole-3-carboxylic acid (Ha)
  • SGT 211 was synthesized according to Scheme 1A (as shown above) by the following general procedure. Alkylation of an indole-3-carboxylic acid or indazole-3-carboxylic acid (Ha) to provide the desired l-alkyl-indole-3-carboxylic acid or l-alkyl-indazole-3-carboxylic (lie) was carried out according to the general procedure described above for SGT 174.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates generally to cannabinoid compounds, more particularly indole and indazole compounds of formula I and la and pharmaceutical compositions comprising the compounds. The compounds are useful treating pain, treating nausea and/or emesis, stimulating appetite, inducing a euphoric effect, inducing relaxation, and inducing a positive mood change, in particular for treating pain, treating nausea and/or emesis, and stimulating appetite.

Description

CANNABINOID COMPOUNDS
1. FIELD OF THE INVENTION The present invention relates generally to cannabinoid compounds and compositions, more particularly new indole and indazole cannabinoids and compositions, and applications of these.
2. BACKGROUND OF THE INVENTION
Cannabinoids are a class of diverse chemical compounds that activate cannabinoid receptors. The broader definition of the term "cannabinoids" refers to a group of compounds that are structurally related to tetrahydrocannabinol (THC) or that bind to cannabinoid receptors. Such compounds include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (produced chemically by humans). The most notable cannabinoid is delta-9 THC, the primary psychoactive compound of cannabis. However, there are numerous other known synthetic and natural cannabinoids. Delta-9 THC, the principle active component of cannabis, is a member of a large family of cannabinoid compounds that mediate physiological and psychotropic effects including immunosuppression, analgesia, inflammation, emesis, and intraocular pressure.
Cannabinoids work through selective binding to G-protein coupled cannabinoid receptors. Two types of cannabinoid receptors have been cloned: CBi and CB2. The CBi receptor is found mainly on cells of the central nervous system, while the CB2 receptor is found mainly on cells of the peripheral nervous system including cells comprising the immune system, such as lymphoid cells.
Cannabinoid compounds that bind to CBi and/or CB2 receptors, such as delta-9 THC, are known to have gastrointestinal, cardiovascular, and/or central nervous system activity. Such compounds may, therefore, offer therapeutic approaches to a variety of diseases or conditions.
There is a need to provide alternatives to known cannabinoid compounds. It is an object of the invention to at least go some way towards meeting this need, and/or to at least provide the public with a useful choice.
In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.
3. SUMMARY OF THE INVENTION
In a first aspect, the present invention provides a compound of formula I,
Figure imgf000003_0001
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH,
(C=S)NH, SCH2, OCH2, CH2S02, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted; R2-R5 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NR12aRi2b, CONRi2aRi2b, halo, CrC8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Cr Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring; and
R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
Ri2a and Ri¾ are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In a second aspect, the present invention provides a compound of formula I,
Figure imgf000004_0001
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH,
(C=S)NH, SCH2, OCH2, CH2S02, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Q- Cs alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-Cs alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
R6c is selected from Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg haloalkyl, C2-Cs haloalkenyl, C2-C8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
Ri2a and Ri2b are each independently selected from hydrogen, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In a third aspect, the invention provides the present invention provides a compound of formula I,
Figure imgf000005_0001
wherein
R6a and R6b together form 3 to 7 membered heterocycle; and
Y, B, Ri, R2-R5, and R6c are as defined in first aspect above;
a pharmaceutically acceptable salt or prodrug thereof. In a fourth aspect, the invention provides the present invention provides a compound of formula I,
Figure imgf000006_0001
wherein
R6c is cyano; and
Y, B, Ri, R2-R5, R6a and R6b are as defined in the first aspect above;
a pharmaceutically acceptable salt or prodrug thereof. a fifth aspect, the invention the present invention provides a compound of formula la,
Figure imgf000006_0002
la
wherein
Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Q-Q alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or 3 to 7 membered heterocyclyl ring; and
Ri2a and R12b are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-Cg alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In a sixth aspect, the presen la la,
Figure imgf000007_0001
wherein
Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONR12aRi2b, COR12a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cg bromoalkyl, C2-Cg haloalkenyl, C2-Cg haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and Ri2a and Ri2b are each independently selected from hydrogen, Ci-Cg alkyl, C2-C8 alkenyl, C2-Cs alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In seventh aspect, the invention provides the present invention provides a compound of formula la,
Figure imgf000008_0001
R6a and R6b together form 3 to 7 membered heterocycle; and
Yi, Y2, B, Ri, R2-R5 and R7-R11 are as defined in fifth aspect above;
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the invention relates to a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.
In another aspect, the invention relates to a compound of the invention for use in treating pain in a subject.
In another aspect, the invention related to a compound of the invention for use in treating nausea and/or emesis in a subject. In another aspect, the invention relates to a compound of the invention for use in stimulating appetite in a subject. In another aspect, the invention relates to a compound of the invention for use in inducing a euphoric effect in a subject.
In another aspect, the invention relates to a compound of the invention for use in relaxing a subject.
In another aspect, the invention relates to a compound of the invention for use in inducing a positive mood change in a subject.
To those skilled in the art to which the invention relates, many changes in construction and widely differing embodiments and applications of the invention will suggest themselves without departing from the scope of the invention as defined in the appended claims. The disclosures and the descriptions herein are purely illustrative and are not intended to be in any sense limiting Other features of the invention may become apparent from the following description which is given by way of example only.
4. BRIEF DESCRIPTION OF THE DRAWINGS The invention will now be described with reference to the Figures in which:
Figure 1 shows a 1H NMR scan for the compound SGT-42.
Figure 2 shows a 13C NMR scan for the compound SGT-42. 5. DETAILED DESCRIPTION OF THE INVENTION
5.1 Definitions
As used herein "(s)" following a noun means the plural and/or singular forms of the noun. As used herein the term "and/or" means "and" or "or" or both. As used herein, the term "comprising" as used in this specification means "consisting at least in part of. When interpreting each statement in this specification that includes the term "comprising", features other than that or those prefaced by the term may also be present. Related terms such as "comprise" and "comprises" are to be interpreted in the same manner.
It is intended that reference to a range of numbers disclosed herein (for example, 1 to 10) also incorporates reference to all rational numbers within that range (for example, 1, 1.1, 2, 3, 3.9, 4, 5, 6, 6.5, 7, 8, 9 and 10) and also any range of rational numbers within that range (for example, 2 to 8, 1.5 to 5.5 and 3.1 to 4.7) and, therefore, all sub-ranges of all ranges expressly disclosed herein are hereby expressly disclosed. These are only examples of what is specifically intended and all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application in a similar manner.
The term "therapeutically effective amount", as used herein, means the amount of an active compound, or a material, composition, composition, or dosage form comprising an active compound, which is effective for producing some desired therapeutic or prophylactic effect, commensurate with a reasonable benefit/risk ratio. Therapeutically effective amounts can be determined using routine optimisation techniques well known in the art.
The term "pharmaceutically acceptable" as used herein in conjunction with the terms "salt", "prodrug", or "carrier" refers to compounds of the invention, ingredients, materials and the like, which are within the scope of sound medical judgment, suitable for use in contact with the tissues of a human without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier must also be "acceptable" in the sense of being compatible with the other ingredients of the composition. The term "treatment", and related terms, such as "treating" and "treat" as used herein, in the context of treating a condition, relates generally to treatment of a human, in which some desired therapeutic effect is achieved. The therapeutic effect may, for example, be the inhibition of progress of the condition, including a reduction in the rate of progress; a halt in the rate of progress of the condition; amelioration of the condition; and cure of the condition. Treatment as a prophylactic measure (i.e., prophylaxis) is also included. Treatment also includes combination treatments and therapies, in which two or more treatments or therapies are used, for example, sequentially or simultaneously, in combination. For example, a therapeutically effective amount of a compound of the invention could be combined with or used in conjunction with a known cannabinoid compound.
The term "cannabinomimetic" as used herein means having similar effects to the effects of cannabis when administered to a subject. The term "alkyl" means a saturated hydrocarbon radical containing normal, secondary, or tertiary carbon atoms. Examples of suitable alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1 -butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl- 1-propyl (i- Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl
(-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3 -methyl- 1 -butyl (-CH2CH2CH(CH3)2), 2-methyl- 1- butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl
(-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (- CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (- CH(CH3)C(CH3)3, and octyl (-(CH2)7CH3). The term "alkenyl" means a hydrocarbon radical containing normal, secondary, tertiary or cyclic carbon atoms with at least one double bond. Examples of suitable alkenyl groups include, but are not limited to, ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), cyclopentenyl (-C5H7), and 5-hexenyl (-CH2CH2CH2CH2CH=CH2). The term "alkynyl" means a hydrocarbon radical containing normal, secondary, tertiary or cyclic carbon atoms with at least one triple bond. Examples of suitable alkynyl groups include, but are not limited to, acetylenic (-C≡CH), propargyl (-CH2C≡CH), and the like. The term "cycloalkyl" means a hydrocarbon radical containing a saturated ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle. Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system, or spiro-fused rings.
The terms "cycloalkenyl" and "cycloalkynyl" have analogous meanings. The term "aryl" means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. For example, an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms. Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like.
The term "alkoxy" means a group having the formula -O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom. Examples of suitable alkoxy groups include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy
(-OCH2CH3 or -OEt), t-butoxy (-0-C(CH3)3 or -OtBu) and the like.
The term "halo" as used herein means iodo, bromo, chloro, or fluoro.
The term "haloalkyl" means an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halo group. Examples of suitable haloalkyl groups include, but are not limited to, -(CH2)nF, -CF3, -CHF2, -CFH2, -CH2CF3, and the like.
The terms "haloalkenyl" and "haloalkynyl" have analogous meanings. The term "optionally substituted" in reference to a particular moiety of the compound of the invention (e.g., an optionally substituted aryl group) refers to a moiety having 0, 1, 2, or more substituents. The term "substituted" in reference to alkyl, alkenyl, alkynyl, halogen, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl means alkyl, alkenyl, alkynyl, halogen, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent. Typical substituents include, but are not limited to, -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR, where each X is independently halo; and each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci-Cs alkyl, C3-Ci2 cycloalkyl, bridged C6-Ci2 cycloalkyl, halo or perhalo substituted C3-Ci2 cycloalkyl, a C3-Ci2 heterocycle, or a protecting group (PG). When the number of carbon atoms is designated for a substituted group, the number of carbon atoms refers to the group, not the substituent (unless otherwise indicated). For example, a C1-4 substituted alkyl refers to a C1-4 alkyl, which can be substituted with groups having more than the, e.g., 4 carbon atoms.
The term "prodrug" as used herein refers to any compound that when administered to a biological system generates the compound of the invention, i.e., active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalysed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s). A prodrug is thus a covalently modified analogue or latent form of a therapeutically active compound.
One skilled in the art will recognise that substituents and other moieties of the compounds of Formula I should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition. Compounds of the invention which have such stability are contemplated as falling within the scope of the present invention. The term "heteroalkyl" refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S. For example, if the carbon atom of the alkyl group which is attached to the parent molecule is replaced with a heteroatom (e.g., O, N, or S) the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., -OCH3, etc.), an amine (e.g., -NHCH3, -N(CH3)2, etc.), or a thioalkyl group (e.g., -SCH3). If a non-terminal carbon atom of the alkyl group which is not attached to the parent molecule is replaced with a heteroatom (e.g., O, N, or S) the resulting heteroalkyl groups are, respectively, an alkyl ether (e.g., -CH2CH2-O-CH3, etc.), an alkyl amine (e.g., -CH2NHCH3, -CH2N(CH3)2, etc.), or a thioalkyl ether (e.g.,-CH2-S-CH3). If a terminal carbon atom of the alkyl group is replaced with a heteroatom (e.g., O, N, or S), the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g., -CH2CH2-OH), an aminoalkyl group (e.g., -CH2NH2), or an alkyl thiol group (e.g., -CH2CH2-SH). A heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. A Ci-C6 heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
The terms "heterocycle" or "heterocyclyl" as used herein include by way of example and not limitation those heterocycles described in Paquette, Leo A.; Principles of Modern
Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and /. Am. Chem. Soc. (1960) 82:5566. The terms "heterocycle" and "heterocyclyl" include saturated rings (i.e., heterocycloalkyls), partially unsaturated rings, and aromatic rings {i.e., heteroaromatic rings). The terms "heterocycle" and "heterocyclyl" also include substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups. Examples of substituted heterocycles include, but are not limited to, 4,4-difluoro-l-piperidinyl and N-methyl-2-piperidinyl.
The term "heterocycle" or "heterocyclyl" employed alone or in combination with other terms means, unless otherwise stated, a saturated or unsaturated non-aromatic monocyclic heterocyclyl ring or a bicyclic heterocyclyl ring. Monocyclic heterocyclyl rings include monovalent 3-, 4-, 5-, 6-, or 7-membered rings containing one or more heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur in the ring. Monocyclic heterocyclyl groups are connected to the parent molecular moiety through any available carbon atom or nitrogen atom within the ring. Examples of monocyclic
heterocyclyl groups include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiopyranyl, and trithianyl.
Bicyclic heterocyclyl rings include monovalent monocyclic heterocyclyl rings fused to phenyl rings, cycloalkyl rings, or other monocyclic heterocyclyl rings. Bicyclic heterocyclyl groups are connected to the parent molecular moiety through any available carbon atom or nitrogen atom within the rings. Examples of bicyclic heterocyclyl groups include, but are not limited to, 1,3-benzodioxolyl, 1,3-benzodithiolyl, 2,3-dihydro-l,4-benzodioxinyl, 2,3- dihydro- 1 -benzofuranyl, 2,3-dihydro-l-benzothienyl, 2,3-dihydro-lH-indolyl, and 1,2,3,4- tetrahydroquinolinyl. In some embodiments the heterocyclyl is monocyclic. "Heteroaryl" refers to an aromatic heterocyclyl. Non-limiting examples of suitable heteroatoms which can be included in the aromatic ring include oxygen, sulphur, and nitrogen. Non-limiting examples of heteroaryl rings include pyridinyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc.
By way of example and not limitation, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan,
tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5- pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4- thiazolyl, or 5-thiazolyl.
The term "halogenating agent" includes phosphorous oxychloride, thionyl chloride, oxalyl chloride, phosphorous trichloride, phosphorous pentachloride, and diphosgene.
The term "halogenated solvent" includes chloroform, dichloromethane, and carbon tetrachloride. The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are
superimposable on their mirror image partner.
The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
"Diastereomer" refers to a stereoisomer with two or more centres of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
"Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
5.2 The compounds of the invention
The invention provides cannabinoid compounds that have a range of therapeutic activities including analgesic, anti-inflammatory, and anti-emetic. The compounds of the invention also have psychotropic effects so can be used as relaxants to induce positive mood change.
In one aspect, the present invention provides a compound of formula I,
Figure imgf000016_0001
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, (C=S)NH, SCH2, OCH2, CH2S02, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S); B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, CrC8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cg bromoalkyl, C2-Cg haloalkenyl, C2-Cg haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Q- Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-Cg haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
Ri2a and Ri¾ are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the present invention provides a compound of formula I,
Figure imgf000017_0001
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, (C=S)NH, SCH2, OCH2, CH2SO2, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C20 aryl, C3-C20 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -Br, -F, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R2-R5 are each independently selected from hydrogen, OH, NO2, CHO, SO2, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aR12b, halo, CrC8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Cr C8 alkoxy, C6-C20 aryl, C3-C2o cycloalkyl, C1-C20 heteroalkyl, C3-C2o heterocyclyl, or C6-C20 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring; and
R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C2o aryl, C6-C2o haloaryl, C3-C2o cycloalkyl, Ci-C2o heteroalkyl, C3-C2o heterocyclyl, C6-C2o heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; Ri2a and Ri2b are each independently selected from hydrogen, Ci-Cg alkyl, C2-C8 alkenyl, C2-Cs alkynyl, C6-C2o aryl, C3-C20 cycloalkyl, C1-C20 heteroalkyl, C3-C20 heterocyclyl, or C6-C20 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN,
-N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cg alkyl, C3-Ci2 cycloalkyl, bridged C6-Ci2 cycloalkyl, halo or perhalo substituted C3-Ci2 cycloalkyl, or a C3-Ci2 heterocycle; or
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the invention provides the present invention provides a compound of formula I,
Figure imgf000019_0001
wherein
R6a and R6b together form 3 to 7 membered heterocycle; and
Y, B, Ri, R2-R5, and R6c are as defined in preceding aspect;
a pharmaceutically acceptable salt or prodrug thereof.
In a fourth aspect, the invention provides the present invention provides a compound of formula I,
Figure imgf000020_0001
wherein
R6c is cyano; and
Y, B, Ri, and R2-R5 are as defined in the preceding aspect; and
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the present invention provides a compound of formula I,
Figure imgf000020_0002
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH,
(C=S)NH, SCH2, OCH2, CH2S02, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C2o aryl, C3-C20 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -Br, -F, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R2-R5 are each independently selected from hydrogen, OH, NO2, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Q- Cs alkoxy, C6-C20 aryl, C3-C20 cycloalkyl, C1-C20 heteroalkyl, C3-C20 heterocyclyl, or C6-C2o heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
R6c is selected from Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cs haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C20 aryl, C6-C20 haloaryl, C3-C20 cycloalkyl, C1-C20 heteroalkyl, C3-C2o heterocyclyl, or C6-C2o heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
Ri2a and R^b are each independently selected from hydrogen, Ci-Cg alkyl, C2-C8 alkenyl, C2-Cs alkynyl, C6-C2o aryl, C3-C2o cycloalkyl, Ci-C2o heteroalkyl, C3-C2o heterocyclyl, or C6-C2o heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
each X is independently halo; and each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl, bridged Cg-Ci2 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle; or
a pharmaceutically acceptable salt or prodrug thereof.
The following embodiments relate to any of the aspects relating to the compound of formula I above, as appropriate.
In one embodiment, Ri2aand Ri2b are each independently selected from hydrogen, Ci-Cg alkyl, or C6-Ci2 aryl, wherein each of said alkyl or aryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle. In one embodiment, Ri2aand Ri2b are each independently selected from hydrogen, Ci-C8 alkyl, or C6-C12 aryl.
In one embodiment, Ri2aand Ri2b are each independently selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, n-pentyl, or phenyl.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH, preferably Y is selected from (C=0)0, (C=S)0, S02CH2, S020, S02NH, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH, preferably Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH. In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, (C=S)NH, CH2(C=0), 0(C=0), CH2(C=0), or NH(C=0). In one embodiment, Y is selected from (C=0)0, (C=0)CH2, (C=0)NH, 0(C=0), CH2(C=0), or NH(C=0). In one embodiment, Y is selected from (C=0)0, (C=0)CH2, (C=0)NH, 0(C=0), CH2(C=0), or NH(C=0).
In one embodiment, Y is selected from (C=0)0, (C=0)CH2, (C=0)NH, or NH(C=0). In one embodiment, Y is selected from (C=0)0, (C=0)CH2, or (C=0)NH. In one embodiment, Y is selected from (C=0)0 or (C=0)NH. In one embodiment, Y is (C=0)NH.
In one embodiment, Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C3-Ci2 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(0H)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR,
-C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- C8 alkyl, C3-Ci2 cycloalkyl, bridged C6-Ci2 cycloalkyl, halo or perhalo substituted C3-Ci2 cycloalkyl, or a C3-Ci2 heterocycle.
In one embodiment, Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C3-Ci2 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-C12 fluoroaryl, C6-Ci2 aryl Cp
Cg alkyl, C3-C12 cycloalkyl, bridged C6-Ci2 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
In one embodiment, Ri is selected from Q-Cg alkyl, Q-Cg bromoalkyl, Ci-Cg fluoroalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, -Br, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-C12 fluoroaryl, C6-Ci2 aryl Ci- Cg alkyl, C3-C12 cycloalkyl, bridged C6-Ci2 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
In one embodiment, Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, -Br, -R, =0, -OR, -CX3, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -
S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cg alkyl, C3-C12 cycloalkyl, bridged C6-Ci2 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
In one embodiment, Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, Ci-Cg cyanoalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, Ci-C6 alkylene- C3-C12 cycloalkyl, Ci-C6 alkylene- C6-C12 aryl, Ci-C6 alkylene- C6-Ci2 fluoroaryl, Ci-C6 alkylene- C3-C12 heterocycle, CrC6 alkylene-C(=0)NRR;
wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl.
In one embodiment, Ri is selected from C1-C6 alkyl, Ci-C6 bromoalkyl, C1-C6 fluoroalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, Ci-C6 alkylene-3,3-difluoro- l-cyclohexyl, Ci-C6 alkylene-p- fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2-bicyclo[2.2.1]heptanyl, or Ci-C6 alkylene- tetrahydropyranyl, wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro- l-cyclohexyl.
In one embodiment, Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, 4-cyano-l -butyl, 3,3-dimethyl- 1-butyl, 1- hexyl, 1-heptyl, methylene cyclohexyl, methylene-4,4-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene-4- tetrahydropyranyl, methyleneC(0)NH(cyclohexyl), methyleneC(0)NH(t-butyl), 1-ethylene- 2-(N-morpholinyl), l-ethylene-2-(N-piperidinyl), and l-ethylene-2-(4,4-difluoro-N- piperidinyl).
In one embodiment, Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene cyclohexyl, methylene-3,3-difluoro- l-cyclohexyl, methylene-p-fluoro-phenyl, methylene- adamantyl, methylene-N-methyl-2-piperidinyl, methylene-cycloheptanyl, methylene-2- bicyclo[2.2.1]heptanyl, and methylene-4-tetrahydropyranyl.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl.
In one embodiment, R2-R5 are each independently selected from hydrogen, OH, NO2, CHO, S02, SO3H, NR12aRi2b, S02NR12aRi2b, CONR12aRi2b, halo, d-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg alkoxy, C6-Ci2 aryl, C3-C12 cycloalkyl, C1-C12 heteroalkyl, C3-C12 heterocyclyl, or C6-C12 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH,
-S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, R2 is hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-Ci2 aryl, C3-Ci2 cycloalkyl, C1-C12 heteroalkyl, C3-Ci2 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; and
R3-R5, X, and R are as defined in the preceding embodiment.
In one embodiment, R2 is hydrogen or halo; and
R3-R5, X, and R are as defined in the preceding embodiment.
In one embodiment, R2-R5 are each independently selected from hydrogen, SO2, NRi2aRi2b> S02NRi2a i2b, CONRi2aRi2b, halo, Ci-C8 alkyl, Ci-Cs alkoxy, wherein each of said alkyl or alkoxy may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; wherein each X is independently halo; and each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C§ heterocycle.
In one embodiment, R2 is hydrogen, S02, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, or CpCs alkyl, wherein each of said alkyl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; and
R3-R5, X, and R are as defined in the preceding embodiment.
In one embodiment, R2 is hydrogen or halo; and
R3-R5, X, and R are as defined in the preceding embodiment.
In one embodiment, R2-R5 are each independently selected from hydrogen or halo, preferably hydrogen.
In one embodiment, R6a and R6b are each independently selected from C1-C4 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring.
In one embodiment, R6a and R6b are each independently selected from C1-C4 alkyl or R6a and R6b together form a C3-C5 cycloalkyl ring, preferably methyl. In another embodiment, R6a and R6b together form a C3-C6 cycloalkyl ring, preferably cyclopropyl.
In one embodiment, R6a and R6b together form a 3 to 6 membered heterocyclyl ring.
In one embodiment, the heterocyclyl ring is a 5 or 6 membered ring.
In one embodiment, the heterocyclyl ring comprises from 3 to 6 carbon atoms, from 3 to 5 carbon atoms, or from 4 to 5 carbon atoms.
In one embodiment, the heterocyclyl ring is a 4,4-tetrahydropyranyl ring.
In one embodiment, R6a and R6b are each methyl or R6a and R6b together form a cyclopropyl or cyclopentyl ring. In one embodiment, R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-Cg haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-Ci2 cycloalkyl, Ci-Ci2 heteroalkyl, C3-Ci2 heterocyclyl, C6-Ci2 heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, R6c is selected from Ci-C8 alkyl, C2-Cg alkenyl, C2-C§ alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-Ci2 cycloalkyl, Ci-Ci2 heteroalkyl, C3-Ci2 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cs alkyl, or C3-C8 heterocycle. In one embodiment, R6c is cyano.
In one embodiment, R6c is selected from Ci-C8 alkyl, C2-C8 alkynyl, C6-Ci2 aryl, or C6-Ci2 haloaryl, wherein each of said alkyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cg alkyl, or C3-C8 heterocycle.
In one embodiment, R6c is selected from Ci-Cg alkyl, C2-Cg alkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said alkyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -0S(=0)20R, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle. In one embodiment, R6c is selected from Ci-C8 alkyl, Ci-C8 haloalkyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-Ci2 cycloalkyl, or C3-Ci2 heterocyclyl, wherein each of said alkyl, haloalkyl, aryl, haloaryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more -X, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, -NHS(=0)2R, - C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R, -C(=0)0R, -C(S)R, -C(0)0R, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, R6c is selected from Ci-C8 alkylene heterocyclyl, C2-C8 alkynyl, C6-Ci2 aryl, or C6-Ci2 haloaryl, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, R6c is selected from Ci-C8 alkylene heterocyclyl, C2-C8 alkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR,
-CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, R6c is selected from Ci-C8 alkylene heterocyclyl, C2-C8 alkynyl, C6-Ci2 aryl, or C6-Ci2 haloaryl, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
In one embodiment, R6c is selected from Ci-C8 alkylene heterocyclyl, C2-C8 alkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
In one embodiment, the Ci-Cs alkylene heterocyclyl is Ci-C6 alkylene heterocyclyl. In one embodiment, the Ci-C6 alkylene heterocyclyl is methylene heterocyclyl. In one embodiment, the heterocyclyl ring is a pyrrolidinyl ring. In one embodiment, the methylene heterocyclyl is methylene pyrrolidinyl, for example methylene-N-pyrrolidinyl.
In one embodiment, the C2-C8 alkynyl is C2-C6 alkynyl. In one embodiment, the C2-C6 alkynyl is ethynyl. In one embodiment, the C6-Ci2 aryl is phenyl.
In one embodiment, the C6-Ci2 haloaryl is halophenyl. In one embodiment, the halophenyl is chlorophenyl or fluorophenyl.
In one embodiment, R6c is selected from methylene heterocyclyl, C2-C6 alkynyl, phenyl, halophenyl or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo. In one embodiment, R6c is selected from methylene pyrrolidinyl, ethynyl, phenyl, chlorophenyl, fluorophenyl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
In one embodiment, R6c is selected from Ci-C6 alkyl, Ci-C6 haloalkyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-C12 cycloalkyl, or C3-C12 heterocyclyl, wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more halo.
In one embodiment, R6c is selected from C1-C6 alkyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo.
In one embodiment, R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, (C=S)NH, CH2(C=0), 0(C=0), CH2(C=0), or NH(C=0);
R6c is selected from Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-C12 cycloalkyl, C1-C12 heteroalkyl, C3-C12 heterocyclyl, C6-Ci2 heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cs alkyl, or C3-C8 heterocycle; and
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cs bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-Ci2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle. In one embodiment, Y is selected from (C=0)0, (C=0)CH2, (C=0)NH, or NH(C=0);
R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-Ci2 cycloalkyl, C1-C12 heteroalkyl, C3-Ci2 heterocyclyl, C6-C12 heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cs alkyl, or C3-Cs heterocycle; and Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, C6-Ci2 aryl, C3- C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkylene- tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, - Br, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, -NHS(=0)2R, - C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-Ci2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-Ci2 heterocycle.
In one embodiment, Y is selected from (C=0)0 or (C=0)NH;
R6c is selected from Ci-Cg alkylene heterocyclyl, C2-C8 alkynyl, C6-C12 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -0S(=0)20R, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cg alkyl, or C3-Cg heterocycle; and
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, Ci-Cs cyanoalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, Ci-C6 alkylene- C3-C12 cycloalkyl, Ci-C6 alkylene- C6-C12 aryl, C1-C6 alkylene- C6-Ci2 fluoroaryl, Ci-C6 alkylene- C3-Ci2 heterocycle, Ci-C6 alkylene-C(=0)NRR;
wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-Ci2 cycloalkyl. In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S , (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C6-C i2 aryl, C p
C6 alkylene-tetrahydropyranyl, C i-C6 alkylene-3,3-difluoro-l-cyclohexyl, C i-C6 alkylene-p- fluoro-phenyl, C i-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C i-C6 alkylene-cycloheptanyl, C i-C6 alkylene-2-bicyclo[2.2.1]heptanyl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo; and
R2-R5, R6a, Rfti, R6c, Ri2a and Ri2b are as defined above in the second aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, Ri is C1-C0 alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B , R2-R5, R6a, 6b, R6c, Ri2a and Ri¾ are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S , (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, C i-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C i-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-C i2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are each independently selected from hydrogen or halo;
R6a> R6b> and R6c are as defined above in the second aspect of the invention, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B , R2-R5, R6a, Rib, and R6c are as defined in the preceding embodiment. In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a, 6b, and R6c are as defined above in the second aspect of the invention, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, Ri is C1-C0 alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6 are each independently selected from methyl or R6a and Rg together form a cyclopropyl ring; and
R6c is as defined above in the second aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and Y, B, R2-R5, 6a> R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and Rg together form a cyclopropyl ring; and
R6c is selected from C1-C6 alkyl, C6-C12 aryl, C6-Ci2 haloaryl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-Ci2 cycloalkyl, wherein each of said alkyl, aryl, heterocyclyl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen; R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from Ci-C6 alkyl, C6-Cio aryl, C6-C10 haloaryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more halo, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Q-Ce alkylene-4,4-difluoro-l-cyclohexyl; and
Y, B, R2-R5, 6a, 6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro- phenyl, C1-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.Ci-C6 alkylene-
In one embodiment, Ri is Ci-Ce alkylene-4,4-difluoro- 1 -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Q-Ce alkylene-4,4-difluoro- 1 -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.Ci-Ce alkylene- one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro- 1 -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is selected from CH or N; Ri is selected from Ci-C6 alkyl, Ci-Ce bromoalkyl, Ci-C6 fluoroalkyl, C1-C6 alkylene- tetrahydropyranyl, C1-C6 alkylene-3,3-difluoro- l-cyclohexyl, C1-C6 alkylene-p-fluoro- phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene- cycloheptanyl, C1-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro- 1 -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is selected from CH or N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is N; Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, R6a, 6b, and R6c are as defined in the preceding embodiment. In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, 6a> R6b, and R6c are as defined in the preceding embodiment.
In one embodiment, Y is selected from CH20, S020, S02NH, (C=0)0, (C=0)NH, or (C=S)NH;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
R6c is selected from 1-pentyl, 1-hexyl, phenyl, p-fluoro-phenyl, or cyclohexyl, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Y, B, R2-R5, R6a, R6b, and R6c are as defined in the preceding embodiment.
In a further aspect, the present invention provides a compound of formula la,
Figure imgf000042_0001
la
wherein
Yi is selected from O, S, or SO2;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N; Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Q-Q alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
Ri2a and R12b are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the present invention provides a compound of formula la,
Figure imgf000043_0001
wherein
Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONR12aRi2b, COR12a, COORi2a, d-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -Br, -F, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R,
-OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg alkoxy, C6-C2o aryl, C3-C2o cycloalkyl, Ci-C2o heteroalkyl, C3-C2o
heterocyclyl, or C6-C20 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-Cg cycloalkyl ring or a 3 to 7 membered heterocyclyl ring; and
Ri2a and Ri¾ are each independently selected from hydrogen, Ci-Cg alkyl, C2-Cg alkenyl, C2-Cs alkynyl, C6-C2o aryl, C3-C2o cycloalkyl, Ci-C2o heteroalkyl, C3-C2o heterocyclyl, or C6-C2o heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-Ci2 cycloalkyl, bridged Cg-Ci2 cycloalkyl, halo or perhalo substituted C3-Ci2 cycloalkyl, or a C3-Ci2 heterocycle; or
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the invention provides the present invention provides a compound of formula la,
Figure imgf000045_0001
wherein
R6a and R6b together form 3 to 7 membered heterocycle; and
Yi, Y2, B, Ri, R2-R5 and R7-R11 are as defined in the preceding aspect;
a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the present invention provides a compound of formula la,
Figure imgf000045_0002
wherein
Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cg bromoalkyl, C2-C§ haloalkenyl, C2-Cg haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -Br, -F, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, - C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R,
-OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NR12aR12b, S02NR12aR12b, CONR12aR12b, halo, CrC8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg alkoxy, C6-C2o aryl, C3-C20 cycloalkyl, C1-C20 heteroalkyl, C3-C20
heterocyclyl, or C6-C20 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
Ri2a and Ri2 are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C2o aryl, C3-C2o cycloalkyl, Ci-C2o heteroalkyl, C3-C2o heterocyclyl, or C6-C2o heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more of -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -0P(=0)(0R)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- C8 alkyl, C3-Ci2 cycloalkyl, bridged C6-Ci2 cycloalkyl, perhalo substituted C3-Ci2 cycloalkyl, or a C3-Ci2 heterocycle; or
a pharmaceutically acceptable salt or prodrug thereof.
The following embodiments relate to any of the aspects of the compound of formula la above, as appropriate.
In one embodiment, Ri2aand Ri2b are each independently selected from hydrogen, Ci-C8 alkyl, or C6-Ci2 aryl, wherein each of said alkyl or aryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cs alkyl, or C3-C8 heterocycle.
In one embodiment, Ri2aand Ri¾ are each independently selected from hydrogen, Ci-Cg alkyl, or C6-C12 aryl.
In one embodiment, Ri2aand Ri¾ are each independently selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, n-pentyl, or phenyl.
In one embodiment, Yi is selected from O, S, or S02> preferably Yi is selected from O or S. In one embodiment, Yi is O.
In one embodiment, Y2 is selected from CH2, O, or NH, preferably Y2 is selected from NH or O. In one embodiment, Yi is O; and Y2 is NH or O. In one embodiment, Yi is O; and Y2 is NH. In one embodiment, B is CH. In one embodiment, B is N.
In one embodiment, Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cs alkyl, C2-Cg alkenyl, C2-Cs alkynyl, Ci-Cg fluoroalkyl, Ci-Cs bromoalkyl, C2-Cg haloalkenyl, C2-Cs haloalkynyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or C1-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -
OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- C8 alkyl, C3-C12 cycloalkyl, bridged C6-Ci2 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
In one embodiment, Ri is selected from CONRi2aRi2b> CORi2a, COORi2a, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -Br, -F, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(0H)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR,
-C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- C8 alkyl, C3-C12 cycloalkyl, bridged C6-C12 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle. In one embodiment, Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C12 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more of -Br, -F, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, -NHS(=0)2R, C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R,
-C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-C12 aryl Ci-C8 alkyl, or C3-C8 heterocycle.
In one embodiment, Ri is selected from Ci-Cg alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, Ci-C8 cyanoalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, Ci-C6 alkylene- C3-C12 cycloalkyl, Ci-C6 alkylene- C6-Ci2 aryl, Ci-C6 alkylene- C6-C12 fluoroaryl, Ci-C6 alkylene- C3-C12 heterocycle, Ci-C6 alkylene-C(=0)NRR; wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl.
In one embodiment, Ri is selected from C1-C6 alkyl, Ci-C6 bromoalkyl, C1-C6 fluoroalkyl, C6-Ci2 aryl, Ci-C6 alkylene-3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2-bicyclo[2.2.1]heptanyl, C3-C12 cycloalkyl, or Ci-C6 alkylene- tetrahydropyranyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo.
In one embodiment, Ri is C1-C6 alkylene-4,4-difluoro- l-cyclohexyl.
In one embodiment, Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, 4-cyano-l -butyl, 3,3-dimethyl- 1-butyl, 1- hexyl, 1-heptyl, methylene cyclohexyl, methylene-4,4-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene-4- tetrahydropyranyl, methyleneC(0)NH(cyclohexyl), methyleneC(0)NH(t-butyl), 1-ethylene- 2-(N-morpholinyl), l-ethylene-2-(N-piperidinyl), and l-ethylene-2-(4,4-difluoro-N- piperidinyl).
In one embodiment, Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- 1-pentyl, methylene- 3, 3- difluoro-1 -cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N- methyl-2-piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2. l]heptanyl, methylene cyclohexyl, and methylene-4-tetrahydropyranyl.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl.
In one embodiment, R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-Cs alkyl, C2-C8 alkenyl, C2-Cg alkynyl, Ci-Cs alkoxy, C6-C12 aryl, C3-C12 cycloalkyl, C1-C12 heteroalkyl, C3- C12 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR,
-C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cs alkyl, or C3-C8 heterocycle.
In one embodiment, R2 is hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-Ci2 aryl, C3-C12 cycloalkyl, C1-C12 heteroalkyl, C3-Ci2 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -0P(=0)(0R)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; and
R3-R5, R7-R11 , X, and R are as defined in the preceding embodiment.
In one embodiment, R2 is hydrogen or halo; and
R3-R5, R7-R11 , X, and R are as defined in the preceding embodiment. In one embodiment, R2-Rs and R7-R11 are each independently selected from hydrogen, S02, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, C C8 alkyl, d-C8 alkoxy, wherein each of said alkyl or alkoxy may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C§ heterocycle.
In one embodiment, R2 is hydrogen, SO2, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, or CpCs alkyl, wherein each of said alkyl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)20H, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(0H)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; and
R3-R5, R7-R11, X, and R are as defined in the preceding embodiment.
In one embodiment, R2 is hydrogen or halo; and
R3-R5, R7-R11, X, and R are as defined in the preceding embodiment.
In one embodiment, R2-R5, R7- R11 are each independently selected from hydrogen or halo.
In one embodiment, R2-R5, R7, Rs, Rio, and Rn are hydrogen and R is halo. In one embodiment, R2-R5, R7, Rs, Rio, and Rn are hydrogen and R9 is fluoro.
In one embodiment, R6a and R6b are each independently selected from C1-C4 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring. In one embodiment, R6a and R6b are each independently selected from C1-C4 alkyl or R6a and R6b together form a C3-C5 cycloalkyl ring.
In one embodiment, R6a and R6b are each methyl or R6a and R6b together form a cyclopropyl or cyclopentyl ring.
In one embodiment, R6a and R6b together form a 3 to 6 membered heterocyclyl ring.
In one embodiment, the heterocyclyl ring is a 5 or 6 membered ring. In one embodiment, the heterocyclyl ring comprises from 3 to 6 carbon atoms, from 3 to 5 carbon atoms, or from 4 to 5 carbon atoms.
In one embodiment, the heterocyclyl ring is a 4,4-tetrahydropyranyl ring.
In one embodiment, R6a and R6b are each independently methyl.
In one embodiment, R6a and R6b together form a cyclopropyl ring. In one embodiment, Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH; and
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-Cs bromoalkyl, C2-Cs haloalkenyl, C2-Cg haloalkynyl, C6-Ci2 aryl, C3-Ci2 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-C12 aryl, C6-Ci2 fluoroaryl, C6-C12 aryl Ci- Cs alkyl, C3-Ci2 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-Ci2 cycloalkyl, or a C3-Ci2 heterocycle.
In one embodiment, Yi is O;
Y2 is selected from NH or O; and
Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C6-Ci2 aryl, C3- C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkylene- tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, - Br, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -N02, -NHC(=0)R, -NHS(=0)2R, - C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-C 12 fluoroaryl, C6-Ci2 aryl Cp Cg alkyl, C3-C 12 cycloalkyl, bridged C6-C i2 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
In one embodiment, Yi is O;
Y2 is selected from NH; and
Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fiuoroalkyl, Ci-Cg cyanoalkyl, C6-C i2 aryl, C3-C12 cycloalkyl, Ci-C6 alkylene- C3-C12 cycloalkyl, Ci-C6 alkylene- C6-C 12 aryl, C 1-C6 alkylene- C6-Ci2 fluoroaryl, Ci-C6 alkylene- C3-C12 heterocycle, Ci-C6 alkylene-C(=0)NRR;
wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
each R is independently H, C 1-C 10 alkyl, C6-Ci2 aryl, C6-C i2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C 12 cycloalkyl.
In one embodiment, Yi is selected from O or S;
Y2 is selected from CH2, O, or NH; and
B, Ri, R2-R5, R6a, R6b, R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O; and
B, Ri, R2-R5, 6a, R6b, R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N; Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, Ci-C alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo; and
R2-R5, R6a, R6b, R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Q-Ce alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, R7-R11, Ri2a and Ri2b are as defined in the preceding embodiment. In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fiuoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen or halo;
R6a, R6b, and R7-R11 and Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, 6a, R6b, R7-R11, Ri2a and Ri2b are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O; B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a, 6b, and R7-R11, Ri2a and Ri2b are as defined above in the sixth aspect of the invention, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, 6a, R6b, R7-R11, Ri2a and Ri2b are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene-
3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7-R11 are each independently selected from hydrogen, OH, NO2, CHO, SO2, SO3H, halo, Ci-Cs alkyl, or Ci-C8 alkoxy, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, 6a, R6b, and R7-R11 are as defined in the preceding embodiment. In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-C8 alkyl, Ci-C8 bromoalkyl, Ci-C8 fluoroalkyl, C1-C6 alkylene-
3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7-R11 are each independently selected from hydrogen, OH, NO2, CHO, SO2, SO3H, halo, methyl, ethyl, n-propyl, methoxy, or ethoxy, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, 6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, Ci-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7-R11 are each independently selected from hydrogen, halo, methyl, ethyl, n-propyl, methoxy, or ethoxy, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro- l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, C1-C6 alkylene-cycloheptanyl, C1-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7-R11 are each independently selected from hydrogen or halo, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro- l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, Ci-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, heterocyclyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen; R6a and R6 are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R IS halo;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment. In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and Rgb together form a cyclopropyl ring; and
Rg is fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is C1-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, 6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-C6 alkyl, C1-C6 bromoalkyl, Ci-C6 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Cio aryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and Rg together form a cyclopropyl ring; and
R9 IS fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Q-Ce alkylene-4,4-difluoro- l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, 6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
Rg is fluoro;
R7, Rg, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N; Ri is selected from Ci-Cs alkyl, Ci-Cg bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, Ci-C alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, heterocyclyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-Cs alkyl, Ci-Cs bromoalkyl, Ci-Cs fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, C1-C6 alkylene-p-fluoro-phenyl, C1-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C6 alkylene-cycloheptanyl, Ci-C6 alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Ci2 aryl, or C3-C12 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and Rg together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is Ci-C6 alkylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S; Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from Ci-C6 alkyl, Ci-C6 bromoalkyl, Ci-C6 fluoroalkyl, C1-C6 alkylene- 3,3-difluoro-l-cyclohexyl, Ci-C6 alkylene-p-fluoro-phenyl, Ci-C6 alkylene-adamantyl, Ci-C6 alkylene-N-methyl-2-piperidinyl, Ci-C alkylene-cycloheptanyl, Ci-C alkylene-2- bicyclo[2.2.1]heptanyl, Ci-C6 alkylene-tetrahydropyranyl, C6-Cio aryl, or C3-C10 cycloalkyl, wherein each of said alkyl, aryl, or cycloalkyl may be optionally substituted by one or more fluoro or bromo;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, Ri is C1-C0 alkylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is selected from CH or N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and Rg together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S; Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
Rg is fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6 together form a cyclopropyl ring; and
Rg is fluoro;
R7, Rg, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S; Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
R IS fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b> and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
Rg is fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is N; Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and
R9 IS fluoro;
R7, Rs, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, 6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and
R9 IS fluoro;
R7, Rg, Rio, and Rn are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment. In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a> R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl or R6a and R6b together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro- l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro- l-pentyl, methylene-3,3-difluoro- l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b are each independently selected from methyl; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, 6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is N;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and R7- Rii are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l-cyclohexyl; and
Yi, Y2, B, R2-R5, 6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, Yi is selected from O or S;
Y2 is selected from NH or O;
B is CH;
Ri is selected from 1-butyl, 1-pentyl, 5-fluoro-l-pentyl, methylene-3,3-difluoro-l- cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2- piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene cyclohexyl, or methylene-4-tetrahydropyranyl;
R2-R5 are hydrogen;
R6a and R6b together form a cyclopropyl ring; and
R7- R11 are hydrogen, or
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, Ri is methylene-4,4-difluoro-l -cyclohexyl; and
Yi, Y2, B, R2-R5, R6a, R6b, and R7-R11 are as defined in the preceding embodiment.
In one embodiment, the compound of the invention is SGT-23, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is SGT-24, or a pharmaceutically acceptable salt or prodrug thereof
In one embodiment, the compound of the invention is SGT-25, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-41, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is SGT-42, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-55, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-56, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-60, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-65, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is SGT-67, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000068_0001
a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000069_0001
or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000069_0002
acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000069_0003
pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000070_0001
, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000070_0002
pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000070_0003
pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000071_0001
, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the com ound of the invention is
Figure imgf000071_0002
pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is
Figure imgf000071_0003
pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000072_0001
, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000072_0002
pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000072_0003
pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is
Figure imgf000073_0001
, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is selected from the group comprising: SGT-23, SGT-24, SGT-25, SGT-41, SGT-42, SGT-55, SGT-56, SGT-60, SGT-65, SGT-67, MJ1-MJ12, MJ14, and MJ15, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the compound of the invention is selected from the compounds listed in Tables 1, 2, and 3 in the Examples, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the compound of the invention is selected from the compounds listed in Tables 1 and 2 in the Examples, or a pharmaceutically acceptable salt or prodrug thereof.
Asymmetric centres may exist in the compounds of the invention. The asymmetric centres may be designated by the symbols "R" or "S", depending on the configuration of substituents in three dimensional space at the chiral carbon atom. All stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and 1- isomers, and mixtures thereof of the compounds are contemplated herein. Individual enantiomers of the compounds can be prepared synthetically from commercially available enantiopure starting materials or by preparing enantiomeric mixtures of the compounds and resolving the mixture into individual enantiomers. Resolution methods include conversion of the enantiomeric mixture into a mixture of diastereomers and separation of the diastereomers by, for example, recrystallisation or chromatography; direct separation of the enantiomers on chiral chromatographic columns; and any other appropriate method known in the art.
Starting materials of defined stereochemistry may be commercially available or made and resolved by techniques well known in the art.
Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral centre(s). The prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereo specificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
The compounds of the invention may also exist as geometric isomers. All cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers, as well as the appropriate mixtures thereof of the compounds are contemplated herein. The compounds may also exist as tautomers, for example, keto/enol; imine/enamine;
amide/imino alcohol; nitroso/oxime; thioketone/enethiol; N- nitroso/hyroxyazo; and nitro/aci- nitro. All tautomeric isomers of the compounds are contemplated herein.
The compounds may also exist as isotopologues and isotopomers, wherein one or more atoms in the compounds are replaced with different isotopes. Suitable isotopes include, for example, 2H (D), 3H (T), 12C, 13C, 14C, 160, and lsO.
The compounds may exist in solvated or unsolvated forms. If the solvent is water, the solvate may be referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, or a tri-hydrate. All solvates of the compounds are contemplated herein.
Pharmaceutically acceptable salts of the compounds of the invention are also contemplated herein. Salts of the compounds include, for example, acid addition salts, base addition salts, and quaternary salts of basic nitrogen-containing groups. Acid addition salts can be prepared by reacting compounds, in free base form, with inorganic or organic acids. Examples of inorganic acids include, but are not limited to, hydrochloric; hydrobromic; hydroiodic; nitric; carbonic; sulfuric; and phosphoric acid. Examples of organic acids include, but are not limited to, cholic; sorbic; lauric; acetic; trifluoroacetic; formic; propionic; succinic; glycolic; gluconic; digluconic; lactic; malic; tartaric; citric; ascorbic; glucuronic; maleic; fumaric; pyruvic; aspartic; glutamic; aryl carboxylic; anthranilic acid; mesylic; stearic; salicylic; phenylacetic; mandelic; embonic (pamoic); alkylsulfonic; ethanesulfonic; arylsulfonic; benzenesulfonic; pantothenic; sulfanilic;
cyclohexylaminosulfonic; β-hydroxybutyric; galactaric; galacturonic; adipic, alginic; butyric; camphoric; camphor sulfonic; cyclopentanepropionic; dodecylsulfic; glycoheptanoic;
glycerophosphic; heptanoic; hexanoic; nicotinic; 2-naphthalesulfonic; oxalic; palmoic;
pectinic; 3-phenylpropionic; picric; pivalic; thiocyanic; tosylic; and undecanoic acid.
Base addition salt can be prepared by reacting compounds, in free acid form, with inorganic or organic bases. Examples of base addition salts include metal salts and organic salts.
Preferred metal salts include alkali metal salts, alkaline earth metal salts, and other physiologically acceptable metal salts. Preferably the metal salt comprises aluminium, calcium, lithium, magnesium, potassium, sodium, or zinc. Organic salts may be made from amines, such as trimethylamine, diethylamine, N,N-dibenzylethylenediamine,
chloroprocaine, ethanolamine, diethanolamine, ethylenediamine, meglumine (Ν- methylglucamine), and procaine.
5.3 Methods of making the compounds of the invention
The abbreviations used in the general methods are defined as follows: "LG" is an appropriate leaving group and includes halo, tosyl, triflate, mesyl, and any other highly stabilised anionic leaving group. Such leaving groups are known to those of skill in the art.
"ΑΙΒΝ" means azobisisobutyronitrile. "NBS" means N-bromo succinimide. "DCM" means dichloromethane (CH2CI2). "Et" means ethyl. "EtOAc" means ethylacetate. "Me" means methyl (-CH3). "MeOH" means methanol. "MeCN" means acetonitrile. "Pr" means propyl. "i-Pr" means isopropyl (-CH(CH3)2). "i-PrOH" means isopropanol. "rt" means room temperature. "THF" means tetrahydrofuran. "TLC" means thin layer chromatography.
In the context of the present invention, protecting groups include prodrug moieties and chemical protecting groups.
Protecting groups (PG) are optionally used to prevent side reactions with the protected group during synthetic procedures, i.e. routes or methods to prepare the compounds of the invention. For the most part the decision as to which groups to protect, when to do so, and the nature of the chemical PG will be dependent upon the chemistry of the reaction to be protected against (e.g., acidic, basic, oxidative, reductive or other conditions) and the intended direction of the synthesis. The PG groups do not need to be, and generally are not, the same if the compound is substituted with multiple PG. In general, PG will be used to protect functional groups such as carboxyl, hydroxyl, thio, or amino groups and to thus prevent side reactions or to otherwise facilitate the synthetic efficiency. The order of depro tection to yield free, deprotected groups is dependent upon the intended direction of the synthesis and the reaction conditions to be encountered, and may occur in any order as determined by the person skilled in the art. Various functional groups of the compounds of the invention may be protected. For example, PGs for -OH groups (whether hydroxyl, carboxylic acid, phosphonic acid, or other functions) include "ether- or ester-forming groups". Ether- or ester-forming groups are capable of functioning as chemical PGs in the synthetic schemes set forth herein. However, some hydroxyl and thio PGs are neither ether- nor ester-forming groups, as will be understood by those skilled in the art, and are included with amides, discussed below.
A very large number of hydroxyl PGs and amide-forming groups and corresponding chemical cleavage reactions are described in Protective Groups in Organic Synthesis, Theodora W. Greene and Peter G. M. Wuts (John Wiley & Sons, Inc., New York, 1999, ISBN 0-471- 16019-9) ("Greene"). See also Kocienski, Philip J.; Protecting Groups (Georg Thieme
Verlag Stuttgart, New York, 1994), which is incorporated by reference in its entirety herein. In particular Chapter 1, Protecting Groups: An Overview, pages 1-20, Chapter 2, Hydroxyl Protecting Groups, pages 21-94, Chapter 3, Diol Protecting Groups, pages 95-117, Chapter 4, Carboxyl Protecting Groups, pages 118-154, Chapter 5, Carbonyl Protecting Groups, pages 155-184. For PGs for carboxylic acid, phosphonic acid, phosphonate, sulfonic acid and other PGs for acids see Greene as set forth below. Such groups include by way of example and not limitation, esters, amides, hydrazides, and the like. Ester-forming groups include: (1) phosphonate ester-forming groups, such as
phosphonamidate esters, phosphorothioate esters, phosphonate esters, and phosphon-bis- amidates; (2) carboxyl ester- forming groups, and (3) sulphur ester- forming groups, such as sulphonate, sulfate, and sulfinate. The compounds of the invention may be synthesised according to the general methods described below.
General method A Compounds of formula (He) can be prepared using the synthetic route detailed in Scheme 1, in which, Ri, R2-R5, R6a-R6c, Yi, Y2, and B are as defined for the invention and LG is an appropriate leaving group.
Scheme 1
Figure imgf000077_0001
Compounds of formula (Ha), (lib), and (lid) can be either obtained from commercial suppliers or synthesised as needed. For example, many compounds of formula (lib) wherein LG is halo, for example bromo, are commercially available. Alternatively, compounds of (lib) may be prepared from their corresponding alcohols. For example, compounds of formula (lib) wherein LG is, for example, tosyl or mesyl, may be prepared from the corresponding alcohol by reaction with p-toluene sulfonyl chloride or methane sulfonyl chloride and a base such as triethylamine in dichloromethane. In the first step, a compound of formula (Ila) together with an appropriate base, such as sodium hydride, is stirred in an anhydrous solvent at 0°C. A solution containing compound (lib) in an anhydrous solvent is added dropwise to the solution containing the compound of formula (Ila), and the resulting mixture is stirred at 0°C for at least 30 minutes, after which the mixture is allowed to return to room temperature and stirred for a further 30 minutes. Suitable reaction conditions would be known to one of skill in the art or could be found in /. Med. Chem. 1991 ; 34(3): 1099- 1110 and Bioorg. Med. Chem. Lett. 1994; 4(4): 563-566.
The compound of formula (lie) is isolated via standard work up procedures known to those of skill in the art. For example, an organic solvent and water is added to the reaction mixture containing the compound of formula (lie). The aqueous phase is extracted with an organic solvent and the combined organic extracts washed with brine, separated, and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, crystallisation, or preparative HPLC.
In the second step, a solution containing a halogenating agent, such as thionyl chloride, oxalyl chloride, or phosphorous oxychloride, in an anhydrous solvent is added dropwise to a stirred solution of compound (lie) in the same anhydrous solvent at 0°. The resulting mixture is stirred at 0°C for at least 30 minutes, returned to room temperature, and stirred for at least 30 minutes. The mixture is then cooled to 0°C.
A solution containing compound (lid) and a base, such as triethylamine or
disopropylethylamine, in the same anhydrous solvent the mixture containing the acid chloride is added dropwise to the above described mixture, and the mixture is stirred at 0° for at least thirty minutes. The mixture is then warmed to room temperature and stirred for at least 30 minutes. A saturated solution of sodium bicarbonate is then added to the reaction mixture. The compound of formula (He) is isolated via standard work up procedures known to those of skill in the art. For example, an organic solvent and water is added to the reaction mixture containing the compound of formula (lie). The aqueous phase is extracted with an organic solvent and the combined organic extracts washed with brine, separated and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, or preparative HPLC. General method B
Compound of formula (He) can also be prepared using the synthetic route detailed in Scheme 1, in which, Ri, R2-R5, R6a-R6c, Yi, Y2, and B are as defined for the invention and LG is an appropriate leaving group may.
The first step of the synthesis is as described above with respect to General method A.
In the second step an activating agent, such as N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l- yl)uronium hexafluorophosphate (HBTU) or Ν,Ν-dicyclohexylcarbodiimide (DCC), is added to a stirred solution of compound (lie) and compound and in dichloromethane at 0°C. The reaction mixture is allowed to warm to room temperature and then stirred for 12 hours. In some embodiments, for example, where the activating agent is HBTU, a base such as diisopropylethylamine is added to reaction mixture following the addition of the activating agent. The order of addition of the reagents may be varied, as appropriate.
S
Figure imgf000079_0001
Standard work-up and, optionally, purification provide the compound of formula (He). For example, after stirring for 12 hours the reaction mixture is filtered through Celite, concentrated under reduced pressure , and then purified by column chromatorgraphy and then crystallisation from an appropriate solvent or mixture of solvents, for example a mixture of hexane-ethyl acetate. General method C Compounds of formula (He) can also be prepared using the synthetic route detailed in Scheme IB, in which Rl5 R2-R5, R6a-R6c> Yi, Y2, and B are as defined for the compounds of the invention and LG is an appropriate leaving group.
Scheme 1 B
Figure imgf000080_0001
Compounds of formula (Ha), (lib), and (lid) can either be obtained from commercial suppliers or synthesised according to standard methods known in the art as needed. In the first step, a compound of formula (Ila) is coupled with a compound of formula (lid). The compound of formula (Ila) is treated with a suitable activating agent, for example N,N,N',N'-tetramethyl-0-(lH-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU), in an ahydrous aprotic organic solvent, typically N,N-dimethylformamide (DMF), at ambient temperature under an atmosphere of argon. Other activating agents may be used, depending on the nature and reactivity of the compound of formula (lib). For example, for certain compounds of formula (lib) wherein one or more of R2-R5 is halo, for example fluoro, N,N- dicyclohexylcarbodiimide (DCC) may be used as the activating agent. A wide range of activating agents are known in the art for activating, for example, carboxylic acid groups for reaction with alcohols and amines.
A base, such as triethylamine or diisopropylamine, is then added dropwise at ambient temperature over suitable period of time, for example 2 hours. The period of time over which the base is added may depend on the scale of the reaction. Depending on the reactivity of the reagents, it may be desirable to cool the reaction mixture prior to and/or during addition of the base.
The reaction mixture is then stirred at ambient temperature for 15 hours before gradually heating to 120°C, for example at 25°C per hour, and then heating at 120°C for 3 hours. The progress of the reaction may be monitored by any suitable means known in the art, for example thin layer chromatography or HPLC.
Standard workup and, optionally, purification provides the compound of formula (X). For example, as described herein in the Examples, the reaction mixture is allowed to cool, the solvent removed under reduced pressure, and then saturated sodium carbonate solution added and resultant mixture cooled to below 5°C to form a precipitate. The precipitate is filtered and washed with water, triturated with saturated sodium carbonate solution, and then filtered and washed again with water. Finally, toluene is added and then evaporated to provide the compound of formula (X).
Alternative, workup and purification methods may be used as appropriate depending on the nature and reactivity of the compound of formula (X). In the second step, the compound of formula (X) is coupled with a compound of formula
(lib) in the presence of a suitable base. For certain compound of formula (X), the reaction is carried out by combining the compound of formula (X) and anhydrous potassium carbonate in a suitable solvent, for example anhydrous DMF, and then adding the compound of formula (lib) at ambient temperature. The reaction mixture is then heated at 70°C for 15 hours.
Standard workup and, optionally, purification provides the compound of formula (He). For example, as described herein in the Examples, the reaction mixture is allowed to cool, the solvent removed under reduced pressure, and then ethyl acetate added. The mixture is then poured onto ice and, once the ice has melted, the organic layer separated. The aqueous layer is then extracted with ethyl acetate, and the combined organic extracts washed with sodium carbonate solution, then dried over sodium sulfate and filtered. The solvent is removed, ethyl acetate added and the solution passed through silica. Fractions containing the compound of formula (He) are combined and the solvent removed to provide the desired compound. Other workup and purification methods may be used, as appropriate.
General method D A compound of formula (IIIc) can be prepared using the synthetic route detailed in Scheme 2, in which, Ri, R2-R5, R6a-R6c> Y2, and B are as defined for the invention, and LG is an appropriate leaving group.
Scheme 2
Figure imgf000082_0001
Compounds of formula (Ilia), (lib), and (lid) can be either obtained from commercial suppliers or synthesised as needed. A compound of formula (Ilia) together with an appropriate base, such as sodium hydride, is stirred in an anhydrous solvent at 0°C. A solution containing compound (lib) in an anhydrous solvent is added dropwise to the solution containing the compound of formula (Ilia), and the resulting mixture is stirred at 0°C for at least 30 minutes, after which the mixture is allowed to return to room temperature and stirred for a further 30 minutes.
The compound of formula (Illb) is isolated as an oil via standard work up procedures known to those of skill in the art. For example, an organic solvent and water is added to the reaction mixture containing the compound of formula (Illb). The aqueous phase is extracted with an organic solvent and the combined organic extracts washed with brine, separated, and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, or preparative HPLC.
A solution containing compound (Illb), AIBN, and NBS in a halogenated solvent and acid is stirred at room temperature for at least five minutes, and then irradiated for at least 4 hours. Water may be added and the mixture extracted with a halogenated solvent. The compound of formula (IIIc) is isolated as an oil via standard work up procedures known to those of skill in the art. For example, a halogenated solvent and water is added to the reaction mixture containing the compound of formula (IIIc). The aqueous phase is extracted with a halogenated solvent and the combined organic extracts washed with brine, separated and dried over anhydrous magnesium sulfate. The combined organic extracts are then concentrated under reduced pressure and purified, as necessary, by processes known in the art, such as flash column chromatography, distillation, or preparative HPLC.
The compounds of the invention may also be synthesised according to the schemes described below using the techniques set out in general methods A and B and using reaction conditions known to those of skill in the art. In the schemes below, Ri, R2-R5, R6a-R6c, PG, and B are as defined for the invention, and LG is an appropriate leaving group.
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000084_0002
A person skilled in the art, understanding the disclosures of the general methods and specific preparation examples, would know how to modify the general methods to accommodate the different substituents that may be present on the compounds of the invention. The embodiments of the invention described above are intended to be merely exemplary, and those skilled in the art will recognise, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific materials, compounds, and procedures. All such equivalents are considered to be within the scope of the invention as set out in the accompanying claims
5.4 Pharmaceutical compositions
The compounds of the invention can be used in a range of medicinal applications. While it is possible for the active ingredients to be administered alone it may be preferable to present them as pharmaceutical compositions. The compositions of the invention comprise one or more compounds of the present invention, together with one or more acceptable carriers and optionally other therapeutic ingredients. The carriers must be "acceptable" in the sense of being compatible with the other ingredients of the composition and physiologically innocuous to the recipient. The carrier must also be suitable for the mode of administration of the active agent.
In one aspect, the invention relates to a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof and a
pharmaceutically acceptable carrier. Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, gel, caps, tablets, troches, lozenges, aqueous or oil
suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents including sweetening agents, flavouring agents, colouring agents and preserving agents, in order to provide a palatable preparation.
The compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain carriers, excipients, glidants, fillers, binders and the like. Aqueous compositions are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All compositions will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986), herein incorporated by reference in its entirety. Carriers and excipients include methylsulfonylmethane (MSM), 2-hydroxypropyl beta-cyclodextrin, mannitol, ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. The pH of the compositions ranges from about 3 to about 11, but is ordinarily about 7 to 10.
The compound of the invention may exist in a suspension. Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more colouring agents, one or more flavouring agents and one or more sweetening agents, such as sucrose or saccharin.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.
Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oil suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth herein, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid. The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavouring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such compositions may also contain a demulcent, a preservative, a flavouring or a colouring agent.
The oily phase of the emulsions may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of cream compositions.
Emulgents and emulsion stabilisers suitable for use in the composition of the invention include Tween® 20 or 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate. Oral compositions
In one embodiment, the composition of the invention is an oral composition. Preferably, the composition is in the form of a pill, tablet, or dragee. A tablet is made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable carrier, which is suitable for manufacture of tablets. These carriers may be, for example, inert diluents, such as 2-hydroxypropyl beta-cyclodextrin, methylsulfonylmethane (MSM), mannitol, calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatine or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including
microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed. In one embodiment, the composition of the invention comprises methylsulfonylmethane (MSM) as the carrier. In one embodiment, the composition of the invention comprises 2- hydroxypropyl beta-cyclodextrin as the carrier. Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules (gel caps), cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste.
Compositions for oral use may be also presented as hard gelatine capsules (gel caps) where the active ingredient is mixed with an inert solid carrier, for example methylsulfonylmethane (MSM), 2-hydroxypropyl beta-cyclodextrin, mannitol, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
In one aspect, the invention provides a pharmaceutical composition for oral administration. In one embodiment, an oral pharmaceutical composition of the invention is prepared as follows: a compound of the invention is dissolved in a solvent, such as acetone or diethyl ether, and is mixed with a suitable diluent at a ratio of active ingredient:diluent of 1:99. Suitable diluents include those that are approved for use in food, dietary supplements, or tabletting, and may include 2-hydroxypropyl beta-cyclodextrin, mannitol or
methylsulfonylmethane, more preferably methylsulfonylmethane. Optional carriers and/or excipients may also be added. The solvent may then be removed.
The resulting powder may be then divided up into capsules or pressed into tablets.
Inhalable compositions
The compounds are of the invention are also absorbed when administered by inhalation. In one embodiment, the composition of the invention is a nasal, e-liquid, or vaporiser composition. Compositions suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 μηι (including particle sizes in a range between 0.1 and 500 μιη in increments such as 0.5 μιη, 1 μιη, 30 μιη, 35 μιτι, etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs. Suitable compositions include aqueous or oily solutions of the active ingredient. Compositions suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other suitable therapeutic agents.
In one aspect, the invention provides an inhalable composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier. In one embodiment, an inhalable composition of the invention is prepared as follows: a compound of the invention is dissolved in a solution of water and propylene glycol, and optionally a surfactant, a fungicide, and/or a bacteriostatic agent. Preferably, the ratio of propylene glycohwater may be in the range of 0.5: 10 to 3: 10, preferably 1.5: 10. Preferably, the ratio of surfactant:water may be in the range of 0.001: 10 to 0.5:10, preferably 0.05:10. Preferably, the surfactant, if present, may be Tween 20.
A compound of the invention is dissolved initially in propylene glycol with stirring.
Optionally, a surfactant, a fungicide, and/or a bacteriostatic agent is then added followed by water. Preferably, the mixture is heated with stirring to ensure the compound of the invention dissolves into solution. After cooling, the mixture is administered nasally. An e-cigarette is an electronic inhaler that vaporises a liquid solution (e-liquid) into an aerosol mist, simulating the act of tobacco smoking. In one aspect, the invention provides an e-liquid comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier. In one embodiment, the e-liquid is a mixture of propylene glycol and glycerine, preferably vegetable glycerine. In one embodiment, the e-liquid has a preferred ratio of propylene glycokglycerine may be from 1:1 to 4: 1, more preferably 3:2. In one embodiment, the e-liquid further comprises a flavour enhancer, such as Tasty Puff or similar.
In one embodiment, the e-liquid optionally includes a surfactant to enhance solubility. The surfactant may be present at a concentration of between 0.01% and 5% by weight, more preferably 0.5% by weight. The surfactant may be chosen from the group consisting of Triton X- 100, Tween 20 and Tween 60, more preferably Tween 20.
In one embodiment, an e-liquid of the invention may be prepared as follows: the compound of the invention is dissolved in propylene glycol, which may be at room temperature or heated. Preferably, the propylene glycol is heated to 60-90 °C, preferably 80 0 C, with stirring until the compound of the invention is in solution.
Vegetable glycerine, and optionally a surfactant, is added with stirring, and the mixture is allowed to slowly return to room temperature. The mixture may be filtered. A smoking composition is intended to be smoked in a cigarette or pipe.
In one aspect, the invention provides a smoking composition comprising a compound of the invention, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier. In one embodiment, a smoking composition of the invention is prepared as follows: the compound of the invention is dissolved in acetone and then mixed with a base herb in a large mixing machine. The base herb is selected from damiana, marshmallow, mugwort, passionflower, lion's tail, blue lotus, calea zacatechichi and salvia divinorum, more preferably damiana. Optionally, food colours are added to the acetone solution to colour the final product. The mixture is mixed for approximately 30-60 minutes, preferably approximately 40 minutes to ensure even distribution of the compound of the invention through the base herb.
The wet mixture is dried to remove the acetone. The dry mixture is then ready for packing and use.
Optionally, the dry mixture is sprayed with flavouring agents, which are dissolved in a propylene glycol and/or ethanol base. Preferably, the mixture is mixed in a mixing machine after being sprayed with a flavouring agent, and then dried for approximately 30 minutes before packing and use.
A preferred blend contains 500g of the compound of the invention and 1kg of powdered food colour (e.g. Brilliant Blue) dissolved in 6 litres of acetone sprayed onto 25kg of damiana. The mixture is then dried over a 12 hour period before being sprayed with 2.5 litres of "Tasty Puff flavour liquid.
The blend may be smoked or used in a vaporiser. Topical compositions The compounds of the invention may be administered topically, for example in a cream. In one embodiment, the composition of the invention is a topical composition. Preferably, the composition is in the form of an ointment, cream, eye drop, or paste.
The choice of suitable oils or fats for a topical composition is based on achieving the desired cosmetic properties. The cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used. If desired, the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical compositions may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogues.
Compositions suitable for administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such compositions in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.
For administration to the eye or other external tissues e.g., mouth and skin, the compositions are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base.
Compositions suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatine and glycerine, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. In one embodiment, the composition of the invention is an oral topical composition, preferably the composition is in the form of a lozenge.
Injectable compositions The pharmaceutical compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilised powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.
In one embodiment, the composition of the invention is an injectable composition.
Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
Other compositions of the invention
Compositions for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray compositions containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Controlled release compositions of the invention
Compounds of the invention can also be formulated to provide controlled release of the active ingredient to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the active ingredient. Accordingly, the invention also provides compositions comprising one or more compounds of the invention formulated for sustained or controlled release.
In one embodiment, the composition of the invention is a time-release composition.
The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a time-release composition intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight: weight). The pharmaceutical composition can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion may contain from about 3 to 500 μg of the active ingredient per millilitre (ml) of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
Unit dosage forms of the compositions of the invention
The pharmaceutical compositions of the invention include those suitable for the foregoing administration routes. The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.), herein incorporated by reference in its entirety. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
The compositions are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage compositions are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
It should be understood that in addition to the ingredients provided by the present invention the compositions of this invention may include other agents conventional in the art having regard to the type of composition in question, for example those suitable for oral
administration may include flavouring agents.
Dosages of the compound of the invention
The effective dose of an active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses) or against an active disease or condition, the method of delivery, and the pharmaceutical composition, and will be determined by the clinician using conventional dose escalation studies. The effective dose can be expected to be from about 0.0001 to about 100 mg/kg body weight per day. Typically, from about 0.01 to about 10 mg kg body weight per day. More typically, from about 0.01 to about 5 mg/kg body weight per day. More typically, from about 0.05 to about 0.5 mg kg body weight per day. For example, the daily candidate dose for an adult human of approximately 70 kg body weight will range from 0.01 mg to 1000 mg, or between 0.05 mg and 500 mg, and may take the form of single or multiple doses.
In one embodiment, the composition of the invention is in a dosage form which contains at least 0.001 mg of the compound of the invention, preferably 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, or 500 mg of the compound of the invention.
In one embodiment, the composition of the invention is in a dosage form which contains 0.001-500 mg of the compound of the invention, preferably 0.005-500, 0.01-500, 0.05-500, 0.1-500, 0.2-500, 0.3-500, 0.4-500, 0.5-500, 0.6-500, 0.7-500, 0.8-500, 0.9-500, 1-500, 2- 500, 3-500, 4-500, 5-500, 6-500, 7-500, 8-500, 9-500, 10-500, 15-500, 20-500, 25-500, 30- 500, 35-500, 40-500, 45-500, 50-500, 60-500, 75-500, 80-500, 85-500, 90-500, 95-500, 100- 500, 110-500, 120-500, 130-500, 140-500, 150-500, 150-500, 160-500, 170-500, 180-500, 190-500, 200-500, 250-500, 300-500, 350-500, 400-500, or 450-500 mg of the compound of the invention.
In one embodiment, the dosage form is in an inhalable, topical, oral, smokable, or injectable dosage form.
In one embodiment, the composition of the invention is an e-liquid which contains at least 0.1 mg/ml of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/ml of the compound of the invention.
In one embodiment, the composition of the invention is an e-liquid which contains 0.1-200 mg/ml of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4-200, 5- 200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40-200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120- 200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190-200 mg/ml of the compound of the invention.
In one embodiment, the composition of the invention is a smoking composition which contains at least 0.1 mg/g of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/g of the compound of the invention.
In one embodiment, the composition of the invention is smoking composition which contains 0.1-200 mg/g of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4- 200, 5-200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40- 200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190-200 mg/g of the compound of the invention.
In one embodiment, the composition of the invention is an inhalable composition which contains at least 1 mg/ml of the compound of the invention, preferably 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 150, 160, 170, 180, 190, or 200 mg/g of the compound of the invention. In one embodiment, the composition of the invention is an inhalable composition which contains 0.1-200 mg/ml of the compound of the invention, preferably 0.5-200, 1-200, 2-200, 3-200, 4-200, 5-200, 6-200, 7-200, 8-200, 9-200, 10-200, 15-200, 20-200, 25-200, 30-200, 35-200, 40-200, 45-200, 50-200, 60-200, 75-200, 80-200, 85-200, 90-200, 95-200, 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 150-200, 160-200, 170-200, 180-200, or 190- 200 mg/ml of the compound of the invention.
5.5 Uses of the compounds of the invention The compounds of the invention bind to CBi and/or CB2 receptors. Compounds that bind to these receptors are known to have gastrointestinal, cardiovascular, and/or central nervous system activity.
In one embodiment, the compound of the invention is a CBi and/or CB2 receptor agonist.
In one embodiment, the EC50 of the compound of the invention in a CBi and/or CB2 receptor affinity assay is less than about 1000 μΜ, 500 μΜ, 250 μΜ, 100 μΜ, 50 μΜ, 25 μΜ, 10 μΜ, 5 μΜ, 3 μΜ, 1 μΜ, 750 ηΜ, 500 ηΜ, 400 ηΜ, 300 ηΜ, 200 ηΜ, 100 ηΜ, 90 ηΜ, 80 ηΜ, 70 ηΜ, 60 ηΜ, 50 ηΜ, 40 ηΜ, 20 ηΜ, 10 ηΜ, 9 ηΜ, 8 ηΜ, 7 ηΜ, 6 ηΜ, 5 ηΜ, 4 ηΜ, 3 ηΜ, 2 nM, 1 ηΜ, 0.9 ηΜ, 0.8 ηΜ, 0.7 ηΜ, 0.6 ηΜ, 0.5 ηΜ, 0.4 ηΜ, 0.3 ηΜ, 0.2 ηΜ, 0.1 ηΜ, 0.05 ηΜ, 0.01 ηΜ, 0.001 nM, or 0.0001 nM, and useful ranges may be selected between any of these values.
In one embodiment, the EC50 is from about 0.0001 nM to about 1000 μΜ, from about 0.0001 nM to about 100 μΜ, from about 0.0001 to about 10 μΜ, from about 0.001 nM to about 500 μΜ, from about 0.001 nM to about 100 μΜ, from about 0.001 nM to about 50 μΜ, from about 0.001 nM to about 10 μΜ, from about 0.001 nM to about 5 μΜ, from about 0.01 nM to about 500 μΜ, from about 0.01 nM to about 100 μΜ, from about 0.01 nM to about 50 μΜ, from about 0.01 nM to about 10 μΜ, from about 0.01 nM to about 5 μΜ, from about 0.05 nM to about 500 μΜ, from about 0.05 nM to about 100 μΜ, from about 0.05 nM to about 50 μΜ, from about 0.05 nM to about 10 μΜ, or from about 0.05 nM to about 5 μΜ. In one embodiment, the CBi and/or CB2 receptor affinity assay measures the effect of the compound on cAMP modulation using the HTRF detection method. In one embodiment, the CBi and/or CB2 receptor affinity assay is substantially as described herein in the Examples. The inventors have advantageously found that certain compounds of formula (I) exhibit selective affinity for CBi and/or CB2.
In one embodiment, the compound of the invention is a selective CBi and/or CB2 receptor agonist.
In one embodiment, the compound of the invention is selective for CBi and/or CB2 over at least one G-protein coupled receptor or ligand-gated ion channel selected from the group consisting of adenosine Al, adenosine A2A, adenosine A3, adrenergic al, adrenergic a2, adrenergic βΐ, adrenergic β2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2, cholecystokinin CCK1, dopamine Dl, dopamine D2S, endothelin ETA, GABA (nonselective), galanin GAL2, chemokine CXCR2, chemokine CCR1, histamine HI, histamine H2, melatonin MT1, muscarininc Ml, muscarininc M2, muscarininc M3, tachykinin NK2, tachykinin NK3, neuropeptide Yl, neuropeptide Y2, neurotensin NTS 1, opioid μ, opioid δ, opioid K, opioid NOP, prostaglandin EP4, serotonin 5-HT1A, serotonin HT1B, serotonin HT2A, serotonin HT2B, serotonin HT3, serotonin HT5A, serotonin HT6, serotonin HT7, somatostatin SST, vasoactive intestinal polypeptide VPACl, vasopressin VIA, Ca2+ channel L, V channel, SKCa channel, Na+ channel (site 2), CI- channel (GABA-gated), noradrenaline transporter, dopamine transporter, and serotonin transporter. In one embodiment, the compounds are selective for CBi and/or CB2 over all of the aforementioned G-protein coupled receptors and ligand-gated ion channels.
In one embodiment, the compounds is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000, or 10000 times more selective for CBi and/or CB2 than for the G-protein coupled receptor or ligand-gated ion channel. Selectivity may be measured by any suitable method known in the art, for example by comparing the Ki or EC50 of the compound for CBi and/or CB2 with the Ki or EC50 of the compound for the G-protein coupled receptor or ligand-gated ion channel. In one embodiment, the compound has an inhibition of control specific binding of less than about 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% and/or a control specific binding of at least 40, 50, 60, 70, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% for at least one G-protein coupled receptor or ligand-gated ion channel selected from the group consisting of adenosine Al, adenosine A2A, adenosine A3, adrenergic al, adrenergic al, adrenergic βΐ, adrenergic β2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2, cholecystokinin CCK1, dopamine Dl, dopamine D2S, endothelin ETA, GABA (non- selective), galanin GAL2, chemokine CXCR2, chemokine CCR1, histamine HI, histamine H2, melatonin MT1, muscarininc Ml, muscarininc M2, muscarininc M3, tachykinin NK2, tachykinin NK3, neuropeptide Yl, neuropeptide Y2, neurotensin NTS1, opioid μ, opioid δ, opioid κ, opioid NOP, prostaglandin EP4, serotonin 5- HT1A, serotonin HT1B, serotonin HT2A, serotonin HT2B, serotonin HT3, serotonin HT5A, serotonin HT6, serotonin HT7, somatostatin SST, vasoactive intestinal polypeptide VPAC1, vasopressin VIA, Ca2+ channel L, KV channel, SKCa channel, Na+ channel (site 2), Cl- channel (GABA-gated), noradrenaline transporter, dopamine transporter, and serotonin transporter.
In one embodiment, the compound has an inhibition of control specific binding of less than about 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% and/or a control specific binding of at least 40, 50, 60, 70, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% for all of the aforementioned G-protein coupled receptors and ligand-gated ion channels.
In one embodiment, the inhibition of control specific binding and/or control specific binding is measured using a reference radioligand for each G-protein coupled receptor and ligand- gated ion channel.
In one embodiment, the reference radioligand is as defined in Table 6 below.
In one aspect, the invention relates to a use of a compound of the invention in the
manufacture of a medicament for treating pain in a subject. In another aspect, the invention related to use of a compound of the invention in the manufacture for treating nausea and/or emesis in a subject. In another aspect, the invention relates to a use of a compound of the invention in the manufacture of a medicament for stimulating appetite in a subject.
In another aspect, the invention relates to a use of a compound of the invention in the manufacture of a medicament for inducing a euphoric effect in a subject.
In another aspect, the invention relates to a use of a compound of the invention in the manufacture of a medicament for relaxing a subject in a subject.
In another aspect, the invention relates to a use of a compound of the invention in the manufacture of a medicament for inducing a positive mood change in a subject.
In another aspect, the invention relates to a method of treating pain in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
In another aspect, the invention relates to a method for treating nausea and/or emesis in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject. In another aspect, the invention relates to a method for stimulating appetite in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
In another aspect, the invention relates to a method of inducing a euphoric effect in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject. In another aspect, the invention relates to a method of relaxing a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject. In another aspect, the invention relates to method of inducing a positive mood change in a subject, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject.
In another aspect, the invention relates to a compound of the invention for use in treating pain in a subject.
In another aspect, the invention relates to a compound of the invention for use in treating nausea and/or emesis in a subject. In another aspect, the invention relates to a compound of the invention for use in stimulating appetite in a subject.
In another aspect, the invention relates to a compound of the invention for use in inducing a euphoric effect in a subject.
In another aspect, the invention relates to a compound of the invention for use in relaxing a subject.
In another aspect, the invention relates to a compound of the invention for use in inducing a positive mood change in a subject.
In the above aspects:
In one embodiment, the nausea and/or emesis is caused by injury, pain, cancer, AIDS, tuberculosis, glaucoma, menstruation, hepatitis, chemotherapy, radiotherapy, or headaches (such as muscle tension headaches, eyes strain headaches, migraines, or cluster headaches). In one embodiment, the appetite is stimulated to treat loss of appetite caused by wasting. Preferably, the wasting is caused by cystic fibrosis, anorexia, old age, cancer, AIDS, tuberculosis, chronic diarrhoea, or cachexia, preferably cancer cachexia. In one embodiment, the pain is selected from nociceptive pain, neuropathic pain, or psychogenic pain. In one embodiment, the nociceptive pain is caused by: inflammation, joint pain (such as arthritis, osteoarthritis, rheumatoid arthritis, or repetitive strain injury), headaches (such as muscle tension headaches, eyes strain headaches, migraines, or cluster headaches), back pain (such as back pain caused by slipped or bulging discs, spinal stenosis, compression fractures (such as those associated with osteoporosis), soft tissue damage, traumatic fractures, or structural deformities (such as scoliosis, kephosis, or lordosis)), fibromyalgia, surgery, or trauma. In one embodiment, the neuropathic pain is caused by: multiple sclerosis, phantom limb pain, peripheral (diabetic) neuropathy, post-mastectomy pain, sciatica, spinal cord injury (such as bulging or slipped discs or trauma), carpel tunnel syndrome, cancer, radiotherapy, chemotherapy, radiation injury, surgery, or HIV- associated peripheral neuropathy. In one embodiment, the psychogenic pain is caused by: headache, muscle pain, back pain, or stomach pain. In one embodiment, the pain is atypical or neuropathic pain. In one embodiment, the pain is phantom limb pain. One or more compounds of the invention (herein also referred to as the active ingredients) are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with, for example the condition of the recipient. An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.
Although the present invention is broadly as defined above, those persons skilled in the art will appreciate that the invention is not limited thereto and that the invention also includes embodiments of which the following description gives examples.
6. EXAMPLES Compounds of the invention
Figure imgf000103_0001
SGT-24 was synthesised according to Scheme 1 (as shown above). l-Pentyl-lH-indazole-3-carboxylic acid (lie) was prepared by reaction of commercially available indazole-3-carboxylic acid (Ila) with 1-bromopentane (lib) in the presence of sodium hydride in dimethylformamide. Reaction conditions were as set out in J. Med. Chem. 1991; 34(3): 1099-1110 and Bioorg. Med. Chem. Lett. 1994; 4(4): 563-566.
Oxalyl dichloride (5.74 g, 45.2 mmol) was slowly added to a stirred solution of 1-pentyl-lH- indazole-3-carboxylic acid (10.0 g, 43.0 mmol) in dichloromethane (100 mL) at 0°C in an ice-bath. The reaction was stirred for 30 minutes. Triethylamine (9.0 mL, 64.58 mmol) was then added, followed by 2-phenylpropan-2-amine (5.82g, 43.0 mmol). The reaction was stirred for 1 hour and monitored by TLC. The reaction was diluted with water and separated into phases. The organic layer was washed with water (2x100 mL), brine (2x100 mL), dried (MgS04), and concentrated. The resulting oil was purified by flash column chromatography using petroleum ethenethyl acetate 60: 1 as eluent. 11.7 g (78%) of SGT-24 was obtained as a light yellow oil in a 78% yield. lH NMR (400 MHz, DMSO-d6) δ 8.01 (1H, d, HI), 7.97 (1H, s, H5), 7.74 (1H, d, H4), 7.43 (1H, ddd, H2), 7.38 (1H, dd, H3), 7.19 (2H, m, H7), 4.48 (2H, t, H8), 1.90 (2H, m, Hl l), 1.74 (6H, m, H6), 1.25 (6H, m, H12, H10, H13), and 0.84 (3H, t, H14). MS (ESI+) m/z 350 (MH+).
SGT-42
Figure imgf000104_0001
SGT-42 was synthesised according to Scheme IB (as shown above). N-( 1 -Methyl- 1 -phenylethyl)- lH-indazole-3-carboxamide lH-Indazole-3-carboxylic acid (100 g, 0.617 mol, 1.0 molar eq.) in anhydrous N V- dimethylformamide (DMF)(10 volumes, 1 L) was mixed with cumylamine (89 mL, 1.0 molar eq.) and HBTU (281 g, 1.2 molar eq.) at room temperature under argon. To this mixture was added N,N-diisopropylethylamine (215 mL, 2.0 molar eq.) drop wise over a period of at least 2 hours. The reaction mixture was then stirred for at least 15 hours at ambient temperature under an argon blanket. The reaction mixture was the gradually heated in increments of 25 °C per hour up to an internal temperature of 120°C. Once the reaction mixture reached 120°C, it was continuously heated at an internal temperature of 120°C for at least 3 hours. The reaction mixture was rotary evaporated to remove the DMF that a bath temperature of 80°C under reduced pressure. The crude product was placed in an ice bath and mixed with saturated sodium carbonate solution (10 volumes, 1 L). The resultant mixture was continuously stirred and the ice bath until the internal temperature dropped below 5°C. A beige coloured precipitate formed that was filtered and washed with cold purified water (10 x 2.5 volumes, 10 x 250 mL). The wet filter cake was then triturated in saturated sodium carbonate solution (5 volumes, 500 mL) for at least one hour at room temperature. The suspension was then filtered and rinsed with purified water (5 1 volume, 5 x 100 mL). The resultant product was dried under air vacuum, and then co-evaporated with toluene four times prior to final drying on a rotary evaporator with a bath temperature of 60°C to constant weight.
N-( 1 -Methyl- 1 -phenylethyl)- 1 -r(tetrahydro-2H-pyran-4-yl)methyll- lH-indazole-3- carboxamide (SGT-42) The quantity of reagents and materials used in the following procedure were based on the quantity of N-(l-Methyl-l-phenylethyl)-lH-indazole-3-carboxamide obtained in the preceding step, as indicated. A solution of N-(l -methyl- l-phenylethyl)-lH-indazole-3-carboxamide (1.0 molar eq.) in anhydrous DMF (5 volumes) was mixed with anhydrous potassium carbonate (5.84 molar eq.). (Tetrahydro-2H-pyran-4-yl) methyl 4-methylbenzenesulfonate (1 molar eq.) was added portion wise over a period of 5 minutes at ambient temperature to the reaction mixture. The resulting reaction mixture was heated to 70°C for at least 15 hours using an oil bath. The reaction mixture was evaporated at a 40°C bath temperature under reduced pressure to remove the DMF. The evaporated residue was mixed with ethyl acetate (5 volumes) and then poured into ice (5 weight equivalents). The mixture was stirred until the ice melted. The bilayer was separated and the aqueous layer extracted with ethyl acetate (4 x 3 volumes). The combined extracts were washed with 50% saturated sodium carbonate solution (4 x 1 volume), then dried over sodium sulfate and filtered. The filtrate was evaporated at a 40° bath temperature and co-evaporated with ethyl acetate (3 x 2.5 volumes). The resultant residue was redissolved and hot ethyl acetate (4 volumes) and filtered through 60 angstrom silica (2.5 volumes) topped with a layer of anhydrous sodium sulphate. The filter bed was washed with hot ethyl acetate (2 volumes per fraction) until all of the product was released. Product containing fractions were evaporated with a bath temperature of 40°C. The crude product was triturated with methyl tert-butyl ether (MTBE)(2 volumes) at room temperature of the 2 hours, and then in an ice bath for one hour. The suspension was filtered, then rinsed with cold MTBE (4 x 1 volume). The resulting white solid was then dried under vacuum to constant weight, mp 112.7 ± 0.5 . IR vmax/cm_1 3328, 1664 (amide). lU NMR (400 MHz, DMSO-d6) δ 8.03 (1H, d, HI), 7.97 (1H, s, H5), 7.82 (1H, d, H4), 7.41-7.44 (3H, m, H2, H3), 7.33 (2H, dt, H8), 7.20 (2H, dd, H7), 4.41 (2H, d, H10), 3.84 (2H, d, H13), 3.25 (2H, m, H14), 2.23 (1H, m, H15), 1.74 (6H , s, H6), and 1.39 (4H, m, Hl l, H12). MS (ESI+) m/z 378 (MH+). Anal. Calcd for C23H27N3O2: C, 73.18; H, 7.21; N, 11.13. Found: C, 73.44; H, 7.22; N, 11.23.
1 13
H and i3C NMR scans for SGT-42 are provided in Figures 1 and 2, respectivley.
SGT 174
Figure imgf000106_0001
SGT 174 was synthesized according to Scheme 1A (as shown above) by the following general procedure. Alkylation of an indole-3-carboxylic acid or indazole-3-carboxylic acid (Ha)
An indole-3-carboxylic acid or indazole-3-carboxylic acid (IIa)(0.1 mol) was dissolved in DMF (100 ml), and treated with NaH (0.2 mol) at 0°C. RxBr (IIb)(0.15 mol) was added in one portion and the mixture stirred at 0°C for 1 hour. Ice water was added, and the mixture extracted with CH2CI2 (3x100 ml). The combined organic extracts were dried over MgS04 and concentrated under vacuum. Crystallisation from EtOAc/Hexane gave the desired 1- alkyl-indole-3-carboxylic acid or l-alkyl-indazole-3-carboxylic (lie) as solid.
Formation of amide (He)
The l-alkyl-indole-3-carboxylic acid or l-alkyl-indazole-3-carboxylic (IIc)(1.0 mmol) and amine (IId)(1.0 mmol) were dissolved in CH2CI2 (5 ml). The mixture was cooled with ice- water. DCC (1.0 mmol) was added in one portion. The reaction mixture was allowed to warm to room temperature and then stirred over night. The reaction mixture was then filtered through celite and the filtrate concentrated under vacuum. The resultant residue was purified by column chromatography. Crystallization from EtOAc/Hexane gave pure (He).
XH NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 7.90 (m, 1H), 7.41-7.27 (m, 6H), 7.15 (m, 1H), 4.51 (m, 2H), 1.82 (s, 6H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H).
SGT-211
Figure imgf000107_0001
SGT 211 was synthesized according to Scheme 1A (as shown above) by the following general procedure. Alkylation of an indole-3-carboxylic acid or indazole-3-carboxylic acid (Ha) to provide the desired l-alkyl-indole-3-carboxylic acid or l-alkyl-indazole-3-carboxylic (lie) was carried out according to the general procedure described above for SGT 174.
Formation of ester (He)
The l-alkyl-indole-3-carboxylic acid or l-alkyl-indazole-3-carboxylic (IIc)(1.0 mmol) and alcohol (IId)(1.0 mmol) were dissolved in acetonitrile (5 ml). The mixture was cooled with ice-water. DCC (1.0 mmol) was added in one portion. The reaction mixture was allowed to warm to room temperature and then stirred over night. The reaction mixture was then filtered through celite and the filtrate concentrated under vacuum. The resultant residue was purified by column chromatography. Crystallization from EtOAc/Hexane gave pure (He). lH NMR (400 MHz, DMSO-d6) δ 7.92 (m, 1H), 7.90 (m, 1H), 7.72 (m, 3H), 7.66 (s, 1H), 7.40 (m, 2H), 7.38 (m, 2H), 4.36 (m, 1H), 4.15 (m, 2H), 1.82 (s, 6H), 1.45-1.27 (m, 11H).
Compounds of formula I of the invention as shown in Table 1 and compounds of formula la were synthesised in an analogous fashion according to the general methods described herein. The aforementioned preparative procedures are representative of the procedures used.
Compounds of formula I of the invention as shown in Table 3 may be synthesised in a similar manner.
Figure imgf000108_0001
Figure imgf000108_0002
Figure imgf000109_0002
Figure imgf000109_0001
Table 2.
Figure imgf000109_0003
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000114_0002
Characterisation data
XH NMR for selected compounds of the invention is as shown below. MS data
provided for selected compounds.
Figure imgf000115_0001
SGT-25
1H NMR (400 MHz, DMSO-d6) δ 8.07 (IH, d, HI), 7.99 (IH, s, H5), 7.92 (IH, d, H4),7.72 (3H, s, H2), 7.40 (2H,s, H3), 7.38 (2H, dt, H), 4.46 (IH, m, H10), 4.31 (2H, s, H14), 2.00- 1.39 (12H, m, H10, Hl l, H12, H13)
Figure imgf000115_0002
SGT-41
lH NMR (400 MHz, CDC13) δ 8.48 (IH, d, HI), 7.45 (2H, d, H5), 7.41-7.35 (5H, m, H2, H3, H4), 7.22 (2H, m, H7), 4.28 (2H, d, Hl l), 1.80 (6H, s, H6), and 1.75-0.75 (12H, m, Hl l, H12, H13, H14, H15, H16). MS m/z 376 (MH+).
Figure imgf000116_0001
SGT-55
lH NMR (400 MHz, DMSO-d6) δ 8.07 (IH, s, H14), 7.97 (IH, d, HI), 7.52 (IH, s, H5), 7.41 (IH, d, H2), 7.38 (2H,s, H3), 7.24 (2H, dt, H8), 7.12 (2H, dd, H7), 7.06 (IH, t, H9), 4.18 (2H, t, H10), 1.77 (2H, m, Hl l), 1.65 (6H, s, H6), 1.28 (2H, m, H12), and 0.89 (H3, t, H13). MS (ESI+) m/z 335 (MH+).
Figure imgf000116_0002
SGT-56
XH NMR (400 MHz, DMSO-d6) δ 8.22 (IH, s, H15), 7.99 (IH, d, H4), 7.52 (IH, s, H5), 7.49 (IH, d, HI), 7.38 (IH, d, H3), 7.34 (2H, t, H2), 7.12 (2H, dd, H7), 7.06 (IH, t, H9), 4.17 (2H, t, H10), 1.77 (2H, m, Hl l), 1.65 (6H, s, H6), 1.31 (4H, m, H12, H13), and 0.90 (H3, t, H14).
Figure imgf000117_0001
SGT-60
1H NMR (400 MHz, DMSO-d6) δ 8.07 (IH, d, HI), 7.98 (IH, s, HI), 7.52 (IH, d, H5), 7.41 (IH, d, H4), 7.38 (lH,s, H3), 7.42 (2H, dt, H2), 7.20 (IH, dd, H7), 4.48 (2H, t, H9), 1.85 (2H, q, Hl l), 1.70 (6H, s, H6), 1.30-1.23 (4H, m, H12), and 0.84 (H3, t, H13).
Figure imgf000117_0002
XH NMR (400 MHz, DMSO-d6) δ 8.01 (dd, =6.0, 1.2Hz, IH), 7.96 (s, IH), 7.73 (dd, =6.0, 1.2Hz, IH), 7.44 (m, IH), 7.39 (m, IH), 7.18 (m, 2H), 4.47 (m, 2H), 1.90 (m, 2H), 1.74 (s, 6H), 1.25 (m, 4H), 0.84 (t, 3H)
Figure imgf000117_0003
1H NMR (400 MHz, DMSO-d6) δ 7.90 (m, IH), 7.68 (s, IH), 7.45 (m, IH), 7.27 (m, 1 7.38 (m, IH), 7.42 (m, 2H), 7.20 (m, 2H), 4,50 (m, IH), 4.36 (m, IH), 4.12 (m, 2H), 1.
2H), 1.82 (s, 6H), 1.70 (m, 2H), 1.45 (m, 2H).
Figure imgf000118_0001
XH NMR (400 MHz, DMSO-d6) δ 8.17 (dd, /=6.0, 1.2Hz, IH), 7.98 (s, IH), 7.52 (m, IH), 7.41 (m, IH), 7.38 (m, IH), 7.42 (m, 2H), 7.20 (m, IH), 4,50 (m, IH), 4.40 (m, 3H), 1.85 (m, 2H), 1.70 (s, 6H), 1.70-1.50 (m, 4H).
Figure imgf000118_0002
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 4.47 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4.36 (m, IH), 4.15 (m, 2H), 1.90 (m, 2H), 1.82 (s, 6H), 1.70 (m, 2H), 1.45 (m, 2H).
SGT-78
Figure imgf000119_0001
*H NMR (400 MHz, DMSO-d6) δ 8.29 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4,50 (m, 2H). 1.87 (m, 2H), 1.74 (m, 2H), 1.66 (m, 2H), 1.70 (s, 6H).
Figure imgf000119_0002
!H NMR (400 MHz, DMSO-d6) δ 8.31 (m, IH), 8.02 (s, 2H), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.71 (m, 2H). 3.54 (m, IH), 1.82 (s, 6H), 1.69-1.11 (m, 10H).
Figure imgf000119_0003
!H NMR (400 MHz, DMSO-d6) δ 8.31 (m, IH), 8.02 (s, 2H), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 5.60 (m, 2H), 1.82 (s, 6H), 1.69 (s, 9H).
Figure imgf000120_0001
!H NMR (400 MHz, DMSO-d6) δ 8.31 (m, IH), 8.02 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.51 (m, 2H), 1.82 (s, 6H), 1.69 (m, 2H), 0.94 (s, 9H).
Figure imgf000120_0002
!H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.02 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.21 (m, 2H), 7.20 (m, IH), 7.12 (m, 2H), 5.51 (m, 2H), 1.82 (s, 6H).
SGT-150
Figure imgf000121_0001
XH NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.02 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.51 (m, 2H), 2.51 (m, 2H), 2.26 (s, 3H), 2.22 (m, IH), 1.82 (s, 6H), 1.69-1.47 (m, 6H).
Figure imgf000121_0002
XH NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.50 (m, 2H), 2.13 (m, IH), 1.88 (m, IH), 1.82 (s, 6H), 1.58-1.40 (m, 9H).
Figure imgf000121_0003
XH NMR (400 MHz, DMSO-d6) δ 7.88 (m, IH), 7.69 (s, IH), 7.41 (m, 3H), 7.29 (m, 4H), 6.26 (s, IH), 4.11 (m, 2H), 1.90 (m, 2H), 1.82 (s, 6H), 1.32 (m, 4H), 0.88 (m, 3H).
Figure imgf000122_0001
XH NMR (400 MHz, DMSO-d6) δ 7.90 (m, IH), 7.68 (s, IH), 7.42 (m, 3H), 7.29 (m, 4H), 6.26 (s, IH), 4,49 (m, IH), 4.35 (m, IH), 4.13 (m, 2H), 1.90 (m, 2H), 1.82 (s, 6H), 1.70 (m, 2H), 1.45 (m, 2H).
Figure imgf000122_0002
XH NMR (400 MHz, DMSO-d6) δ 7.89 (m, IH), 7.65 (s, IH), 7.42 (m, 3H), 7.29 (m, 4H), 6.25 (s, IH), 3.95 (m, 2H), 1.82 (s, 6H), 1.80 (m, IH), 1.70-1.50 (m, 5H), 1.15 (m, 3H), 1.00 (m, 2H).
Figure imgf000122_0003
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, 4.47 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 3.95 (m, 2H), 1.82 (s, 6H), 1.80 (m, IH), 1 (m, 5H), 1.15 (m, 3H), 1.00 (m, 2H).
Figure imgf000123_0001
1H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 7.45-7.35 (m, 5H), 7.30-7.18 (m, 3H), 4.38 (m, 2H), 1.95 (m, 2H), 1.83 (s, 6H), 1.35 (m, 5H).
Figure imgf000123_0002
1H NMR (400 MHz, DMSO-d6) δ 8.30 (m, IH), 7.45-7.35 (m, 5H), 7.30-7.18 (m, 3H), 4.50 (m, IH), 4.39 (m, 3H), 2.00 (m, 2H), 1.83 (s, 6H), 1.75 (m, 2H), 1.50 (m, 2H). SGT-159
Figure imgf000124_0001
XH NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 7.45-7.35 (m, 5H), 7.30-7.18 (m, 3H), 4.20 (m, 2H), 2.03 (m, IH), 1.83 (s, 6H), 1.75-1.50 (m, 5H), 1.25-1.00 (m, 5H).
Figure imgf000124_0002
XH NMR (400 MHz, DMSO-d6) δ 8.31 (m. IH), 8.04 (s, IH), 7.92 (m. IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.51 (m, 2H), 1.74 (m, 2H), 1.31- 1.29 (m, 4H), 0.90 (m, 3H), 0.85 (m, 2H), 0.60 (m, 2H).
Figure imgf000124_0003
lR NMR (400 MHz, DMSO-d6) δ 7.92 (m. IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H). 7.38 (m, 2H), 6.25 (s, IH), 4.51 (m, 2H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H), 0.85 (m, 2H), 0.60 (m, 2H).
Figure imgf000125_0001
1H NMR (400 MHz, DMSO-d6) δ 8.33 (m, IH), 8.00 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4,48 (m, IH), 4.36 (m, IH), 4.15 (m, 2H), 1.75 (m, 2H), 1.50 (m, 2H), 1.29 (m, 2H), 0.85 (m, 2H), 0.60 (m, 2H).
Figure imgf000125_0002
1H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.04 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.51 (m, 2H), 1.45-1.27 (m, 11H), 0.85 (m, 2H), 0.60 (m, 2H).
Figure imgf000125_0003
1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, IH), 8.01 (s, IH), 7.84 (m, IH), 7.70 (m, IH), 7.37-7.27 (m, 5H), 7.14 (m, IH), 4.31 (m, 2H), 1.81 (s, 6H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H).
Figure imgf000126_0001
XH NMR (400 MHz, DMSO-d6) δ 8.37 (s, IH), 8.00 (s, IH), 7.90 (m, IH), 7.69 (m, IH), 7.41 (m, 2H), 7.24 (m, 2H), 7.15 (m, IH), 4.51 (m, 2H), 1.82 (s, 6H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H).
Figure imgf000126_0002
lH NMR (400 MHz, DMSO-d6) δ 8.35 (s, IH), 8.00 (s, IH), 7.84 (m, IH), 7.69 (m, IH), 7.37-7.27 (m, 5H), 7.15 (m, IH), 4.31 (m, 2H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H), 0.85 (m, 2H), 0.60 (m, 2H).
SGT-182
Figure imgf000127_0001
1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, IH), 7.90 (m, IH), 7.41 (m, 2H), 7.31 (m, IH), 7.24 (m, 2H), 7.15 (m, IH), 4.51 (m, 2H), 1.82 (s, 6H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H).
Figure imgf000127_0002
XH NMR (400 MHz, DMSO-d6) δ 8.37 (s, IH), 7.90 (m, IH), 7.37-7.27 (m, 6H), 7.15 (m, IH), 4.51 (m, 2H), 1.74 (m, 2H), 1.31-1.29 (m, 4H), 0.90 (m, 3H), 0.85 (m, 2H), 0.60 (m, 2H).
Figure imgf000127_0003
!H NMR (400 MHz, DMSO-d6) 5 8.29 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.47 (m, IH), 3.75 (m, 2H), 3.65 (m, 4H), 2.36 (m, 4H), 1.83 (s, 6H).
Figure imgf000128_0001
lR NMR (400 MHz, DMSO-d6) 5 8.29 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.47 (m, IH), 1.83 (s, 6H), 1.60 (m, 2H), 0.87 (m, 3H).
Figure imgf000128_0002
XH NMR (400 MHz, DMSO-d6) δ 8.29 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.47 (m, IH), 1.83 (s, 6H), 1.69- 1.24 (m, 8H), 0.87 (m, 3H).
SGT- 187
Figure imgf000129_0001
!H NMR (400 MHz, DMSO-d6) 5 8.29 (m, IH), 8.03 (s, IH). 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.47 (m, IH), 1.83 (s, 6H), 1.69-1.24 (m, 10H), 0.88 (m, 3H).
Figure imgf000129_0002
*H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 4.47 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4.47 (m, IH), 3.65-3.55 (m, 4H), 1.83 (s, 6H), 1.69-1.44 (m, 5H).
Figure imgf000129_0003
*H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.68 (s, IH), 7.42 (m, 3H), 7.29 (m, 4H), 6.26 (s, IH), 4.47 (m, IH), 3.65-3.55 (m, 4H), 1.83 (s, 6H), 1.69-1.44 (m, 5H).
Figure imgf000130_0001
XH NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 7.43 (m, 2H), 7.39 (m, 2H), 7.37 (s, IH), 7.29 (m, 2H), 7.26 (s, IH), 7.21 (m, IH), 4.51 (m, 2H), 3.65-3.55 (m, 4H), 1.70 (s, 6H), 1.69- 1.44 (m, 5H).
Figure imgf000130_0002
XH NMR (400 MHz. DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (s, IH), 7.66 (m, 2H), 7.40 (m, 2H), 7.38 (m, 2H), 6.26 (s, IH), 4.51 (m, 2H), 3.65-3.55 (m, 4H), 1.69-1.44 (m, 5H), 0.85 (m, 2H), 0.60 (m, 2H).
Figure imgf000130_0003
XH NMR (400 MHz, DMSO-d6) δ 8.29 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4.51 (m, 2H), 3.65-3.55 (m, 4H), 1.69-1.44 (m, 5H), 0.85 (m, 2H), 0.60 (m, 2H).
Figure imgf000131_0001
XH NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4.17 (m, 2H), 1.77 (m, 2H), 1.65 (s, 6H), 1.31 (m, 4H), 0.90 (m, 3H)
Figure imgf000131_0002
XH NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4.48 (m, IH), 4.36 (m, IH), 4.15 (m, 2H), 1.90 (m, 2H), 1.82 (s, 6H), 1.70 (m, 2H), 1.45 (m, 2H).
SGT-212
Figure imgf000131_0003
!H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4,50 (m, 2H), 3.65-3.55 (m, 4H), 1.70 (s, 6H), 1.69-1.44 (m, 5H).
Figure imgf000132_0001
!H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4.48 (m, 2H), 1.85 (m, 2H), 1.70 (s, 6H). 1.30-1.23 (m, 4H), 0.84 (m, 3H).
Figure imgf000132_0002
XH NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 3H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, 2H), 4,50 (m, IH), 4.40 (m, 3H), 1.85 (m, 2H), 1.70 (s, 6H), 1.70- 1.50 (m, 4H).
SGT-215
Figure imgf000133_0001
XH NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.04 (s, IH), 7.93 (m, IH), 7.64 (m, IH), 7.44 (m, IH), 7.42 (m, 2H), 7.37 (m, 2H), 7.21 (m, IH), 4,50 (m, 2H), 1.70 (s, 6H), 1.69-1.27 (m, 11H).
Figure imgf000133_0002
1H NMR (400 MHz, DMSO-d6) δ 8.31 (m, IH), 8.03 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 7.40 (m, 2H), 7.38 (m, 2H), 7.20 (m, IH), 4,50 (m, 2H), 3.65-3.55 (m, 4H), 1.70 (s, 6H), 1.69-1.44 (m, 5H).
Figure imgf000133_0003
XH NMR (400 MHz, DMSO-d6) δ 7.89 (m, IH), 7.68 (s, IH), 7.60 (s, IH), 7.43 (m, IH), 7.33 (m, 2H), 4,45 (m, 2H), 3.26 (s, IH), 1.74 (m, 2H), 1.70 (s, 6H), 1.30 (m, 4H), 0.89 (m, 3H).
Figure imgf000134_0001
XH NMR (400 MHz, DMSO-d6) δ 7.91 (m, IH), 7.68 (s, IH), 7.56 (s, IH), 7.41 (m, IH), 7.28 (m, 2H), 4.46 (m, IH), 4.376 (m, IH), 4.14 (m, 2H), 3.27 (s, IH), 1,75 (m, 2H), 1.59 (s, 6H), 1.49 (m, 2H), 1.29 (m, 2H) .
Figure imgf000134_0002
XH NMR (400 MHz, DMSO-d6) δ 7.91 (m, IH), 7.68 (s, IH), 7.60 (s, IH), 7.43 (m, IH), 7.28 (m, 2H), 4.45 (m, 2H), 3.26 (s, IH), 1.70 (s, 6H), 1.69-1.27 (m, 9H).
Figure imgf000134_0003
XH NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 8.0 (s, IH), 7.80 (s, IH), 7.43 (m, IH), 7.28 (m, 2H), 4, 1 (m, 2H), 3.65 (m, 2H), 3.55 (m, 2H), 3.26 (s, IH), 1.70 (s, 6H), 1.69-1.60 (m, 4H), 1.60 (m, IH).
Figure imgf000135_0001
XH NMR (400 MHz, DMSO-d6) δ 8.30 (m, IH), 7.98 (s, IH), 7.92 (m, IH), 7.61 (m, IH), 7.48 (m, IH), 4.48 (m, 2H), 3.25 (s, IH), 1.75 (m, 2H), 1.70 (s, 6H), 1.30-1.28 (m, 4H), 0.84 (m, 3H).
Figure imgf000135_0002
1H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.02 (s, IH), 7.91 (m, IH), 7.63 (m, IH), 7.48 (m, IH), 4,50 (m, 2H), 3.65 (m, 2H), 3.55 (m, 2H), 3.26 (s, IH), 1.74 (m, IH), 1.70 (s, 6H), 1.69-1.44 (m, 4H), 1.60 (m, IH).
Figure imgf000135_0003
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.90 (m, IH), 7.72 (m, 2H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, IH), 4.36 (m, 2H), 3.75 (m, 2H), 2.45 (m, 4H), 1.90 (m, 2H), 1.82 (s, 6H), 1.59-1.50(m, 6H).
Figure imgf000136_0001
1H NMR (400 MHz, DMSO-d6) δ 7.91 (m, IH), 7.89 (m, IH), 7.72 (m, 2H), 7.66 (s, IH), 7.40 (m, 2H), 7.38 (m, IH), 5.36 (m, 2H), 3.74 (m, 2H), 2.45 (m, 4H), 1.82 (s, 6H), 1.80 (m, 4H).
Figure imgf000136_0002
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.58 (m, IH), 7.57-7.37 (m, 6H), 7.25 (m, IH), 4.15 (m, 2H), 2.65 (s, 2H), 1.70 (m, 2H), 1.45 (s, 6H), 1.31 (m, 2H), 0.90 (m, 3H).
SGT-238
Figure imgf000137_0001
*H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.68 (s, IH), 7.57 (m, IH), 7.45 (m, 2H), 6.28 (s, IH), 4.35 (m, 2H), 1.70 (m, 2H), 1.65 (s, 6H), 1.31 (m, 4H), 0.90 (m. 3H).
Figure imgf000137_0002
*H NMR (400 MHz, DMSO-d6) δ 7.94 (m, IH), 7.67 (s, IH), 7.57 (m, IH), 7.43 (m, 2H), 6.27 (s, IH), 4.25 (m, 2H), 2.53 (m, 6H), 1.72 (m, 2H), 1.69 (m, 4H), 1.65 (s. 6H), 1.31 (m. 4H), 0.90 (m, 3H).
Figure imgf000137_0003
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.68 (s, IH), 7.58 (m, IH), 7.57-7.37 (m, 7H), 7.25 (m, IH), 4.25 (m, 2H), 3.66 (m, 4H), 2.25 (m, 4H), 1.70 (m, 2H), 1.31 (m, 2H), 0.90 (m, 3H).
Figure imgf000138_0001
lH NMR (400 MHz, DMSO-d6) δ 8.31 (m, IH), 8.04 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 4.35 (m, 2H), 1.70 (m, 2H), 1.65 (s, 6H), 1.31 (m, 4H), 0.90 (m, 3H).
Figure imgf000138_0002
!H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.04 (s, IH), 7.92 (m, IH), 7.62 (m, IH), 7.42 (m, IH), 4.25 (m, 2H), 2.53 (m, 6H), 1.72 (m, 2H), 1.69 (m, 4H), 1.65 (s, 6H), 1.31 (m, 4H), 0.90 (m, 3H).
Figure imgf000138_0003
1H NMR (400 MHz, DMSO-d6) δ 8.32 (m, IH), 8.04 (s, IH), 7.57-7.37 (m, 7H), 7.25 (m, IH), 4.25 (m, 2H), 3.66 (m, 4H), 2.25 (m, 4H), 1.70 (m, 2H), 1.31 (m, 2H), 0.90 (m, 3H).
Figure imgf000139_0001
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 8.0 (s, IH), 7.80 (s, IH), 7.43 (m, IH), 7.28 (m, 2H), 4.35 (m, 2H), 3.55 (m, 4H), 1.65 (s, 6H), 1.61 (m, IH), 1.48 (m, 4H).
Figure imgf000139_0002
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 8.0 (s, IH), 7.80 (s, IH), 7.43 (m, IH), 7.28 (m, 2H), 4.35 (m, 2H), 3.55 (m, 4H), 2.51 (m, 6H), 1.69 (m, 8H), 1.66 (s, 6H), 1.61 (m, IH), 1.48 (m, 4H).
Figure imgf000139_0003
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 8.0 (s, IH), 7.80 (s, IH), 7.43 (m, IH), 7.35- 7.27 (m, 7H), 4.35 (m, 2H), 3.55 (m, 8H), 2.23 (m, 4H), 1.61 (m, IH), 1.48 (m, 4H).
Figure imgf000140_0001
1H NMR (400 MHz, DMSO-d6) δ 7.92 (m, IH), 7.68 (s, IH), 7.58 (m, IH), 7.57-7.37 (m, 7H), 7.25 (m, IH), 4.47 (m, 2H), 2.15 (m, 4H), 1.77 (m, 2H), 1.55 (m, 4H), 1.31 (m, 4H), 0.90 (m, 3H)
Figure imgf000140_0002
lH NMR (400 MHz, DMSO-d6) δ 8.22 (s, IH), 7.99 (dd, /=7.0, 1.2Hz, IH), 7.52 (s, IH), 7.49 (dd, =7.0, 1.2Hz, IH), 7.38 (m, IH), 7.34 (m, 2H), 7.12 (m, 2H), 7.06 (m, IH), 4.47 ( 2H), 2.15 (m, 4H), 1.77 (m, 2H), 1.55 (m, 4H), 1.31 (m, 4H). 0.90 (m, 3H)
Figure imgf000140_0003
1H NMR (400 MHz, DMSO-d6) δ 7.91 (m, IH), 7.67 (s, IH), 7.59 (m, IH), 7.57-7.37 (m, 7H), 7.25 (m, IH), 4.47 (m, 2H), 3.55 (m, 4H), 2.15 (m, 4H), 1.67 (m, 4H), 1.62 (m, IH), 1.55 (m, 4H).
Figure imgf000141_0001
1H NMR (400 MHz, DMSO-d6) δ 7.61 (m, IH), 7.57-7.37 (m, 7H), 7.23 (s, IH), 7.19 (s, IH), 7.12 (m, IH), 4.47 (m, 2H), 1.77 (s, 6H), 1.67 (m, 2H), 1.32 (m, 4H), 0.91 (m, 3H). Solubility of SGT-42
The solubility of SGT-42 was tested in water, dimethyl sulfoxide, and propane- 1,2-diol (propylene glycol) according to British Pharmacopoeia procedures for determining solubility. Approximately 50 mg of SGT-42 was added to each solvent. The results are summarised in Table 4 below.
Table 4.
Figure imgf000141_0002
6.2 Cannabinoid receptor binding affinity The cannabinoid receptor binding affinity of selected compounds of the invention was evaluated using the following tests.
GPCR functional assay: Human cannabinoid CB1 receptor - agonist effect
This test evaluated the agonist activity of compounds of the invention at the human CB 1 receptor expressed in transfected CHO cells, as determined by measuring their effects on cAMP modulation using the HTRF detection method.
The cells were suspended in HBSS buffer (Invitrogen) complemented with 20 mM HEPES (pH 7.4), then distributed in microplates at a density of 5.103 cells/well in the presence of either of the following: HBSS (basal control), the reference agonist at 30 nM (stimulated control) or various concentrations (EC50 determination), or the test compound.
Thereafter, the adenylyl cyclase activator NKH 477 was added at a final concentration of 3 μΜ.
Following 20 min incubation at 37°C, the cells were lysed and the fluorescence acceptor (D2- labeled cAMP) and fluorescence donor (anti-cAMP antibody labeled with europium cryptate) were added.
After 60 min at room temperature, the fluorescence transfer was measured at ex=337 nm and em=620 and 665 nm using a microplate reader (Rubystar, BMG).
The cAMP concentration was determined by dividing the signal measured at 665 nm by that measured at 620 nm (ratio).
The results are expressed as a percent of the control response to 30 nM CP 55940.
The standard reference agonist was CP 55940, which was tested in each experiment at several concentrations to generate a concentration-response curve from which its EC50 value was calculated.
Reference: FELDER, C.C., JOYCE, K.E., BRILET, E.M., MANSOURI, J., MACKIE, K., BLOND, O., LAI, Y., MA, A.L. and MITCHELL, R.L. (1995), Comparison of the pharmacology and signal transduction of the human cannabinoid CBi and CB2 receptors, Mol. Pharmacol., 48: 443.
Assay volume and format: 20 μΐ in 96-well plate
Compound addition: [lOOx] solution in solvent then
[lOx] solution in HBSS and 0.1% BSA
Maximum tolerable DMSO concentration: 1%
The results of the tests are summarised in Table 5 below.
GPCR functional assay: Human cannabinoid CB2 receptor - agonist effect
This test evaluated the agonist activity of compounds of the invention at the human CB2 receptor expressed in transfected CHO cells, as determined by measuring their effects on cAMP modulation using the HTRF detection method.
The cells were suspended in HBSS buffer (Invitrogen) complemented with 20 mM HEPES (pH 7.4), then distributed in microplates at a density of 7.5xl03 cells/well in the presence of either of the following: HBSS (basal control), the reference agonist at 100 nM (stimulated control) or various concentrations (EC50 determination), or the test compound.
Thereafter, the adenylyl cyclase activator NKH 477 was added at a final concentration of 3 μΜ.
Following 10 min incubation at 37°C, the cells were lysed and the fluorescence acceptor (D2- labeled cAMP) and fluorescence donor (anti-cAMP antibody labeled with europium cryptate) were added.
After 60 min at room temperature, the fluorescence transfer was measured at
Figure imgf000143_0001
nm and em=620 and 665 nm using a microplate reader (Rubystar, BMG).
The cAMP concentration was determined by dividing the signal measured at 665 nm by that measured at 620 nm (ratio).
The results are expressed as a percent of the control response to 100 nM WIN 55212-2. The standard reference agonist was WIN 55212-2, which was tested in each experiment at several concentrations to generate a concentration-response curve from which its EC 50 value was calculated.
Reference: FELDER, C.C., JOYCE, K.E., BRILET, E.M., MANSOURI, J., MACKIE, K., BLOND, O., LAI, Y., MA, A.L. and MITCHELL, R.L. (1995), Comparison of the pharmacology and signal transduction of the human cannabinoid CBi and CB2 receptors, Mol. Pharmacol., 48: 443.
Assay volume and format: 20 μΐ in 96-well plate
Compound addition: [lOOx] solution in solvent then
[lOx] solution in HBSS and 0.1% BSA
Maximum tolerable DMSO concentration: 1%
The results of the tests are summarised in Table 5 below.
Table 5.
Figure imgf000144_0001
# EC50 value below the lowest test concentration. Concentration-response curve shows more than 50 % effect at the lowest validated testing concentration.
## EC50 value not calculable. Concentration-response curve shows less than 25% effect at the highest validated testing concentration. 6.3 Off-target G-protein coupled receptor and ligand-gated ion channel screen
Fifteen compounds (SGT-24, SGT-25, SGT-42, SGT-56, SGT-60, SGT-65, SGT-149, SGT- 153, SGT-161, SGT-209, SGT-214, SGT-238, SGT-239, SGT-240 and SGT-247) were tested at ΙμΜ to measure their binding affinity against a panel of 53 common G-protein coupled receptor and ligand-gated ion channel targets, to assess their potential to cause side effects.
The receptors and channels tested against were adenosine Al, A2A and A3, adrenergic al, a2, βΐ and β2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2,
cholecystokinin CCK1, dopamine Dl and D2S, endothelin ETA, GABA (non- selective), galanin GAL2, chemokine CXCR2 and CCR1, histamine HI and H2, melatonin MT1, muscarininc Ml, M2 and M3, tachykinin NK2 and NK3, neuropeptide Y Yl and Y2, neurotensin NTS1, opioid μ, δ, κ and NOP, prostaglandin EP4, serotonin 5-HT1A, IB, 2A, 2B, 3, 5A, 6 and 7, somatostatin SST, vasoactive intestinal polypeptide VPAC1, vasopressin VIA, Ca2+ channel L, KV channel, SKCa channel, Na-i- channel (site 2), CI- channel (GABA-gated), noradrenaline transporter, dopamine transporter and serotonin transporter. In general, the affinity of the compounds tested at these targets was significantly lower than that recorded against the cannabinoid CB 1 and CB2 receptors.
Only two target - ligand combinations achieved more than 50% displacement of the appropriate reference ligand at ΙμΜ. SGT-153 achieved 53% displacement of IB-MECA from adenosine A3 receptor at ΙμΜ and SGT-60 achieved 60% displacement of diazepam from central benzodiazepine receptor at ΙμΜ.
Some weak affinity was seen against 5-HT1A and MT1 receptors. However, due to their high CB 1 and CB2 affinity, the tested compounds are still generally highly selective for CB 1 and CB2 receptors. The data in Table 6 shows that the Ki of compounds SGT-24, SGT-25, SGT-42, SGT-60, SGT-65 and SGT-149 is greater than 1000 nM. The data in Table 5 shows that the EC50 for these compounds is less than 1 nM. This suggests that these compounds were over l,000x selective for CB 1 and CB2 receptors over all other receptors and channels tested, and that compound SGT-42 was close to 10,000x selectivite for CB 1 and CB2.
The results of the assay screen for SGT-24, SGT-42, SGT-65 and SGT-149 are provided in Table 6 below (each assay is in bold, followed by the reference radioligand used in that assay).
Most of the compounds were selective for CBl over CB2. SGT-56 the highest selectivity, being 19.7x selective for CB l over CB2.
SGT-214, by contrast was 23.4x selective for CB2 over CB l.
Table 6.
Figure imgf000146_0001
SGT-42 -3 103.2 1.6E-10 4.1E-11 0.9
SGT-65 -6 106.2 1.6E-10 4.1E-11 0.9
SGT-149 -6 105.9 1.6E-10 4.1E-11 0.9 alpha 2 (non-selective) (antagonist radioligand) yohimbine
SGT-24 -4 103.5 3.9E-08 1.7E-08 0.8
SGT-42 -14 113.8 3.9E-08 1.7E-08 0.8
SGT-65 -17 116.7 3.9E-08 1.7E-08 0.8
SGT-149 -8 108.0 3.9E-08 1.7E-08 0.8 beta 1 (h) ( agonist
atenolol
radioliganc )
SGT-24 0 99.8 2.3E-07 1.3E-07 0.9
SGT-42 8 92.1 2.3E-07 1.3E-07 0.9
SGT-65 3 97.4 2.3E-07 1.3E-07 0.9
SGT-149 -2 102.3 2.3E-07 1.3E-07 0.9 beta 2 (h) ( agonist
ICI 118551
radioliganc )
SGT-24 -1 100.7 7.2E-10 2.4E-10 1.2
SGT-42 1 98.6 7.2E-10 2.4E-10 1.2
SGT-65 0 100.2 7.2E-10 2.4E-10 1.2
SGT-149 -4 103.8 7.2E-10 2.4E-10 1.2
ATI (h) (ai itagonist
saralasin
radioligant )
SGT-24 -14 113.8 4.5E-10 2.2E-10 0.8
SGT-42 6 94.4 4.5E-10 2.2E-10 0.8
SGT-65 9 90.6 4.5E-10 2.2E-10 0.8
SGT-149 1 98.7 4.5E-10 2.2E-10 0.8
BZD (central) (agonist radioligand) diazepam
SGT-24 -45 144.6 6.5E-09 5.5E-09 0.8
SGT-42 -25 125.1 6.5E-09 5.5E-09 0.8
SGT-65 -42 141.9 6.5E-09 5.5E-09 0.8
SGT-149 -41 140.6 6.5E-09 5.5E-09 0.8
B2 (h) (agonist radioligand) NPC 567
SGT-24 -7 106.7 2.7E-08 1.4E-08 0.8
SGT-42 -3 102.6 2.7E-08 1.4E-08 0.8
SGT-65 -5 104.8 2.7E-08 1.4E-08 0.8
SGT-149 0 100.3 2.7E-08 1.4E-08 0.8
CB1 (h) (agonist radioligand) CP 55940
SGT-24 105 -4.7 6.6E-10 5.8E-10 1.0
SGT-42 100 -0.4 6.6E-10 5.8E-10 1.0
SGT-65 103 -2.5 6.6E-10 5.8E-10 1.0
SGT-149 99 0.8 6.6E-10 5.8E-10 1.0
CCKl (CC £A) (h) (agonist radioligand) CCK-8s
SGT-24 -11 110.7 8.8E-11 6.6E-11 1.4
SGT-42 -9 109.5 8.8E-11 6.6E-11 1.4
SGT-65 2 97.9 8.8E-11 6.6E-11 1.4 SGT-149 -41 141.3 8.8E-11 6.6E-11 1.4
Dl (h) (ant agonist
SCH 23390
radioliganc )
SGT-24 -1 101.4 2.7E-10 l.lE-10 1.2
SGT-42 10 90.1 2.7E-10 l.lE-10 1.2
SGT-65 9 90.9 2.7E-10 l.lE-10 1.2
SGT-149 14 86.1 2.7E-10 l.lE-10 1.2
D2S (h) (ai itagonist
(+)butaclamol
radioliganc )
SGT-24 9 90.8 2.8E-09 9.5E-10 1.1
SGT-42 9 90.9 2.8E-09 9.5E-10 1.1
SGT-65 -4 104.3 2.8E-09 9.5E-10 1.1
SGT-149 13 87.3 2.8E-09 9.5E-10 1.1
ETA (h) (agonist radioligand) endothelin- 1
SGT-24 -3 102.7 3.0E-11 1.5E-11 0.8
SGT-42 8 92.5 3.0E-11 1.5E-11 0.8
SGT-65 -3 102.6 3.0E-11 1.5E-11 0.8
SGT-149 -2 102.4 3.0E-11 1.5E-11 0.8
GABA (non-selective) (agonist radioligand) GABA
SGT-24 -3 103.5 6.7E-08 4.0E-08 1.0
SGT-42 -1 100.9 6.7E-08 4.0E-08 1.0
SGT-65 0 99.5 6.7E-08 4.0E-08 1.0
SGT-149 -12 111.9 6.7E-08 4.0E-08 1.0
GAL2 (h) ( agonist
galanin
radioliganc )
SGT-24 -5 104.8 2.8E-10 2.6E-10 0.9
SGT-42 -5 105.0 2.8E-10 2.6E-10 0.9
SGT-65 -5 104.8 2.8E-10 2.6E-10 0.9
SGT-149 -12 111.5 2.8E-10 2.6E-10 0.9
CXCR2 (IL-8B) (h) (agonist radioligand) IL-8
SGT-24 -14 114.2 2.3E-10 l.lE-10 1.5
SGT-42 -13 113.2 2.3E-10 l.lE-10 1.5
SGT-65 -12 111.9 2.3E-10 l.lE-10 1.5
SGT-149 -1 101.3 2.3E-10 l.lE-10 1.5
CCRl (h) ( agonist
MIP-1 alpha
radioliganc )
SGT-24 -4 104.1 8.3E-11 5.5E-11 1.3
SGT-42 -4 103.7 8.3E-11 5.5E-11 1.3
SGT-65 -14 114.1 8.3E-11 5.5E-11 1.3
SGT-149 -7 107.4 8.3E-11 5.5E-11 1.3
HI (h) (anl agonist
pyrilamine
radioliganc )
SGT-24 -16 115.5 2.4E-09 1.5E-09 1.2
SGT-42 -19 118.6 2.4E-09 1.5E-09 1.2
SGT-65 -5 104.8 2.4E-09 1.5E-09 1.2 SGT-149 -12 111.8 2.4E-09 1.5E-09 1.2
H2 (h) (ant agonist
cimetidine
radioliganc )
SGT-24 0 100.0 4.5E-07 4.3E-07 1.1
SGT-42 -5 104.8 4.5E-07 4.3E-07 1.1
SGT-65 -18 118.2 4.5E-07 4.3E-07 1.1
SGT-149 1 99.4 4.7E-07 4.5E-07 0.7
MTl (MLIA) (h) (agonist radioligand) melatonin
SGT-24 9 91.0 5.5E-10 4.4E-10 0.9
SGT-42 13 86.8 5.5E-10 4.4E-10 0.9
SGT-65 39 60.8 5.5E-10 4.4E-10 0.9
SGT-149 19 80.7 5.5E-10 4.4E-10 0.9
Ml (h) (an tagonist
pirenzepine
radioliganc )
SGT-24 -13 113.5 2.3E-08 2.0E-08 1.1
SGT-42 -20 120.0 2.3E-08 2.0E-08 1.1
SGT-65 -15 115.3 2.3E-08 2.0E-08 1.1
SGT-149 -21 121.4 2.3E-08 2.0E-08 1.1
M2 (h) (an tagonist
methoctramine
radioliganc )
SGT-24 -9 109.5 3.1E-08 2.1E-08 1.1
SGT-42 -5 105.5 3.1E-08 2.1E-08 1.1
SGT-65 -4 104.4 3.1E-08 2.1E-08 1.1
SGT-149 -4 103.8 3.1E-08 2.1E-08 1.1
M3 (h) (an tagonist
4-DAMP
radioliganc )
SGT-24 1 99.3 6.0E-10 4.3E-10 0.9
SGT-42 -2 102.0 6.0E-10 4.3E-10 0.9
SGT-65 0 100.1 6.0E-10 4.3E-10 0.9
SGT-149 -10 110.4 6.0E-10 4.3E-10 0.9
NK2 (h) (a gonist radioligand) [NleulO]-NKA (4-10)
SGT-24 -4 103.9 4.2E-09 2.3E-09 0.8
SGT-42 -7 106.9 4.3E-09 2.3E-09 0.8
SGT-65 10 90.3 4.3E-09 2.3E-09 0.8
SGT-149 4 96.3 4.3E-09 2.3E-09 0.8
NK3 (h) (a ntagonist
SB 222200
radioliganc )
SGT-24 -8 107.8 5.5E-09 2.9E-09 0.8
SGT-42 -4 104.1 5.5E-09 2.9E-09 0.8
SGT-65 -6 106.2 5.5E-09 2.9E-09 0.8
SGT-149 -3 103.5 5.5E-09 2.9E-09 0.8
Yl (h) (agonist radioligand) NPY
SGT-24 -17 117.1 8.4E-11 5.9E-11 1.0
SGT-42 -26 125.9 8.4E-11 5.9E-11 1.0
SGT-65 -12 112.1 8.4E-11 5.9E-11 1.0 SGT-149 -13 113.4 8.4E-11 5.9E-11 1.0
Y2 (h) (agonist radioligand) NPY
SGT-24 1 98.5 2.7E-11 l.lE-11 0.7
SGT-42 6 94.5 2.7E-11 l.lE-11 0.7
SGT-65 12 87.7 2.7E-11 l.lE-11 0.7
SGT-149 15 85.5 2.7E-11 l.lE-11 0.7
NTSl (NTl) (h) (agonist radioligand) neurotensin
SGT-24 -22 122.0 2.5E-10 2.0E-10 0.7
SGT-42 -21 121.3 2.5E-10 2.0E-10 0.7
SGT-65 -28 127.6 2.5E-10 2.0E-10 0.7
SGT-149 -10 109.8 2.5E-10 2.0E-10 0.7 delta 2 (DOP) (h) (agonist radioligand) DPDPE
SGT-24 6 94.4 3.7E-09 2.2E-09 1.1
SGT-42 4 96.4 3.7E-09 2.2E-09 1.1
SGT-65 3 97.5 3.7E-09 2.2E-09 1.1
SGT-149 12 87.5 3.7E-09 2.2E-09 1.1 kappa (KOP) (agonist radioligand) U 50488
SGT-24 -4 103.9 9.4E-10 6.2E-10 1.1
SGT-42 5 95.2 9.4E-10 6.2E-10 1.1
SGT-65 0 99.7 9.4E-10 6.2E-10 1.1
SGT-149 36 64.1 9.4E-10 6.2E-10 1.1 mu (MOP) (h) (agonist radioligand) DAMGO
SGT-24 1 99.0 9.8E-10 4.1E-10 1.1
SGT-42 9 90.6 9.8E-10 4.1E-10 1.1
SGT-65 -4 104.3 9.8E-10 4.1E-10 1.1
SGT-149 -6 105.5 1.1E-09 4.4E-10 0.9
NOP (ORL1) (h) (agonist radio igand) nociceptin
SGT-24 7 93.2 8.7E-10 1.7E-10 1.4
SGT-42 8 91.9 8.7E-10 1.7E-10 1.4
SGT-65 -8 107.7 8.7E-10 1.7E-10 1.4
SGT-149 -6 105.9 8.7E-10 1.7E-10 1.4
EP4 (h) (agonist radioligand) PGE2
SGT-24 10 89.7 4.4E-10 1.7E-10 0.8
SGT-42 2 98.3 4.4E-10 1.7E-10 0.8
SGT-65 4 96.0 4.4E-10 1.7E-10 0.8
SGT-149 4 95.6 4.4E-10 1.7E-10 0.8
5-HT1A (h) (agonist
8-OH-DPAT
radioligant )
SGT-24 15 85.5 6.0E-10 3.7E-10 1.4
SGT-42 23 76.6 6.0E-10 3.7E-10 1.4
SGT-65 6 93.8 6.0E-10 3.7E-10 1.4
SGT-149 12 88.4 6.0E-10 3.7E-10 1.4
5-HT1B (antagonist
serotonin
radioligand)
SGT-24 -6 105.6 6.6E-09 4.1E-09 0.7 SGT-42 -3 103.4 6.6E-09 4.1E-09 0.7
SGT-65 -6 105.8 6.6E-09 4.1E-09 0.7
SGT-149 -9 108.5 6.6E-09 4.1E-09 0.7
5-HT2A (h) (antagonist radioligand) ketanserin
SGT-24 1 99.2 1.3E-09 6.9E-10 1.1
SGT-42 2 98.3 1.3E-09 6.9E-10 1.1
SGT-65 -4 103.8 1.3E-09 6.9E-10 1.1
SGT-149 9 90.5 1.3E-09 6.9E-10 1.1
5-HT2B (h) (agonist (±)D0I
radioliganc )
SGT-24 -8 107.6 2.5E-09 1.2E-09 1.0
SGT-42 -18 117.8 2.5E-09 1.2E-09 1.0
SGT-65 4 95.6 2.5E-09 1.2E-09 1.0
SGT-149 11 88.5 2.5E-09 1.2E-09 1.0
5-HT3 (h) (antagonist radioligand) MDL 72222
SGT-24 1 99.0 1.4E-08 9.6E-09 1.2
SGT-42 -6 105.9 1.4E-08 9.6E-09 1.2
SGT-65 -3 103.0 1.4E-08 9.6E-09 1.2
SGT-149 -1 100.9 1.4E-08 9.6E-09 1.2
5-HT5a (h) (agonist
. serotonin
radioliganc )
SGT-24 -3 103.0 1.6E-07 8.0E-08 0.8
SGT-42 -1 101.2 1.6E-07 8.0E-08 0.8
SGT-65 1 99.4 1.6E-07 8.0E-08 0.8
SGT-149 -11 110.6 1.6E-07 8.0E-08 0.8
5-HT6 (h) (agonist
serotonin
radioligant )
SGT-24 -9 108.7 9.4E-08 4.5E-08 0.9
SGT-42 -3 103.3 9.4E-08 4.5E-08 0.9
SGT-65 -5 104.5 9.4E-08 4.5E-08 0.9
SGT-149 -4 104.1 9.4E-08 4.5E-08 0.9
5-HT7 (h) agonist
" serotonin
radioligant )
SGT-24 5 95.5 4.5E-10 1.6E-10 1.1
SGT-42 7 93.0 4.5E-10 1.6E-10 1.1
SGT-65 -13 113.1 4.5E-10 1.6E-10 1.1
SGT-149 2 97.7 4.5E-10 1.6E-10 1.1
. , . .. . , . . ,. somatostatin- sst (non-selective) (agonist radioligand) ^
SGT-24 -8 108.1 3.4E-10 2.1E-10 1.0
SGT-42 -11 110.5 3.4E-10 2.1E-10 1.0
SGT-65 -25 124.8 3.4E-10 2.1E-10 1.0
SGT-149 -26 125.7 3.4E-10 2.1E-10 1.0
VPACl (VIPl) (h) (agonist radioligand) VIP
SGT-24 -2 102.3 2.4E-10 1.3E-10 0.9 SGT-42 -3 103.4 2.4E-10 1.3E-10 0.9
SGT-65 -1 101.2 2.4E-10 1.3E-10 0.9
SGT-149 -5 104.9 2.4E-10 1.3E-10 0.9
[d(CH2)51,Tyr( Me)2]-
Via (h) (agonist radioligand)
AVP
SGT-24 -4 104.2 7.6E-10 4.8E-10 0.9
SGT-42 5 94.5 7.6E-10 4.8E-10 0.9
SGT-65 1 98.5 7.6E-10 4.8E-10 0.9
SGT-149 -4 104.4 7.6E-10 4.8E-10 0.9
Ca2+ channel (L, verapamil site)
D 600
(phenylalkylamine) (antagonist radioligand)
SGT-24 -8 108.5 1.4E-08 7.0E-09 0.5
SGT-42 -4 103.8 1.4E-08 7.0E-09 0.5
SGT-65 -12 111.8 1.4E-08 7.0E-09 0.5
SGT-149 -7 107.5 1.4E-08 7.0E-09 0.5
KV channe (antagonist radioligand) alpha -dendrotoxin
SGT-24 -15 115.1 2.0E-10 1.6E-10 0.9
SGT-42 -12 111.8 2.0E-10 1.6E-10 0.9
SGT-65 -9 108.7 2.0E-10 1.6E-10 0.9
SGT-149 -4 104.1 2.0E-10 1.6E-10 0.9
SKCa channel (antagonist radioligand) apamin
SGT-24 1 99.2 8.5E-12 4.3E-12 0.8
SGT-42 -15 114.8 8.5E-12 4.3E-12 0.8
SGT-65 5 94.9 8.5E-12 4.3E-12 0.8
SGT-149 1 99.2 8.5E-12 4.3E-12 0.8
Na+ channel (site 2) (antagonist radioligand) veratridine
SGT-24 -8 108.1 8.6E-06 7.7E-06 1.3
SGT-42 6 94.4 8.6E-06 7.7E-06 1.3
SGT-65 -10 110.2 8.6E-06 7.7E-06 1.3
SGT-149 1 98.9 8.6E-06 7.7E-06 1.3
CI- channel (GABA-gated) (antagonist
picrotoxinin
radioliganc )
SGT-24 45 55.1 1.4E-07 1.2E-07 0.8
SGT-42 4 96.5 1.4E-07 1.2E-07 0.8
SGT-65 47 53.3 1.4E-07 1.2E-07 0.8
SGT-149 28 71.5 1.4E-07 1.2E-07 0.8 norepineph rine transporter (h) (antagonist
protriptyline
radioligant )
SGT-24 0 99.9 3.1E-09 2.3E-09 1.0
SGT-42 -7 107.0 3.1E-09 2.3E-09 1.0
SGT-65 -4 104.4 3.1E-09 2.3E-09 1.0
SGT-149 -1 100.8 3.1E-09 2.3E-09 1.0 dopamine transporter (h) (antagonist
BTCP
radioligand)
SGT-24 -6 105.7 9.7E-09 5.1E-09 1.1 SGT-42 -11 110.6 9.7E-09 5.1E-09 1.1
SGT-65 -1 100.6 9.7E-09 5.1E-09 1.1
SGT-149 12 88.5 9.7E-09 5.1E-09 1.1
5-HT trans jorter (h) (antagonist radioligand) imipramine
SGT-24 -7 107.5 1.9E-09 8.9E-10 0.8
SGT-42 -7 107.0 1.9E-09 8.9E-10 0.8
SGT-65 -8 108.4 1.9E-09 8.9E-10 0.8
SGT-149 3 97.1 1.9E-09 8.9E-10 0.8
6.4 Pharmaceutical compositions
Pharmaceutical compositions of the invention were prepared by dissolving a compound of the invention in a solvent, such as diethyl ether or acetone or a mixture thereof, and mixing the solution with a suitable carrier. The solvent was removed and the mixture divided up into gel caps (capsules) in equal portions so that each gel cap contained a known dose of the compound of the invention. SGT-24 with mannitol (capsule 1)
Gel caps containing 4 mg of SGT-24 and -196 mg mannitol as carrier were prepared as described above. 40 mg of SGT-42 was dissolved in 20 ml of diethyl ether and 1960 mg of mannitol. The mixture was dried and 200 mg of the mixture was placed in each gel cap. SGT-24 with MSM (capsule 2)
Gel caps containing 4 mg of SGT-24 and ~ 196 mg methylsulfonylmethane (MSM) as carrier were prepared as described above. 40 mg of SGT-42 was dissolved in 20 ml of diethyl ether (or 20 ml of 2: 1 diethyl ether: acetone) and 1960 mg of MSM. The mixture was dried and 200 mg of the mixture was placed in each gel cap.
SGT-42 with MSM (capsule 3)
Gel caps containing 5 mg of SGT-42 and ~ 196 mg methylsulfonylmethane (MSM) as carrier were prepared as described above. 50 mg of SGT-42 was dissolved in 20 ml of diethyl ether and 1950 mg of MSM. The mixture was dried and 200 mg of the mixture was placed in each gel cap.
6.5 E-liquid composition E-liquid compositions of the invention for use in e-cigarettes were prepared by dissolving a compound of the invention in a solvent, such as propylene glycol, glycerine, and optionally a surfactant with stirring. Optionally, a flavour enhancer may also be added. The composition may also be filtered before use.
SGT-42 e-liquid composition (E-liquid 1)
An e-liquid containing 350mg of SGT-42 was prepared with 10 ml propylene glycol, 3 ml vegetable glycerin, 2 drops of Tween 20, and 10 drops of Tasty Puff flavour enhancer were prepared as described above. The mixture was filtered through glass wool and was then used to fill 2 ml e-cigarette cartridges.
SGT-42 tablets
A batch of tablets containing SGT-42, beta cyclodextrin, microcrystalline cellulose, magnesium stearate, and magnesium silicate in tablet form was produced as described below. The content of each component by weight is listed in Table 7.
Table 7.
Figure imgf000154_0001
The cyclodextrin was weighed and placed in a ribbon blender. The SGT-42 active was weighed and fine sieved in to the ribbon blender. The ingredients were then blended for ten minutes. The Microcrystallme Cellulose, Magnesium Silicate, and Crosscarmellose Sodium were then weighed, added to the blender, and the mixture was blended for a further ten minutes.
Finally, the Magnesium Sterate was weighed, added to the mix, and blended for 5 minutes. The blended mixture of ingredients was then tabletted. 6.6 Use of cannabinoid compounds of the invention Capsule 1
One volunteer initially took one "capsule 1" orally.
Effects were first observed after approximately 180 minutes. The volunteer experienced strong cannabinomimetic effects. The test was not continued beyond 180 minutes.
Capsule 2
Six volunteers were breath tested to ensure they had not consumed alcohol. The volunteers were each fed a three course meal before commencement of the test. Blood pressure and heart rate of the volunteers were measured and monitored for the duration of the test.
One "capsule 2" was provided per volunteer, which was swallowed. The volunteers were asked questions every 60 minutes regarding how they were feeling and what effects they were observing.
Surprisingly, effects were first observed after approximately 20-60 minutes (when compared to 180 minutes when mannitol was used as carrier). All volunteers experienced strong cannabinomimetic effects, were relaxed, and reported a positive mood change. After a further 60 minutes, all volunteers reported that the cannabinomimetic effects had intensified and that they felt more relaxed and had an increased positive mood.
The test concluded after a further 60 minutes (180 minutes in total). The cannabinomimetic effects persisted after the test concluded.
After approximately 90 minutes, all volunteers reported experiencing voracious hunger. None of the volunteers experienced a significant increase in blood pressure and only one volunteer experienced a significant increase in heart rate.
Capsule 3
Four volunteers were breath tested to ensure they had not consumed alcohol. Blood pressure and heart rate of the volunteers were measured and monitored for the duration of the test.
One "capsule 3" was provided per volunteer, which was swallowed. The volunteers were asked questions every 30 minutes regarding how they were feeling and what effects they were observing.
Surprisingly, effects were first observed after approximately 30 minutes (when compared to 180 minutes when mannitol was used as carrier). All volunteers experienced strong cannabinomimetic effects, were relaxed, and reported a positive mood change.
After 60 minutes, three volunteers were provided with a second "capsule 3", which was swallowed. All three volunteers reported that the cannabinomimetic effects had intensified and that they felt more relaxed and had an increased positive mood. After 110 minutes, two of the volunteers were provided with a third "capsule 3", which was swallowed. Both volunteers reported that the cannabinomimetic effects had intensified and that they felt more relaxed and had an increased positive mood.
The test concluded after 180 minutes. The cannabinomimetic effects persisted after the test concluded.
After approximately 100 minutes, all volunteers reported experiencing voracious hunger.
None of the volunteers experienced a significant increase in blood pressure and only one volunteer experienced a significant increase in heart rate.
E-liquid 1
Five volunteers were breath tested to ensure they had not consumed alcohol. Blood pressure and heart rate of the volunteers were measured and monitored for the duration of the test. Each volunteer was allowed to inhale two puffs of e-liquid from an e-cigarette. The volunteers were asked questions every 30 minutes regarding how they were feeling and what effects they were observing.
Effects were first observed after approximately 1-2 minutes. All volunteers experienced mild to moderate cannabinomimetic effects, were relaxed, and reported a positive mood change.
After 30 minutes most volunteers reported that the cannabinomimetic effects were diminishing, but two volunteers reported feeling cannabinomimetic effects for up to 60 minutes.
At 60 minutes the volunteers were allowed to inhale two further puffs of e-liquid from an e- cigarette. Most volunteers inhaled three or four puffs of e-liquid from the e-cigarette. All volunteers reported moderate cannabinomimetic effects at three puffs and strong
cannabinomimetic effects after four puffs.
All volunteers reported cannabinomimetic effects diminishing after approximately 40 minutes after inhalation and all volunteers reported feeling no cannabinomimetic effects after 90 minutes after inhalation.
All volunteers reported feeling more relaxed and had an increased positive mood. All volunteers reported experiencing voracious hunger. It is not the intention to limit the scope of the invention to the abovementioned examples only. As would be appreciated by a skilled person in the art, many variations are possible without departing from the scope of the invention.
7. INDUSTRIAL APPLICATION The compounds of the invention described herein have central nervous system activity and can, therefore, be used to treat a variety of diseases or conditions. The compounds are especially useful treating pain, treating nausea and/or emesis, stimulating appetite, inducing a euphoric effect, inducing relaxation, and inducing a positive mood change, in particular for treating pain, treating nausea and/or emesis, and stimulating appetite.

Claims

1. A compound of formula I,
Figure imgf000159_0001
wherein
Y is selected from CH2CH2, CH2S, CH20, S02CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH,
(C=S)NH, SCH2, OCH2, CH2S02, OS02, NHS02,0(C=0), 0(C=S), S(C=0), CH2(C=0), CH2(C=S), CH2(C=S02), 0(C=S02), NH(C=S02), NH(C=0), or NH(C=S);
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 are each independently selected from hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Q- C8 alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring or a 3 to 7 membered heterocyclyl ring; and
R6c is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
Ri2a and R121) are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl which may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof. 2. The compound of claim 1, wherein
R6a and R6b are each independently selected from Ci-Cg alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring; and
R6c is selected from Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cs haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted.
3. The compound of claim 1 , wherein R6a and R6 together form 3 to 7 membered heterocycle.
4. The compound of claim 1 wherein R6c is cyano.
5. The compound of any one of claims 1 to 4, wherein Y is selected from CH2CH2, CH2S, CH20, SO2CH2, S020, S02NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2,
(C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, or (C=S)NH.
6. The compound of any one of claims 1 to 4, wherein Y is selected from CH2CH2, CH2S, CH20, SO2CH2, S020, SO2NH, (C=0)0, (C=S)0, (C=0)S, (C=0)CH2, (C=S)CH2, (C=S02)CH2, (C=S02)0, (C=S02)NH, (C=0)NH, (C=S)NH, CH2(C=0), 0(C=0),
CH2(C=0), or NH(C=0).
7. The compound of any one of claims 1 to 4, wherein Y is selected from (C=0)0, (C=0)CH2, (C=0)NH, or NH(C=0).
8. The compound of any one of claims 1 to 4, wherein Y is selected from (C=0)0 or (C=0)NH.
The compound of any one of claims 1 to 4, wherein Y is (C=0)NH.
10. The compound of any one of claims 1 to 9, wherein R2- 5 are each independently selected from hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b,
CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 alkoxy, C6-Ci2 aryl, C3- C12 cycloalkyl, C1-C12 heteroalkyl, C3-Ci2 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-C8 alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-C8 alkyl, or C3-C8 heterocycle. 11. The compound of any one of claims 1 to 10, wherein R2-R5 are each independently selected from hydrogen or halo.
12. The compound of any one of claims 1 to 11, wherein Rec is selected from Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-Ci2 cycloalkyl, C1-C12 heteroalkyl, C3-Ci2 heterocyclyl, C6-Ci2 heteroaryl, or cyano, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Q-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Q-Cg alkyl, or C3-C8 heterocycle.
13. The compound of any one of claims 1 to 12, wherein R6c is selected from Ci-C8 alkyl, C2-Q alkenyl, C2-Q alkynyl, Ci-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, C3-C12 cycloalkyl, C1-C12 heteroalkyl, C3-C12 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, haloaryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cg alkyl, or C3-Cg heterocycle.
14. The compound of any one of claims 1 to 12, wherein R6c is selected from Ci-Cg alkylene heterocyclyl, C2-Cs alkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO,
-N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - 0S(=0)20R, -S(=0)2NR, -S(=0)R, -0P(=0)(0R)2, -P(=0)(0R)2, -P(=0)(0H)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cg alkyl, or C3-Cg heterocycle.
15. The compound of any one of claims 1 to 12, wherein R6c is selected from Ci-Cs alkylene heterocyclyl, C2-Cg alkynyl, C6-Ci2 aryl, C6-Ci2 haloaryl, or cyano, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
16. The compound of any one of claims 1 to 12, wherein R^c is selected from Ci-C§ alkylene heterocyclyl, C2-Cg alkynyl, C6-Ci2 aryl, or C6-Ci2 haloaryl, wherein each of said heterocyclyl, alkynyl, aryl, or haloaryl may be optionally substituted by one or more halo.
A compound of formula la,
Figure imgf000163_0001
wherein
Yi is selected from O, S, or S02;
Y2 is selected from CH2, O, or NH;
B is selected from CH or N;
Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, aryl, cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted;
R2-R5 and R7-R11 are each independently selected from hydrogen, OH, N02, CHO, S02, S03H, NRi2aRi2b, S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-Cg alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted;
R6a and R6b are each independently selected from Ci-C8 alkyl or R6a and R6b together form a C3-Cg cycloalkyl ring or 3 to 7 membered heterocyclyl ring; and
Ri2a and Ri2b are each independently selected from hydrogen, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted; or
a pharmaceutically acceptable salt or prodrug thereof.
18. The compound of claim 17, wherein R6a and R6b are each independently selected from Ci-Cs alkyl or R6a and R6b together form a C3-C6 cycloalkyl ring.
19. The compound of claim 17, wherein R6a and R6b together form 3 to 7 membered heterocycle.
20. The compound of any one of claims 17 to 19, wherein Yi is selected from O, S, or S02.
21. The compound of any one of claims 17 to 20, wherein Yi is O.
22. The compound of any one of claims 17 to 21, wherein Y2 is selected from CH2, O, or NH.
23. The compound of any one of claims 17 to 22, wherein Y2 is selected from NH or O.
24. The compound of any one of claims 17 to 23, wherein Y2 is NH.
25. The compound of any one of claims 17 to 24, wherein R2-R5 and R7-Rnare each independently selected from hydrogen, OH, N02, CHO, S02, SO3H, NRi2aRi2h,
S02NRi2aRi2b, CONRi2aRi2b, halo, Ci-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ci-C8 alkoxy, C6-Ci2 aryl, C3-Ci2 cycloalkyl, Ci-Ci2 heteroalkyl, C3-Ci2 heterocyclyl, or C6-C12 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cg alkyl, C6-Ci2 aryl, C6-Ci2 aryl Ci-Cg alkyl, or C3-Cg heterocycle.
26. The compound of any one of claims 17 to 24, wherein R2-R5 and R7-R11 are each independently selected from hydrogen or halo.
27. The compound of any one of claims 1 to 26, wherein B is CH.
28. The compound of any one of claims 1 to 26, wherein B is N.
29. The compound of any one of claims 1 to 28, wherein Ri2a and Ri2b are each
independently selected from hydrogen, Ci-C8 alkyl, or C6-Ci2 aryl, wherein each of said alkyl or aryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, - +R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, - NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, - S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR; wherein each X is independently halo; and
each R is independently H, Ci-Cs alkyl, C6-Ci2 aryl, C6-C12 aryl Ci-Cs alkyl, or C3-C8 heterocycle. 30. The compound of any one of claims 1 to 29, wherein R12a and R12b are each independently selected from hydrogen, C1-C8 alkyl, or C6-C12 aryl.
31. The compound of any one of claims 1 to 30, wherein R2 is hydrogen, OH, N02, CHO, S02, S03H, NR12aR12b, S02NR12aR12b, CONR12aR12b, halo, d-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C12 aryl, C3-Ci2 cycloalkyl, Ci-Ci2 heteroalkyl, C3-Ci2 heterocyclyl, or C6-Ci2 heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroalkyl, heterocyclyl, or heteroaryl may be optionally substituted by one or more -X, -R, =0, -OR, -SR, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, - NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, - S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR.
32. The compound of any one of claims 1 to 31, wherein R2 is hydrogen or halo.
33. The compound of any one of claims 1 to 32, wherein Ri is selected from CONRi2aRi2b, CORi2a, COORi2a, Ci-Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Ct-Cg fluoroalkyl, Ci-C8 bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-C12 aryl, C3-Ci2 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NCS, -NO, -N02, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, - C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, - P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, Ci-Cio alkyl, C6-Ci2 aryl, C6-C12 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl, bridged Cg-Ci2 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
34. The compound of any one of claims 1 to 33, wherein Ri is selected from CONRi2aRi2t>, CORi2a, COORi2a, Q-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Q-Cg fluoroalkyl, Q-Cg bromoalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene-tetrahydropyranyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkenyl, haloalkynyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more -F,- Br, -R, =0, -OR, -SR, -NMeEt, -NEtEt, -N+R3, =NR, -CX3, -OCN, -SCN, -N=C=0, -NCS, -NO, -NO2, =N2, -N3, -NHC(=0)R, -NHS(=0)2R, C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -OP(=0)(OR)2, -P(=0)(OR)2, -P(=0)(OH)2, -C(=0)R, -C(=0)OR, -C(=0)X, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl, bridged C6-C12 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
35. The compound of any one of claims 1 to 33, wherein Ri is selected from Q-Cg alkyl, Ci-Cg bromoalkyl, Ci-Cg fluoroalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene- tetrahydropyranyl, wherein each of said alkyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, -Br, -R, =0, -OR, -CX3, -CN, -OCN, -SCN, -N=C=0, -NO2, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, -OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- Cs alkyl, C3-C12 cycloalkyl, bridged C6-C12 cycloalkyl, halo or perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
36. The compound of any one of claims 1 to 33, wherein Ri is selected from Ci-C8 alkyl, CpCs bromoalkyl, Ci-C8 fluoroalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, or Ci-C6 alkylene- tetrahydropyranyl, wherein each of said alkyl, alkylene-tetrahydropyranyl, aryl, or cycloalkyl may be optionally substituted by one or more of -F, -Br, -R, =0, -OR, -CX3, -OCN, -SCN, -N=C=0, -NO2, -NHC(=0)R, -NHS(=0)2R, -C(=0)R, -C(=0)NRR, -S(=0)2OH, -S(=0)2R, - OS(=0)2OR, -S(=0)2NR, -S(=0)R, -C(=0)R, -C(=0)OR, -C(S)R, -C(0)OR, -C(S)OR, -C(0)SR, -C(S)SR, -C(0)NRR, -C(S)NRR, or -C(=NR)NRR;
wherein each X is independently halo; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-Ci2 fluoroaryl, C6-Ci2 aryl Ci- C8 alkyl, C3-C12 cycloalkyl, bridged C6-C12 cycloalkyl, perhalo substituted C3-C12 cycloalkyl, or a C3-C12 heterocycle.
37. The compound of any one of claims 1 to 33, wherein Ri is selected from Ci-C8 alkyl, Ci-Cs bromoalkyl, Ci-C8 fluoroalkyl, Ci-C8 cyanoalkyl, C6-Ci2 aryl, C3-C12 cycloalkyl, Ci-Cg alkylene- C3-C12 cycloalkyl, Ci-C6 alkylene- C6-Ci2 aryl, Ci-C6 alkylene- C6-Ci2 fluoroaryl,
Ci-C6 alkylene- C3-C12 heterocycle, Ci-C6 alkylene-C(=0)NRR;
wherein each of said alkyl, aryl, cycloalkyl, or heterocyclyl may be optionally substituted by one or more bromo or fluoro; and said alkyl may also be optionally substituted by one or more -CN; and
each R is independently H, C1-C10 alkyl, C6-Ci2 aryl, C6-C12 fluoroaryl, C6-Ci2 aryl Ci-
Cg alkyl, C3-C12 cycloalkyl.
38. The compound of any one of claims 1 to 33, wherein Ri is selected from 1 -butyl, 1- pentyl, 5-fluoro-l-pentyl, 4-cyano-l -butyl, 3,3-dimethyl-l-butyl, 1- hexyl, 1-heptyl, methylene cyclohexyl, methylene-4,4-difluoro-l -cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2-piperidinyl, methylene-cycloheptanyl, methylene-2-bicyclo[2.2.1]heptanyl, methylene-4-tetrahydropyranyl,
methyleneC(0)NH(cyclohexyl), methyleneC(0)NH(t-butyl), l-ethylene-2-(N-mo holinyl), l-ethylene-2-(N-piperidinyl), and l-ethylene-2-(4,4-difluoro-N-piperidinyl).
39. The compound of any one of claims 1 to 33, wherein RI is selected from 1 -butyl, 1- pentyl, 5-fluoro-l-pentyl, methylene cyclohexyl, methylene-3,3-difluoro-l -cyclohexyl, methylene-p-fluoro-phenyl, methylene-adamantyl, methylene-N-methyl-2-piperidinyl, methylene-cycloheptanyl, methylene- 2-bicyclo[2.2.1]heptanyl, and methylene-4- tetrahydropyranyl.
40. The compound of any one of claims 1 to 39, wherein R6a and !½, are each
independently selected from CpC4 alkyl or R6a and R6b together form a C3-C6 cycloalkyl rinj or a 3 to 7 membered heterocyclyl ring.
41. The compound of any one of claims 1 to 40, wherein R6a and R6b are each
independently selected from C1-C4 alkyl or R6a and R6b together form a C3-C5 cycloalkyl ring.
42. The compound of any one of claims 1 to 41, wherein R6a and R6b are each methyl or R6a and Rg together form a cyclopropyl or cyclopentyl ring.
43. The compound of any one of claims 1 to 40, wherein R6a and R6b together form a 3 to 6 membered heterocyclyl ring.
44. The compound of claim 43, wherein R6a and R6b together form a 4,4-tetrahydropyranyl ring. 45. The compound of any one of claims 1 to 44, wherein the EC50 of the compound of the invention in a CBi and/or CB2 receptor affinity assay is less than about 50 μΜ.
46. The compound of any one of claims 1 to 45, wherein the compound has an inhibition of control specific binding of less than about 65% and/or a control specific binding of at least 40% for at least one G-protein coupled receptor or ligand-gated ion channel selected from the group consisting of adenosine Al, adenosine A2A, adenosine A3, adrenergic al, adrenergic a2, adrenergic βΐ, adrenergic β2, angiotensin ATI, central benzodiazepine BZD, bradykinin B2, cholecystokinin CCK1, dopamine Dl, dopamine D2S, endothelin ETA, GAB A (nonselective), galanin GAL2, chemokine CXCR2, chemokine CCR1, histamine HI, histamine H2, melatonin MT1, muscarininc Ml, muscarininc M2, muscarininc M3, tachykinin NK2, tachykinin NK3, neuropeptide Yl, neuropeptide Y2, neurotensin NTS 1, opioid μ, opioid δ, opioid K, opioid NOP, prostaglandin EP4, serotonin 5-HT1A, serotonin HT1B, serotonin HT2A, serotonin HT2B, serotonin HT3, serotonin HT5A, serotonin HT6, serotonin HT7, somatostatin SST, vasoactive intestinal polypeptide VPACl, vasopressin VIA, Ca2+ channel L, KV channel, SKCa channel, Na+ channel (site 2), CI- channel (GABA-gated), noradrenaline transporter, dopamine transporter, and serotonin transporter.
47. A pharmaceutical composition comprising a compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier.
48. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in treating pain in a subject.
49. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in treating nausea and/or emesis in a subject.
50. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in stimulating appetite in a subject.
51. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in inducing a euphoric effect in a subject.
52. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in relaxing a subject.
53. A compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt or prodrug thereof for use in inducing a positive mood change in a subject.
PCT/IB2014/060636 2013-04-11 2014-04-11 Cannabinoid compounds WO2014167530A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361810968P 2013-04-11 2013-04-11
US61/810,968 2013-04-11

Publications (1)

Publication Number Publication Date
WO2014167530A1 true WO2014167530A1 (en) 2014-10-16

Family

ID=51689019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/060636 WO2014167530A1 (en) 2013-04-11 2014-04-11 Cannabinoid compounds

Country Status (1)

Country Link
WO (1) WO2014167530A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10045567B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10045568B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10058130B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10104915B2 (en) 2013-12-23 2018-10-23 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10111470B2 (en) 2013-12-23 2018-10-30 Juul Labs, Inc. Vaporizer apparatus
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
US10512282B2 (en) 2014-12-05 2019-12-24 Juul Labs, Inc. Calibrated dose control
WO2020077462A1 (en) 2018-10-19 2020-04-23 Top Canada Pharmaceuticals Inc. Powdered botanical extract preparations and formulations thereof
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
US10865001B2 (en) 2016-02-11 2020-12-15 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
CN112375027A (en) * 2020-12-07 2021-02-19 中国药科大学 Indolesulfonamide derivative and medical application thereof
WO2021155227A1 (en) * 2020-01-30 2021-08-05 Rti International, Inc. Indazole derivatives as cannabanoid receptor partial agonists
US11084789B2 (en) 2016-01-14 2021-08-10 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN116438162A (en) * 2020-09-17 2023-07-14 伊赛恩特制药公司 Modulators of MAS-related G protein receptor X4 and related products and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028297A1 (en) * 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Kg Substituted indoles, having a thrombin inhibiting effect

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028297A1 (en) * 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Kg Substituted indoles, having a thrombin inhibiting effect

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIECHY, A AND ZARD, S. Z: "A Flexible, Convergent Approach to Polycyclic Indole Structures: Formal Synthesis of (±)-Mersicarpine", ORGANIC LETTERS, vol. 11, no. 13, 2009, pages 2800 - 2803 *
DATABASE CAPLUS 1999, accession no. 999:375527 *
DATABASE CAPLUS 2009, accession no. 009:666523 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10638792B2 (en) 2013-03-15 2020-05-05 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10111470B2 (en) 2013-12-23 2018-10-30 Juul Labs, Inc. Vaporizer apparatus
US10117466B2 (en) 2013-12-23 2018-11-06 Juul Labs, Inc. Vaporization device systems and methods
US10058130B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10070669B2 (en) 2013-12-23 2018-09-11 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10104915B2 (en) 2013-12-23 2018-10-23 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US11752283B2 (en) 2013-12-23 2023-09-12 Juul Labs, Inc. Vaporization device systems and methods
US10117465B2 (en) 2013-12-23 2018-11-06 Juul Labs, Inc. Vaporization device systems and methods
US10058124B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10667560B2 (en) 2013-12-23 2020-06-02 Juul Labs, Inc. Vaporizer apparatus
US10201190B2 (en) 2013-12-23 2019-02-12 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10912331B2 (en) 2013-12-23 2021-02-09 Juul Labs, Inc. Vaporization device systems and methods
US10045568B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10264823B2 (en) 2013-12-23 2019-04-23 Juul Labs, Inc. Vaporization device systems and methods
US10045567B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10701975B2 (en) 2013-12-23 2020-07-07 Juul Labs, Inc. Vaporization device systems and methods
US10512282B2 (en) 2014-12-05 2019-12-24 Juul Labs, Inc. Calibrated dose control
US11084789B2 (en) 2016-01-14 2021-08-10 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
US10865001B2 (en) 2016-02-11 2020-12-15 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD929036S1 (en) 2016-06-16 2021-08-24 Pax Labs, Inc. Vaporizer cartridge and device assembly
USD913583S1 (en) 2016-06-16 2021-03-16 Pax Labs, Inc. Vaporizer device
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
EP3866823A4 (en) * 2018-10-19 2022-11-09 Fong, Sonny POWDERED PLANT EXTRACT PREPARATIONS AND FORMULATIONS THEREOF
WO2020077462A1 (en) 2018-10-19 2020-04-23 Top Canada Pharmaceuticals Inc. Powdered botanical extract preparations and formulations thereof
WO2021155227A1 (en) * 2020-01-30 2021-08-05 Rti International, Inc. Indazole derivatives as cannabanoid receptor partial agonists
EP4097088A4 (en) * 2020-01-30 2024-01-24 Research Triangle Institute Indazole derivatives as cannabanoid receptor partial agonists
CN116438162A (en) * 2020-09-17 2023-07-14 伊赛恩特制药公司 Modulators of MAS-related G protein receptor X4 and related products and methods
EP4213839A4 (en) * 2020-09-17 2024-08-07 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x4 and related products and methods
CN112375027A (en) * 2020-12-07 2021-02-19 中国药科大学 Indolesulfonamide derivative and medical application thereof
CN112375027B (en) * 2020-12-07 2023-03-31 中国药科大学 Indolesulfonamide derivative and medical application thereof

Similar Documents

Publication Publication Date Title
WO2014167530A1 (en) Cannabinoid compounds
JP7644517B2 (en) KRAS Mutant Protein Inhibitors
AU2003220384B2 (en) Combination treatments for chemokine-mediated diseases
CN111848616B (en) Pyridone derivative and application thereof in preparation of anti-influenza virus medicines
AU2015365587B2 (en) Fused ring heteroaryl compounds and their use as TRK inhibitors
ES2331153T3 (en) N-SULFONYLAMINOFENILETIL-2-PHENOXYACETAMIDE SUBSTITUTED COMPOUNDS.
KR20060072142A (en) CrF antagonists and bicyclic heterocyclic compounds
CN109153687A (en) Compound of the one kind containing tricyclic heteroaryl
JP7245918B2 (en) Sarsasapogenin structure-based derivative, pharmaceutical composition and use thereof
JP6966425B2 (en) Heterocyclic limited tricyclic sulfonamides as anti-cancer agents
JP2007514746A (en) Thiadiazole as CXC-chemokine receptor ligand and CC-chemokine receptor ligand
WO2008134036A1 (en) ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES
TW201726678A (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
CN112125911A (en) CDK9 inhibitor and preparation method and application thereof
CN111303147B (en) Pyridone derivatives, compositions thereof and use as anti-influenza virus medicaments
JP2024545189A (en) Tricyclic fused heterocyclic PDE3/4 dual inhibitors and their uses
JP2020520960A (en) Azaaryl derivative, its production method and pharmaceutical application
WO2021052501A1 (en) Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof
CN101198606A (en) α-(aryl- or heteroaryl-methyl-)-β-piperidinopropionamide compounds as ORL1-receptor antagonists
KR20170117407A (en) Compound having antitumor activity
CN113045569B (en) Compounds as RET kinase inhibitors and their applications
CN112574212B (en) Pyrimido five-membered nitrogen heterocyclic derivative, preparation method and medical application thereof
AU2014365915B2 (en) Tetrahydro-tetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors
RU2534804C1 (en) SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRIDINES, DEMONSTRATING PROPERTIES OF ANTAGONISTS OF ADENOSINE A2A RECEPTORS, AND THEIR APPLICATION
MX2007016215A (en) Alpha-(aryl-or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14782376

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14782376

Country of ref document: EP

Kind code of ref document: A1